

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 5/06, 5/10, 7/01, 7/02, 15/86

A1

(11) International Publication Number:

WO 98/17783

(43) International Publication Date:

30 April 1998 (30.04.98)

(21) International Application Number: PCT/US97/19541

(22) International Filing Date: 23 October 1997 (23.10.97)

(30) Priority Data:
08/735,609 23 October 1996 (23.10.96) US

(71) Applicant: REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 3003 South State Street, Ann Arbor, MI 48109-1280 (US).

(72) Inventors: CHAMBERLAIN, Jeffrey, S.; 1209 Henry, Ann Arbor, MI 48104 (US). AMALFITANO, Andrea; 3305 Middle Brook Court, Durham, NC 27705 (US). HAUSER, Michael, A.; 13774 Sanford Road, Milan, MI 48160 (US). KUMAR-SINGH, Rajendra; Apartment 204, 219 S. Barrington Avenue, Los Angeles, CA 90049 (US). HARTIGAN-O'CONNOR, Dennis, J.; 1106 Maiden Lane Court #109, Ann Arbor, MI 48105 (US).

(74) Agents: CARROLL, Peter, G. et al.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: IMPROVED ADENOVIRUS VECTORS

(57) Abstract

The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NB	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IMPROVED ADENOVIRUS VECTORS**FIELD OF THE INVENTION**

The invention relates to improved adenovirus vectors, and more specifically,
5 adenovirus vectors useful for gene therapy.

BACKGROUND

Adenoviruses (Ad) are double-stranded DNA viruses. The genome of adenoviruses (~36 kb) is complex and contains over 50 open reading frames (ORFs). These ORFs are
10 overlapping and genes encoding one protein are often embedded within genes coding for other Ad proteins. Expression of Ad genes is divided into an early and a late phase. Early genes are those transcribed prior to replication of the genome while late genes are transcribed after replication. The early genes comprise E1a, E1b, E2a, E2b, E3 and E4. The E1a gene products are involved in transcriptional regulation; the E1b gene products are involved in the shut-off of host cell functions and mRNA transport. E2a encodes the a DNA-binding protein (DBP); E2b encodes the viral DNA polymerase and preterminal protein (pTP). The E3 gene products are not essential for viral growth in cell culture. The E4 region encodes regulatory
15 protein involved in transcriptional and post-transcriptional regulation of viral gene expression: a subset of the E4 proteins are essential for viral growth. The products of the late genes (e.g., L1-5) are predominantly components of the virion as well as proteins involved in the assembly of virions. The VA genes produce VA RNAs which block the host cell from shutting down viral protein synthesis.

Adenoviruses or Ad vectors have been exploited for the delivery of foreign genes to cells for a number of reasons including the fact that Ad vectors have been shown to be highly
25 effective for the transfer of genes into a wide variety of tissues *in vivo* and the fact that Ad infects both dividing and non-dividing cells: a number of tissues which are targets for gene therapy comprise largely non-dividing cells.

The current generation of Ad vectors suffer from a number of limitations which preclude their widespread clinical use including: 1) immune detection and elimination of cells
30 infected with Ad vectors, 2) a limited carrying capacity (about 8.5 kb) for the insertion of foreign genes and regulatory elements, and 3) low-level expression of Ad genes in cells infected with recombinant Ad vectors (generally, the expression of Ad proteins is toxic to cells).

The latter problem was thought to be solved by using vectors containing deletions in the E1 region of the Ad genome (E1 gene products are required for viral gene expression and replication). However, even with such vectors, low-level expression of Ad genes is observed. It is now thought that most mammalian cells contain E1-like factors which can substitute for the missing Ad E1 proteins and permit expression of Ad genes remaining on the E1 deleted vectors.

What is needed is an approach that overcomes the problem of low level expression of Ad genes. Such an approach needs to ensure that adenovirus vectors are safe and non-immunogenic.

10

SUMMARY OF THE INVENTION

The present invention contemplates two approaches to improving adenovirus vectors. The first approach generally contemplates a recombinant plasmid, together with a helper adenovirus, in a packaging cell line. The helper adenovirus is rendered safe by utilization of *loxP* sequences. In the second approach, "damaged" adenoviruses are employed. While the "damaged" adenovirus is capable of self-propagation in a packaging cell line, it is not capable of expressing certain genes (e.g., the DNA polymerase gene and/or the adenovirus preterminal protein gene).

20

In one embodiment of the first approach, the present invention contemplates a recombinant plasmid, comprising in operable combination: a) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element; b) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone; c) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs; and d) a first gene of interest operably linked to said promoter element.

25

While it is not intended that the present invention be limited by the precise size of the plasmid, it is generally desirable that the recombinant plasmid have a total size of between 27 and 40 kilobase pairs. It is preferred that the total size of the DNA packaged into an EAM derived from these recombinant plasmids is about the length of the wild-type adenovirus genome (~36 kb). It is well known in the art that DNA representing about 105% of the wild-type length may be packaged into a viral particle; thus the EAM derived from recombinant plasmid may contain DNA whose length exceeds by ~105% the size of the wild-type genome.

The size of the recombinant plasmid may be adjusted using reporter genes and genes of interest having various sizes (including the use of different sizes of introns within these genes) as well as through the use of irrelevant or non-coding DNA fragment which act as "stuffer" fragments (e.g., portions of bacteriophage genomes).

5 In one embodiment of the recombinant plasmid, said 5' end of said packaging sequence is linked to said 3' end of said left ITR. In this embodiment, said first gene of interest is linked to said 3' end of said packaging sequence. It is not intended that the present invention be limited by the nature of the gene of interest: a variety of genes (including both cDNA and genomic forms) are contemplated: any gene having therapeutic value may be
10 inserted into the recombinant plasmids of the present invention. For example, the transfer of the adenosine deaminase (ADA) gene is useful for the treatment of ADA- patients: the transfer of the CFTR gene is useful for the treatment of cystic fibrosis. A wide variety of diseases are known to be due to a defect in a single gene. The plasmids, vectors and EAMs of the present invention are useful for the transfer of a non-mutated form of a gene which is
15 mutated in a patient thereby resulting in disease. The present invention is illustrated using recombinant plasmids capable of generating encapsidated adenovirus minichromosomes (EAMs) containing the dystrophin cDNA gene (the cDNA form of this gene is preferred due to the large size of this gene): the dystrophin gene is non-functional in muscular dystrophy (MD) patients. However, the present invention is not limited toward the use of the dystrophin
20 gene for treatment of MD: the use of the utrophin (also called the dystrophin related protein) gene is also contemplated for gene therapy for the treatment of MD [Tinsley *et al.* (1993) Curr. Opin. Genet. Dev. 3:484 and (1992) Nature 360:591]; the utrophin gene protein has been reported to be capable of functionally substituting for the dystrophin gene [Tinsley and Davies (1993) Neuromusc. Disord. 3:539]. As the utrophin gene product is expressed in the
25 muscle of muscular dystrophy patients, no immune response would be directed against the utrophin gene product expressed in cells of a host (including a human) containing the recombinant plasmids, Ad vectors or EAMs of the present invention. While the present invention is illustrated using plasmids containing the dystrophin gene, the plasmids, Ad vectors and EAMs of the present invention have broad application for the transfer of any gene
30 whose gene product is missing or altered in activity in cells.

Embodiments are contemplated wherein the recombinant plasmid further comprises a second gene of interest. In one embodiment, said second gene of interest is linked to said 3' end of said right ITR. In one embodiment, said second gene of interest is a reporter gene. A

variety of reporter genes are contemplated, including but not limited to *E. coli* β-galactosidase gene, the human placental alkaline phosphatase gene, the green fluorescent protein gene and the chloramphenicol acetyltransferase gene.

As mentioned above, the first approach also involves the use of a helper adenovirus in combination with the recombinant plasmid. In one embodiment, the present invention contemplates a helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end. It is preferred that said first *loxP* sequence is linked to the 5' end of said packaging sequence and said second *loxP* sequence is linked to said 3' end of said packaging sequence. In one embodiment, the helper virus comprises at least one adenovirus gene coding region.

The present invention contemplates a mammalian cell line containing the above-described recombinant plasmid and the above-described helper virus. It is preferred that said cell line is a 293-derived cell line. Specifically, in one embodiment, the present invention contemplates a mammalian cell line, comprising: a) a recombinant plasmid, comprising, in operable combination: i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element, ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone, iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs, and iv) a first gene of interest operably linked to said promoter element; and b) a helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end. As noted previously, said helper can further comprise at least one adenovirus gene coding region.

Overall, the first approach allows for a method of producing an adenovirus minichromosome. In one embodiment, this method comprises: A) providing a mammalian cell line containing: a) a recombinant plasmid, comprising, in operable combination, i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element, ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone, iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of the ITRs; and iv) a first gene of interest operably linked to said promoter element; and b) a helper adenovirus comprising i) first and a

second *loxP* sequences. ii) at least one adenovirus gene coding region, and iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end; and
5 B) growing said cell line under conditions such that said adenovirus gene coding region is expressed and said recombinant plasmid directs the production of at least one adenoviral minichromosome. It is desired that said adenovirus minichromosome is encapsidated.

In one embodiment, the present invention contemplates recovering said encapsidated adenovirus minichromosome and, in turn, purifying said recovered encapsidated adenovirus minichromosome. Thereafter, said purified encapsidated adenovirus minichromosome can be administered to a host (e.g., a mammal). Human therapy is thereby contemplated.

10 It is not intended that the present invention be limited by the nature of the administration of said minichromosomes. All types of administration are contemplated, including direct injection (intra-muscular, intravenous, subcutaneous, etc.), inhalation, etc.

15 As noted above, the present invention contemplates a second approaches to improving adenovirus vectors. In the second approach, "damaged" adenoviruses are employed. In one embodiment, the present invention contemplates a recombinant adenovirus comprising the adenovirus E2b region having a deletion, said adenovirus capable of self-propagation in a packaging cell line and said E2b region comprising the DNA polymerase gene and the adenovirus preterminal protein gene. In this embodiment, said deletion can be within the adenovirus DNA polymerase gene. Alternatively, said deletion is within the adenovirus 20 preterminal protein gene. Finally, the present invention also contemplates embodiments wherein said deletion is within the adenovirus DNA polymerase and preterminal protein genes.

The present invention further provides cell lines capable of supporting the propagation of Ad virus containing deletions within the E2b region. In one embodiment the invention 25 provides a mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase. In one embodiment, these cell lines comprise a recombinant adenovirus comprising a deletion within the E2b region, this E2b-deleted recombinant adenovirus being capable of self-propagation in the cell line. The present invention is not limited by the nature of the deletion within the E2b region. In one 30 embodiment, the deletion is within the adenoviral DNA polymerase gene.

The present invention provides cells lines stably expressing E1 proteins and the adenoviral DNA polymerase, wherein the genome of the cell line contains a nucleotide sequence encoding adenovirus DNA polymerase operably linked to a heterologous promoter.

In a particularly preferred embodiment, the cell line is selected from the group consisting of the B-6, B-9, C-1, C-4, C-7, C-13, and C-14 cell lines.

The present invention further provides cell lines which further constitutively express the adenovirus preterminal protein (pTP) gene product (in addition to E1 proteins and DNA polymerase). In one embodiment, these pTP-expressing cell lines comprise a recombinant adenovirus comprising a deletion within the E2b region, the recombinant adenovirus being capable of self-propagation in the pTP-expressing cell line. In a preferred embodiment, the deletion within the E2b region comprises a deletion within the adenoviral preterminal protein gene. In another preferred embodiment, the deletion within the E2b region comprises a deletion within the adenoviral (Ad) DNA polymerase and preterminal protein genes.

In a preferred embodiment, the cell lines coexpressing pTP and Ad DNA polymerase, contain within their genome, a nucleotide sequence encoding adenovirus preterminal protein operably linked to a heterologous promoter. In the invention is not limited by the nature of the heterologous promoter chosen. The art knows well how to select a suitable heterologous promoter to achieve expression in the desired host cell (e.g., 293 cells or derivative thereof). In a particularly preferred embodiment, the pTP- and Ad polymerase-expressing cell line is selected from the group consisting of the C-1, C-4, C-7, C-13, and C-14 cell lines.

The present invention provides a method of producing infectious recombinant adenovirus particles containing an adenoviral genome containing a deletion within the E2b region, comprising: a) providing: i) a mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase; ii) a recombinant adenovirus comprising a deletion within the E2b region, the recombinant adenovirus being capable of self-propagation in said cell line; b) introducing the recombinant adenovirus into the cell line under conditions such that the recombinant adenovirus is propagated to form infectious recombinant adenovirus particles; and c) recovering the infectious recombinant adenovirus particles. In a preferred embodiment, the method further comprises d) purifying the recovered infectious recombinant adenovirus particles. In yet another preferred embodiment, the method further comprises e) administering the purified recombinant adenovirus particles to a host which is preferably a mammal and most preferably a human.

In another preferred embodiment the mammalian cell line employed in the above method further constitutively expresses the adenovirus preterminal protein.

The present invention further provides a recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, the E2b sequences containing a deletion within the polymerase gene, the deletion resulting in reduced polymerase activity. The present invention is not limited by the specific deletion employed to reduce polymerase activity. In a preferred embodiment, the deletion comprises a deletion of nucleotides 8772 to 9385 in SEQ ID NO:4. In one preferred embodiment, the recombinant plasmid has the designation pΔpol. In another preferred embodiment, the recombinant plasmid has the designation pBHG11Δpol.

The present invention also provides a recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, the E2b sequences containing a deletion within the preterminal protein gene, the deletion resulting in the inability to express functional preterminal protein without disruption of the VA RNA genes. The present invention is not limited by the specific deletion employed to render the pTP inactive; any deletion within the pTP coding region which does not disrupt the ability to express the Ad VA RNA genes may be employed. In a preferred embodiment, the deletion comprises a deletion of nucleotides 10,705 to 11,134 in SEQ ID NO:4. In one preferred embodiment, the recombinant plasmid has the designation pΔpTP. In another preferred embodiment, the recombinant plasmid has the designation pBHG11ΔpTP.

In a preferred embodiment, the recombinant plasmid containing a deletion with the pTP region further comprises a deletion within the polymerase gene, this deletion resulting in reduced (preferably absent) polymerase activity. The present invention is not limited by the specific deletion employed to inactivate the polymerase and pTP genes. In a preferred embodiment, the deletion comprises a deletion of nucleotides 8,773 to 9586 and 11,067 to 12,513 in SEQ ID NO:4. In one preferred embodiment, the recombinant plasmid has the designation pAXBΔpolΔpTPVARNA+t13. In another preferred embodiment, the recombinant plasmid has the designation pBHG11ΔpolΔpTPVARNA+t13.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A is a schematic representation of the Ad polymerase expression plasmid pRSV-pol indicating that the Ad2 DNA polymerase sequences are under the transcriptional control of the RSV-LTR/promoter element and are flanked on the 3' end by the SV-40 small t intron and SV-40 polyadenylation addition site.

Figure 1B is a schematic representation of the expression plasmid pRSV-pTP indicating that the Ad2 preterminal protein sequences are under the transcriptional control of the RSV-LTR/promoter element and are flanked on the 3' end by the SV-40 small-t intron and SV-40 polyadenylation signals.

5 Figure 2 is an ethidium bromide-stained gel depicting the presence of Ad pol DNA sequences in genomic DNA from LP-293 cells and several hygromycin-resistant cell lines. The ~750 bp PCR products are indicated by the arrow.

10 Figure 3 is an autoradiograph depicting the results of a viral replication-complementation assay analyzing the functional activity of the Ad polymerase protein expressed by LP-293 cells and several hygromycin resistant cell lines. The 8.010 bp *Hind*III fragments analyzed by densitometry are indicated by an arrow.

15 Figure 4 is an autoradiograph indicating that cell lines B-6 and C-7 contained a smaller and a larger species of Ad polymerase mRNA while LP-293 derived RNA had no detectable hybridization signal. The location of the two species of Ad polymerase mRNA are indicated relative to the 28S and 18S ribosomal RNAs, and the aberrant transcript expressed by the B-9 cell line is indicated by an arrow.

20 Figure 5 is an autoradiograph showing which of the cell lines that received the preterminal protein expression plasmid indicated the presence of pRSV-pTP sequences (arrow labelled "pTP") and E1 sequences (arrow labelled "E1").

Figure 6 is an autoradiograph indicating in which of the cell lines transcription of preterminal protein is occurring (arrow labelled "~ 3kb").

Figure 7 is an autoradiograph indicating that the expression of the Ad-polymerase could overcome the replication defect of H5sub100 at non-permissive temperatures.

25 Figure 8 graphically depicts plaque titre for LP-293, B-6 and C-7 cell lines infected with wtAd5, H5ts36, or H5sub100, and the results demonstrate that the C-7 cell line can be used as a packaging cell line to allow the high level growth of E1, preterminal, and polymerase deleted Ad vectors.

30 Figure 9 is an autoradiograph showing that the recombinant pol⁻ virus is viable on pol-expressing 293 cells but not on 293 cells which demonstrates that recombinant Ad viruses containing the 612 bp deletion found within pΔpol lack the ability to express Ad polymerase.

Figure 10 is a schematic representation of the structure of pAd5βdys wherein the two inverted adenovirus origins of replication are represented by a left and right inverted terminal repeat (LITR/RITR). P1 and P2 represent location of probes used for Southern blot analysis.

Figure 11 graphically illustrates the total number of transducing adenovirus particles produced (output) per serial passage on 293 cells, total input virus of either the helper (hpAP) or Ad5 β dys, and the total number of cells used in each infection.

Figures 12A-B show Southern blot analyses of viral DNA from lysates 3, 6, 9 and 12, digested with the restriction enzymes *Bss*HII, *Nru*I and *Eco*RV. For the analyses, fragments from the C terminus of *mus musculus* dystrophin cDNA (A) or the N terminus of *E. coli* β -galactosidase (B) were labeled with dCTP 32 and used as probes.

Figures 13A-B show the physical separation of Ad5 β dys from hpAP virions at the third (A) and final (B) stages of CsCl purification.

Figure 14 graphically depicts the level of contamination of Ad5 β dys EAMs by hpAP virions obtained from the final stage of CsCl purification as measured by β -galactosidase and alkaline phosphatase expression. The ratio of the two types of virions - Ad5 β dys EAMs (LacZ) or hpAP (AP) in each fraction is indicated in the lower graph.

Figures 15A-B are western blot (immunoblot) analyses of protein extracts from *mdx* myoblasts and myotubes demonstrating the expression of β -galactosidase (A) and dystrophin (B) in cells infected with Ad5 β dys EAMs.

Figures 16A-C depict immunofluorescence of dystrophin expression in wild type MM14 myotubes (A), uninfected *mdx* (B) and infected *mdx* myotubes (C).

Figure 17 is a schematic representation of the MCK/lacZ constructs tested to determine what portion of the ~ 3.3 kb DNA fragment containing the enhancer/promoter of the MCK gene is capable of directing high levels of expression of linked genes in muscle cells.

Figure 18 is a schematic representation of a GFP/ β -gal reporter construct suitable for assaying the expression of *Cre* recombinase in mammalian cells.

Figure 19 is a schematic representation of the recombination event between the *loxP* shuttle vector and the Ad5 β dys genome.

DEFINITIONS

To facilitate understanding of the invention, a number of terms are defined below.

The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of a polypeptide or precursor thereof. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired enzymatic activity is retained. The term "gene" encompasses both cDNA and genomic forms of a given gene.

The term "wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the "normal" or "wild-type" form of the gene. In contrast, the term "modified" or "mutant" refers to a gene or gene product which displays modifications in sequence and/or functional properties (*i.e.*, altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

The term "oligonucleotide" as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, usually more than three (3), and typically more than ten (10) and up to one hundred (100) or more (although preferably between twenty and thirty). The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof.

As used herein, the term "regulatory element" refers to a genetic element which controls some aspect of the expression of nucleic acid sequences. For example, a promoter is a regulatory element which facilitates the initiation of transcription of an operably linked coding region. Other regulatory elements are splicing signals, polyadenylation signals, termination signals, etc. (*defined infra*).

Transcriptional control signals in eucaryotes comprise "promoter" and "enhancer" elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription [Maniatis, T. *et al.*, *Science* 236:1237 (1987)]. Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, *i.e.*, promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types [for review see Voss, S.D. *et al.*, *Trends Biochem. Sci.*, 11:287 (1986) and Maniatis, T. *et al.*, *supra* (1987)].

The term "recombinant DNA vector" as used herein refers to DNA sequences containing a desired coding sequence and appropriate DNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g.

mammal). DNA sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals and enhancers.

The terms "in operable combination", "in operable order" and "operably linked" as used herein refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.

The term "genetic cassette" as used herein refers to a fragment or segment of DNA containing a particular grouping of genetic elements. The cassette can be removed and inserted into a vector or plasmid as a single unit. A plasmid backbone refers to a piece of DNA containing at least plasmid origin of replication and a selectable marker gene (e.g., an antibiotic resistance gene) which allows for selection of bacterial hosts containing the plasmid; the plasmid backbone may also include a polylinker region to facilitate the insertion of genetic elements within the plasmid. When a particular plasmid is modified to contain non-plasmid elements (e.g., insertion of Ad sequences and/or a eukaryotic gene of interest linked to a promoter element), the plasmid sequences are referred to as the plasmid backbone.

Because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage, an end of an oligonucleotide is referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also may be said to have 5' and 3' ends.

When two different, non-overlapping oligonucleotides anneal to different regions of the same linear complementary nucleic acid sequence, and the 3' end of one oligonucleotide points towards the 5' end of the other, the former may be called the "upstream" oligonucleotide and the latter the "downstream" oligonucleotide.

The term "primer" refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. An oligonucleotide "primer" may occur naturally, as in a purified restriction digest or may be produced synthetically.

A primer is selected to be "substantially" complementary to a strand of specific sequence of the template. A primer must be sufficiently complementary to hybridize with a template strand for primer elongation to occur. A primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the strand. Non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridize and thereby form a template primer complex for synthesis of the extension product of the primer.

"Hybridization" methods involve the annealing of a complementary sequence to the target nucleic acid (the sequence to be detected). The ability of two polymers of nucleic acid containing complementary sequences to find each other and anneal through base pairing interaction is a well-recognized phenomenon. The initial observations of the "hybridization" process by Marmur and Lane, *Proc. Natl. Acad. Sci. USA* 46:453 (1960) and Doty *et al.*, *Proc. Natl. Acad. Sci. USA* 46:461 (1960) have been followed by the refinement of this process into an essential tool of modern biology.

The complement of a nucleic acid sequence as used herein refers to an oligonucleotide which, when aligned with the nucleic acid sequence such that the 5' end of one sequence is paired with the 3' end of the other, is in "antiparallel association." Certain bases not commonly found in natural nucleic acids may be included in the nucleic acids of the present invention and include, for example, inosine and 7-deazaguanine. Complementarity need not be perfect; stable duplexes may contain mismatched base pairs or unmatched bases. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length of the oligonucleotide, base composition and sequence of the oligonucleotide, ionic strength and incidence of mismatched base pairs.

Stability of a nucleic acid duplex is measured by the melting temperature, or " T_m ." The T_m of a particular nucleic acid duplex under specified conditions is the temperature at which on average half of the base pairs have disassociated. The equation for calculating the T_m of nucleic acids is well known in the art.

The term "probe" as used herein refers to a labeled oligonucleotide which forms a duplex structure with a sequence in another nucleic acid, due to complementarity of at least one sequence in the probe with a sequence in the other nucleic acid.

The term "label" as used herein refers to any atom or molecule which can be used to provide a detectable (preferably quantifiable) signal, and which can be attached to a nucleic acid or protein. Labels may provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption, magnetism, enzymatic activity, and the like.

The terms "nucleic acid substrate" and "nucleic acid template" are used herein interchangeably and refer to a nucleic acid molecule which may comprise single- or double-stranded DNA or RNA.

"Oligonucleotide primers matching or complementary to a gene sequence" refers to oligonucleotide primers capable of facilitating the template-dependent synthesis of single or double-stranded nucleic acids. Oligonucleotide primers matching or complementary to a gene sequence may be used in PCRs, RT-PCRs and the like.

A "consensus gene sequence" refers to a gene sequence which is derived by comparison of two or more gene sequences and which describes the nucleotides most often present in a given segment of the genes; the consensus sequence is the canonical sequence.

The term "polymorphic locus" is a locus present in a population which shows variation between members of the population (*i.e.*, the most common allele has a frequency of less than 0.95). In contrast, a "monomorphic locus" is a genetic locus at little or no variations seen between members of the population (generally taken to be a locus at which the most common allele exceeds a frequency of 0.95 in the gene pool of the population).

The term "microorganism" as used herein means an organism too small to be observed with the unaided eye and includes, but is not limited to bacteria, viruses, protozoans, fungi, and ciliates.

The term "microbial gene sequences" refers to gene sequences derived from a microorganism.

The term "bacteria" refers to any bacterial species including eubacterial and archaeabacterial species.

The term "virus" refers to obligate, ultramicroscopic, intracellular parasites incapable of autonomous replication (*i.e.*, replication requires the use of the host cell's machinery). Adenoviruses, as noted above, are double-stranded DNA viruses. The left and right inverted terminal repeats (ITRs) are short elements located at the 5' and 3' termini of the linear Ad genome, respectively and are required for replication of the viral DNA. The left ITR is located between 1-130 bp in the Ad genome (also referred to as 0-0.5 mu). The right ITR is

located from ~3.7500 bp to the end of the genome (also referred to as 99.5-100 mu). The two ITRs are inverted repeats of each other. For clarity, the left ITR or 5' end is used define the 5' and 3' ends of the ITRs. The 5' end of the left ITR is located at the extreme 5' end of the linear adenoviral genome: picturing the left ITR (LITR) as an arrow extending from the 5' end of the genome, the tail of the 5' ITR is located at mu 0 and the head of the left ITR is located at ~ 0.5 mu (further the tail of the left ITR is referred to as the 5' end of the left ITR and the head of the left ITR is referred to as the 3' end of the left ITR). The tail of the right or 3' ITR is located at mu 100 and the head of the right ITR is located at ~ mu 99.5; the head of the right ITR is referred to as the 5' end of the right ITR and the tail of the right ITR is referred to as the 3' end of the right ITR (RITR). In the linear Ad genome, the ITRs face each other with the head of each ITR pointing inward toward the bulk of the genome. When arranged in a "tail to tail orientation" the tails of each ITR (which comprise the 5' end of the LITR and the 3' end of the RITR) are located in proximity to one another while the heads of each ITR are separated and face outward (see for example, the arrangement of the ITRs in the EAM shown in Figure 10 herein). The "adenovirus packaging sequence" refers to the Ψ sequence which comprises five (AI-AV) packaging signals and is required for encapsidation of the mature linear genome: the packaging signals are located from ~194 to 358 bp in the Ad genome (about 0.5-1.0 mu).

The phrase "at least one adenovirus gene coding region" refers to a nucleotide sequence containing more than one adenovirus gene coding gene. A "helper adenovirus" or "helper virus" refers to an adenovirus which is replication-competent in a particular host cell (the host may provide Ad gene products such as E1 proteins), this replication-competent virus is used to supply *in trans* functions (e.g., proteins) which are lacking in a second replication-incompetent virus: the first replication-competent virus is said to "help" the second replication-incompetent virus thereby permitting the propagation of the second viral genome in the cell containing the helper and second viruses.

The term "containing a deletion within the E2b region" refers to a deletion of at least one basepair (preferably more than one bp and preferably at least 100 and most preferably more than 300 bp) within the E2b region of the adenovirus genome. An E2b deletion is a deletion that prevents expression of at least one E2b gene product and encompasses deletions within exons encoding portions of E2b-specific proteins as well as deletions within promoter and leader sequences.

An "adenovirus minichromosome" refers to a linear molecule of DNA containing the Ad ITRs on each end which is generated from a plasmid containing the ITRs and one or more gene of interest. The term "encapsidated adenovirus minichromosome" or "EAM" refers to an adenovirus minichromosome which has been packaged or encapsidated into a viral particle: plasmids containing the Ad ITRs and the packaging signal are shown herein to produce EAMs. When used herein, "recovering" encapsidated adenovirus minichromosomes refers to the collection of EAMs from a cell containing an EAM plasmid and a helper virus; this cell will direct the encapsidation of the minichromosome to produce EAMs. The EAMs may be recovered from these cells by lysis of the cell (e.g., freeze-thawing) and pelleting of the cell debris to a cell extract as described in Example 1 (Ex. 1 describes the recovery of Ad virus from a cell, but the same technique is used to recover EAMs from a cell). "Purifying" such minichromosomes refers to the isolation of the recovered EAMs in a more concentrated form (relative to the cell lysate) on a density gradient as described in Example 7: purification of recovered EAMs permits the physical separation of the EAM from any helper virus (if present).

The term "transfection" as used herein refers to the introduction of foreign DNA into eukaryotic cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.

The term "stable transfection" or "stably transfected" refers to the introduction and integration of foreign DNA into the genome of the transfected cell. The term "stable transfectant" refers to a cell which has stably integrated foreign DNA into the genomic DNA.

As used herein, the term "gene of interest" refers to a gene inserted into a vector or plasmid whose expression is desired in a host cell. Genes of interest include genes having therapeutic value as well as reporter genes. A variety of such genes are contemplated, including genes of interest encoding a protein which provides a therapeutic function (such as the dystrophin gene, which is capable of correcting the defect seen in the muscle of MD patients), the utrophin gene, the CFTR gene (capable of correcting the defect seen in cystic fibrosis patients), etc..

The term "reporter gene" indicates a gene sequence that encodes a reporter molecule (including an enzyme). A "reporter molecule" is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical

assays), fluorescent, radioactive, and luminescent systems. In one embodiment, the present invention contemplates the *E. coli* β -galactosidase gene (available from Pharmacia Biotech, Piscataway, NJ), green fluorescent protein (GFP) (commercially available from Clontech, Palo Alto, CA), the human placental alkaline phosphatase gene, the chloramphenicol acetyltransferase (CAT) gene; other reporter genes are known to the art and may be employed.

As used herein, the terms "nucleic acid molecule encoding," "DNA sequence encoding," and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.

DESCRIPTION OF THE INVENTION

The present invention provides improved adenovirus vectors for the delivery of recombinant genes to cells *in vitro* and *in vivo*. As noted above, the present invention contemplates two approaches to improving adenovirus vectors. The first approach generally contemplates a recombinant plasmid containing the minimal region of the Ad genome required for replication and packaging (*i.e.*, the left and right ITR and the packaging or Ψ sequence) along with one or more genes of interest; this recombinant plasmid is packaged into an encapsidated adenovirus minichromosome (EAM) when grown in parallel with an E1-deleted helper virus in a cell line expressing the E1 proteins (*e.g.*, 293 cells). The recombinant adenoviral minichromosome is preferentially packaged. To prevent the packaging of the helper virus, a helper virus containing *loxP* sequences flanking the Ψ sequence is employed in conjunction with 293 cells expressing *Cre* recombinase: *Cre-loxP* mediated recombination removes the packaging sequence from the helper genome thereby preventing packaging of the helper during the production of EAMs. In the second approach, "damaged" or "deleted" adenoviruses containing deletions within the E2b region are employed. While the "damaged" adenovirus is capable of self-propagation in a packaging cell line expressing the appropriate E2b protein(s), the E2b-deleted recombinant adenovirus are incapable of replicating and expressing late viral gene products outside of the packaging cell line.

In one embodiment, the self-propagating recombinant adenoviruses containing deletions in the E2b region of the adenovirus genome. In another embodiment, "gutted"

viruses are contemplated: these viruses lack all viral coding regions. In addition, packaging cell lines co-expressing E1 and E2b gene products are provided which allow the production of infectious recombinant virus containing deletions in the E1 and E2b regions without the use of helper virus.

5 The Description of the Invention is divided into the following sections: I. Self-Propagating Adenovirus Vectors; II. Packaging Cell Lines; and III. Encapsidated Adenoviral Minichromosomes.

I. Self-Propagating Adenovirus Vectors

10 Self-propagating adenovirus (Ad) vectors have been extensively utilized to deliver foreign genes to a great variety of cell types *in vitro* and *in vivo*. "Self-propagating viruses" are those which can be produced by transfection of a single piece of DNA (the recombinant viral genome) into a single packaging cell line to produce infectious virus: self-propagating viruses do not require the use of helper virus for propagation.

15 Existing Ad vectors have been shown to be problematic *in vivo*. This is due in part because current or first generation Ad vectors are deleted for only the early region 1 (E1) genes. These vectors are crippled in their ability to replicate normally without the trans-complementation of E1 functions provided by human 293 cells, a packaging cell line [ATCC CRL 1573; Graham *et al.* (1977) J. Gen. Virol. 36:59]. Unfortunately, with the use of high 20 titres of E1 deleted vectors, and the fact that there are E1-like factors present in many cell types, E1 deleted vectors can overcome the block to replication and express other viral gene products [Imperiale *et al.* (1984) Mol. Cell Biol. 4:867; Nevins (1981) Cell 26:213; and Gaynor and Berk (1983) Cell 33:683]. The expression of viral proteins in the infected target 25 cells elicits a swift host immune response, that is largely T-cell mediated [Yang and Wilson (1995) J. Immunol. 155:2564 and Yang *et al.* (1994) Proc. Natl. Acad. Sci. USA 91:4407]. The transduced cells are subsequently eliminated, along with the transferred foreign gene. In immuno-incompetent animals, Ad delivered genes can be expressed for periods of up to one year [Yang *et al.* (1994), *supra*; Vincent *et al.* (1993) Nature Genetics 5:130; and Yang *et al.* (1995) Proc. Natl. Acad. Sci. USA 92:7257].

30 Another shortcoming of first generation Ad vectors is that a single recombination event between the genome of an Ad vector and the integrated E1 sequences present in 293 cells can generate replication competent Ad (RCA), which can readily contaminate viral stocks.

In order to further cripple viral protein expression, and also to decrease the frequency of generating RCA, the present invention provides Ad vectors containing deletions in the E2b region. Propagation of these E2b-deleted Ad vectors requires cell lines which express the deleted E2b gene products. The present invention provides such packaging cell lines and for the first time demonstrates that the E2b gene products, DNA polymerase and preterminal protein, can be constitutively expressed in 293 cells along with the E1 gene products. With every gene that can be constitutively expressed in 293 cells comes the opportunity to generate new versions of Ad vectors deleted for the respective genes. This has immediate benefits: increased carrying capacity, since the combined coding sequences of the polymerase and preterminal proteins that can be theoretically deleted approaches 4.6 kb and a decreased incidence of RCA generation, since two or more independent recombination events would be required to generate RCA. Therefore, the novel E1, Ad polymerase and preterminal protein expressing cell lines of the present invention enable the propagation of Ad vectors with a carrying capacity approaching 13 kb, without the need for a contaminating helper virus [Mitani *et al.* (1995) Proc. Natl. Acad. Sci. USA 92:3854]. In addition, when genes critical to the viral life cycle are deleted (e.g., the E2b genes), a further crippling of Ad to replicate and express other viral gene proteins occurs. This decreases immune recognition of virally infected cells, and allows for extended durations of foreign gene expression. The most important attribute of E1, polymerase, and preterminal protein deleted vectors, however, is their inability to express the respective proteins, as well as a predicted lack of expression of most of the viral structural proteins. For example, the major late promoter (MLP) of Ad is responsible for transcription of the late structural proteins L1 through L5 [Doertler, In *Adenovirus DNA. The Viral Genome and Its Expression* (Martinus Nijhoff Publishing Boston, 1986)]. Though the MLP is minimally active prior to Ad genome replication, the rest of the late genes get transcribed and translated from the MLP only *after* viral genome replication has occurred [Thomas and Mathews (1980) Cell 22:523]. This cis-dependent activation of late gene transcription is a feature of DNA viruses in general, such as in the growth of polyoma and SV-40. The polymerase and preterminal proteins are *absolutely* required for Ad replication (unlike the E4 or protein IX proteins) and thus their deletion is extremely detrimental to Ad vector late gene expression.

II. Packaging Cell Lines Constitutively Expressing E2b Gene Products

The present invention addresses the limitations of current or first generation Ad vectors by isolating novel 293 cell lines coexpressing critical viral gene functions. The present invention describes the isolation and characterization of 293 cell lines capable of constitutively expressing the Ad polymerase protein. In addition, the present invention describes the isolation of 293 cells which not only express the E1 and polymerase proteins, but also the Ad-preterminal protein. The isolation of cell lines coexpressing the E1, Ad polymerase and preterminal proteins demonstrates that three genes critical to the life cycle of Ad can be constitutively coexpressed, without toxicity.

In order to delete critical genes from self-propagating Ad vectors, the proteins encoded by the targeted genes have to first be coexpressed in 293 cells along with the E1 proteins. Therefore, only those proteins which are non-toxic when coexpressed constitutively (or toxic proteins inducibly-expressed) can be utilized. Coexpression in 293 cells of the E1 and E4 genes has been demonstrated (utilizing inducible, not constitutive, promoters) [Yeh *et al.* (1996) J. Virol. 70:559; Wang *et al.* (1995) Gene Therapy 2:775; and Gorziglia *et al.* (1996) J. Virol. 70:4173]. The E1 and protein IX genes (a virion structural protein) have been coexpressed [Caravokyri and Leppard (1995) J. Virol. 69:6627], and coexpression of the E1, E4, and protein IX genes has also been described [Krougliak and Graham (1995) Hum. Gene Ther. 6:1575].

The present invention provides for the first time, cell lines coexpressing E1 and E2b gene products. The E2b region encodes the viral replication proteins which are absolutely required for Ad genome replication [Doerfler, *supra* and Pronk *et al.* (1992) Chromosoma 102:S39-S45]. The present invention provides 293 cells which constitutively express the 140 kD Ad-polymerase. While other researchers have reported the isolation of 293 cells which express the Ad-preterminal protein utilizing an inducible promoter [Schaack *et al.* (1995) J. Virol. 69:4079], the present invention is the first to demonstrate the high-level, constitutive coexpression of the E1, polymerase, and preterminal proteins in 293 cells, without toxicity. These novel cell lines permit the propagation of novel Ad vectors deleted for the E1, polymerase, and preterminal proteins.

III. Encapsidated Adenoviral Minichromosomes

The present invention also provides encapsidated adenovirus minichromosome (EAM) consisting of an infectious encapsidated linear genome containing Ad origins of replication, packaging signal elements, a reporter gene (e.g., a β -galactosidase reporter gene cassette) and a gene of interest (e.g., a full length (14 kb) dystrophin cDNA regulated by a muscle specific enhancer/promoter). EAMs are generated by cotransfected 293 cells with supercoiled plasmid DNA (e.g., pAd5 β dys) containing an embedded inverted origin of replication (and the remaining above elements) together with linear DNA from E1-deleted virions expressing human placental alkaline phosphatase (hpAP) (a helper virus). All proteins necessary for the generation of EAMs are provided *in trans* from the hpAP virions and the two can be separated from each other on equilibrium CsCl gradients. These EAMs are useful for gene transfer to a variety of cell types both *in vitro* and *in vivo*.

Adenovirus-mediated gene transfer to muscle is a promising technology for gene therapy of Duchenne muscular dystrophy (DMD). However, currently available recombinant adenovirus vectors have several limitations, including a limited cloning capacity of ~8.5 kb, and the induction of a host immune response that leads to transient gene expression of 3 to 4 weeks in immunocompetent animals. Gene therapy for DMD could benefit from the development of adenoviral vectors with an increased cloning capacity to accommodate a full length (~14 kb) dystrophin cDNA. This increased capacity should also accommodate gene regulatory elements to achieve expression of transduced genes in a tissue-specific manner. Additional vector modifications that eliminate adenoviral genes, expression of which is associated with development of a host immune response, might greatly increase long term expression of virally delivered genes *in vivo*. The constructed encapsidated adenovirus minichromosomes of the present invention are capable of delivering up to 35 kb of non-viral exogenous DNA. These minichromosomes are derived from bacterial plasmids containing two fused inverted adenovirus origins of replication embedded in a circular genome, the adenovirus packaging signals, a β galactosidase reporter gene and a full length dystrophin cDNA regulated by a muscle specific enhancer/promoter. The encapsidated minichromosomes are propagated *in vitro* by *trans*-complementation with a replication defective (E1+E3 deleted) helper virus. These minichromosomes can be propagated to high titer ($>10^8/\text{ml}$) and purified on CsCl gradients due to their buoyancy difference relative to helper virus. These vectors are able to transduce myogenic cell cultures and express dystrophin in myotubes. These results

demonstrate that encapsidated adenovirus minichromosomes are useful for gene transfer to muscle and other tissues.

The present invention further provides methods for modifying the above-described EAM system to enable the generation of high titer stocks of EAMs with minimal helper virus contamination. Preferably the EAM stocks contain helper virus representing less than 1%, 5 preferably less than 0.1% and most preferably less than 0.01% (including 0.0%) of the final viral isolate.

The amount of helper virus present in the EAM preparations is reduced in two ways. The first is by selectively controlling the relative packaging efficiency of the helper virus 10 versus the EAM virus. The *Cre-loxP* excision method is employed to remove the packaging signals from the helper virus thereby preventing the packaging of the helper virus used to provide in trans viral proteins for the encapsidation of the recombinant adenovirus minichromosomes. The second approach to reducing or eliminating helper virus in EAM stocks is the use of improve physical methods for separating EAM from helper virus.

15

EXPERIMENTAL

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

In the experimental disclosure which follows, the following abbreviations apply: M 20 (molar); mM (millimolar); μ M (micromolar); mol (moles); mmol (millimoles); μ mol (micromoles); nmol (nanomoles); mu or m.u. (map unit); g (gravity); gm (grams); mg (milligrams); μ g (micrograms); pg (picograms); L (liters); ml (milliliters); μ l (microliters); cm (centimeters); mm (millimeters); μ m (micrometers); nm (nanometers); hr (hour); min (minute); msec (millisecond); °C (degrees Centigrade); AMP (adenosine 5'-monophosphate); 25 cDNA (copy or complimentary DNA); DTT (dithiotheritol); ddH₂O (double distilled water); dNTP (deoxyribonucleotide triphosphate); rNTP (ribonucleotide triphosphate); ddNTP (dideoxyribonucleotide triphosphate); bp (base pair); kb (kilo base pair); TLC (thin layer chromatography); tRNA (transfer RNA); nt (nucleotide); VRC (vanadyl ribonucleoside complex); RNase (ribonuclease); DNase (deoxyribonuclease); poly A (polyriboadenylic acid); 30 PBS (phosphate buffered saline); OD (optical density); HEPES (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]); HBS (HEPES buffered saline); SDS (sodium dodecyl sulfate); Tris-HCl (tris[Hydroxymethyl]aminomethane-hydrochloride); rpm (revolutions per minute); ligation buffer (50 mM Tris-HCl, 10 mM MgCl₂, 10 mM

dithiothreitol, 25 µg/ml bovine serum albumin, and 26 µM NAD⁺, and pH 7.8); EGTA (ethylene glycol-bis(β-aminoethyl ether) N, N, N', N'-tetraacetic acid); EDTA (ethylenediaminetetraacetic acid); ELISA (enzyme linked immunosorbant assay); LB (Luria-Bertani broth: 10 g tryptone, 5 g yeast extract, and 10 g NaCl per liter, pH adjusted to 7.5 with 1N NaOH); superbroth (12 g tryptone, 24 g yeast extract, 5 g glycerol, 3.8 g KH₂PO₄, and 12.5 g K₂HPO₄ per liter); DMEM (Dulbecco's modified Eagle's medium); ABI (Applied Biosystems Inc., Foster City, CA); Amersham (Amersham Corporation, Arlington Heights, IL); ATCC (American Type Culture Collection, Rockville, MD); Beckman (Beckman Instruments Inc., Fullerton CA); BM (Boehringer Mannheim Biochemicals, Indianapolis, IN); Bio-101 (Bio-101, Vista, CA); BioRad (BioRad, Richmond, CA); Brinkmann (Brinkmann Instruments Inc., Wesbury, NY); BRL, Gibco BRL and Life Technologies (Bethesda Research Laboratories, Life Technologies Inc., Gaithersburg, MD); CRI (Collaborative Research Inc., Bedford, MA); Eastman Kodak (Eastman Kodak Co., Rochester, NY); Eppendorf (Eppendorf, Eppendorf North America, Inc., Madison, WI); Falcon (Becton Dickenson Labware, Lincoln Park, NJ); IBI (International Biotechnologies, Inc., New Haven, CT); ICN (ICN Biomedicals, Inc., Costa Mesa, CA); Invitrogen (Invitrogen, San Diego, CA); New Brunswick (New Brunswick Scientific Co., Inc., Edison, NJ); NEB (New England Biolabs Inc., Beverly, MA); NEN (Du Pont NEN Products, Boston, MA); Pharmacia (Pharmacia LKB Gaithersburg, MD); Promega (Promega Corporation, Madison, WI); Stratagene (Stratagene Cloning Systems, La Jolla, CA); UVP (UVP, Inc., San Gabriel, CA); USB (United States Biochemical Corp., Cleveland, OH); and Whatman (Whatman Lab. Products Inc., Clifton, NJ).

Unless otherwise indicated, all restriction enzymes and DNA modifying enzymes were obtained from New England Biolabs (NEB) and used according to the manufacturers directions.

25

EXAMPLE 1

Generation Of Packaging Cell Lines That Coexpress The Adenovirus E1 And DNA Polymerase Proteins

In this example, packaging cell lines coexpressing Ad E1 and polymerase proteins were described. These cell lines were shown to support the replication and growth of H5ts36, an Ad with a temperature-sensitive mutation of the Ad polymerase protein. These

polymerase-expressing packaging cell lines can be used to prepare Ad vectors deleted for the E1 and polymerase functions.

5 **a) Tissue Culture And Virus Growth**

LP-293 cells (Microbix Biosystems, Toronto) were grown and serially passaged as suggested by the supplier.

Plaque assays were performed in 60 mm dishes containing cell monolayers at ~ 90% confluence. The appropriate virus dilution in a 2% DMEM solution was dripped onto the cells, and the plates incubated at the appropriate temperature for one hour. The virus 10 containing media was aspirated, the monolayer was overlaid with 10 mls of a pre-warmed EMEM agar overlay solution (0.8% Noble agar, 4% fetal calf serum, and antibiotics) and allowed to solidify. After the appropriate incubation time (usually 7 days for incubations at 38.5°C and 10-12 days for incubations at 32°C), five mls of the agar-containing solution 15 containing 1.3% neutral red was overlaid onto the infected dishes and plaques were counted the next day. An aliquot of the virus H5ts36 [Freimuth and Ginsberg (1986) Proc. Natl. Acad. Sci. USA 83:7816] was utilized to produce high titre stocks after infection of 293 cells at 32°C. H5ts36 is an Ad5-derived virus defective for viral replication at the nonpermissive temperature [Miller and Williams (1987) J. Virol. 61:3630].

The infected cells were harvested after the onset of extensive cytopathic effect, 20 pelleted by centrifugation and resuspended in 10 mM Tris-Cl, pH 8.0. The lysate was freeze-thawed three times and centrifuged to remove the cell debris. The cleared lysate was applied to CsCl₂ step gradients (heavy CsCl at density of 1.45 g/ml, the light CsCl at density of 1.20 g/ml), ultracentrifuged, and purified using standard techniques [Graham and Prevec (1991) In *Methods in Molecular Biology, Vol 7: Gene Transfer and Expression Protocols*, Murray 25 (ed.), Humana Press, Clifton, NJ, pp. 109-128]. The concentration of plaque forming units (pfu) of this stock was determined at 32°C as described above. Virion DNA was extracted from the high titre stock by pronase digestion, phenol-chloroform extraction, and ethanol precipitation. The leakiness of this stock was found to be <1 in 2000 pfu at the non-permissive temperature, consistent with previous reports [Miller and Williams (1987), *supra*].

30 **b) Plasmids**

The expression plasmid pRSV-pol [Zhao and Padmanabhan (1988) Cell 55:1005] contains sequences encoding the Ad2 polymerase mRNA (including the start codon from the

exon at map unit 39) under the transcriptional control of the Rous Sarcoma Virus

LTR/promoter element: the Ad2 DNA polymerase sequences are flanked on the 3' end by the SV-40 small t intron and SV-40 polyadenylation addition site (see Fig. 1A). Figure 1A provides a schematic representation of the Ad polymerase expression plasmid pRSV-pol.

5 pRSV-pol includes the initiator methionine and amino-terminal peptides encoded by the exon at m.u. 39 of the Ad genome. The location of the PCR primers p602a and p2158c, the two *Scal* 1 kb probes utilized for Northern analyses, the polymerase terminator codon, and the polyadenylation site of the IVa2 gene (at 11.2 m.u. of the Ad genome) are indicated.

10 The expression plasmid pRSV-pTP [Zhao and Padmanabhan (1988), *supra*] contains sequences encoding the Ad2 preterminal protein (including the amino terminal peptides encoded by the exon at map unit 39 of the Ad genome) under the transcriptional control of the Rous Sarcoma Virus LTR/promoter element; the pTP sequences are flanked on the 3' end by the SV-40 small-t intron and SV-40 polyadenylation signals (see Figure 1B for a schematic of pRSV-PTP). Figure 1B also shows the location of the *EcoRV* subfragment utilized as a 15 probe in the genomic DNA and cellular RNA evaluations, as well as the initiator methionine codon present from map unit 39 in the Ad5 genome. The locations of the H5in190 and H5sub100 insertions are shown relative to the preterminal protein open-reading frame. The following abbreviations are used in Figure 1: ORF, open reading frame; small-t, small tumor antigen, and m.u., map unit.

20 pCEP4 is a plasmid containing a hygromycin expression cassette (Invitrogen).

pFG140 (Microbix Biosystems Inc. Toronto, Ontario) is a plasmid containing sequences derived from Ad5d/309 which contain a deletion/substitution in the E3 region [Jones and Shek (1979) Cell 17:683]. pFG140 is infectious in single transfections of 293 cells and is used as a control for transfection efficiency.

25

c) Transfection Of 293 Cells

LP-293 cells were cotransfected with *Bam*HI linearized pRSV-pol and *Bam*HI linearized pCEP4 at a molar ratio of 10:1 using a standard CaPO₄ precipitation method [Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press. Plainview, NY, pp.16.33-16.36]. In addition, 293 cells were cotransfected with or with *Bam*HI linearized pRSV-pol, *Bam*HI linearized pRSV-pTP and pCEP using a molar ratio of 10:1 (non-selectable:selectable plasmids).

Forty-eight hours after transfection, the cells were passaged into media containing hygromycin at 100 µg/mL. Individual hygromycin resistant colonies were isolated and expanded.

5

d) Isolation Of Ad Polymerase Expressing 293 Cell Lines

Twenty hygromycin resistant cell lines were expanded and screened for the ability to express the Ad polymerase protein. Initially, the individual cell lines were assayed for the ability to support growth of the viral polymerase mutant H5ts36 using the plaque assay described in section a) above. It was speculated that constitutive expression of the wild type 10 Ad polymerase protein in a clonal population of 293 cells should allow the growth of H5ts36 at 38.5°C. However, it was unclear if constitutive expression of the Ad polymerase would be toxic when coexpressed with the E1 proteins present in 293 cells. Similar toxicity problems have been observed with the Ad ssDBP, and the pTP [Klessig *et al.* (1984) Mol. Cell. Biol. 4:1354 and Schaack *et al.* (1995) J. Virol. 69:4079].

15

Of the twenty hygromycin resistant cell lines isolated, seven were able to support plaque formation with H5ts36 at the non-permissive temperature, unlike the parental LP-293 cells: these cell lines were named B-6, B-9, C-1, C-4, C-7, C-13 and C-14 (see Table 1) (the B-6 and B-9 cell lines received only the pRSV-pol and CEP4 plasmids; C-1, C-4, C-7, C-13 and C-14 cell lines received the pRSV-pol, pRSV-pTP and CEP4 plasmids). For the results 20 shown in Table 1, dishes (60 mm) of near confluent cells of each cell line were infected with the same dilution of H5ts36 at the temperature indicated, overlaid with agar media, and stained for plaques as outlined in section a. Passage number refers to the number of serial passages after initial transfection with the plasmid pRSV-pol.

25

The cell line B-6 produced plaques one day earlier than the other Ad polymerase-expressing cell lines, which may reflect increased polymerase expression (see below). Cell line B-9 demonstrated an increased doubling time whereas each of the other cell lines displayed no growth disadvantages relative to the parental LP-293 cells. As shown in Table 1, even after multiple passages (in some instances up to four months of serial passaging) the cells were still capable of H5ts36 plaque formation at the non-permissive temperature, 30 indicating that the RSV-LTR/promoter remained active for extended periods of time. However, the cell lines B-9 and C-13 displayed a decreased ability to plaque the virus at 32°C as well as at 38.5°C, suggesting that a global viral complementation defect had occurred in

these cell lines after extended passaging. The remaining cell lines screened at later passages demonstrated no such defect, even after 20 passages (e.g., cell line B-6, Table 1).

TABLE I

Plaques Ability Of H5ts36 At The Non-Permissive Temperature Utilizing 293-Ad Polymerase Expressing Cell Lines

Cell Line	Passage Number	Number Of Plaques At:	
		32.0°C	38.5°C
293	-	>500	0
B-6	9	>500	>500
	20	>500	>500
B-9	5	>500	>500
	14	90	18
C-1	5	>500	>500
	13	>500	>500
C-4	5	>500	>500
	14	>500	>500
C-7	5	>500	>500
	14	>500	>500
C-13	5	>500	>500
	27	120	4
C-14	5	>500	>500
	27	>500	370

e) Genomic Analysis Of Ad Polymerase-Expressing Cell Lines

Genomic DNA from LP-293 cells and each of the seven cell lines able to complement H5ts36 at 38.5°C were analyzed by PCR for the presence of pRSV-pol derived sequences. Genomic DNA from LP-293 cells and the hygromycin resistant cell lines were harvested using standard protocols (Sambrook *et al.*, *supra*) and 200 ng of DNA from each cell line was analyzed by PCR in a solution containing 2 ng/mL of primers p602a and p2158c, 10 mM Tris HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, and 0.001% gelatin. The forward primer, p602a [5'-TTCATTTATGTTCAAGGTTC AGGG-3' (SEQ ID NO:2)] is located in the SV-40 polyadenylation sequence. The reverse primer p2158c [5'-TTACCGCCACACTCGCAGGG-3' (SEQ ID NO:3)] is Ad-sequence specific with the 5' nucleotide located at position 3394 of the Ad 5 genome [numbering according to Doerfler

(1986) *Adenovirus DNA. The Viral Genome and Its Expression.* Nijhoff. Boston, MA. pp. 1-95].

PCR was performed with a Perkin Elmer 9600 Thermocycler utilizing the following cycling parameters: initial denaturation at 94°C for 3 min. 3 cycles of denaturation at 94°C for 30 sec. annealing at 50°C for 30 sec. and extension at 72°C for 60 sec. followed by another 27 cycles with an increased annealing temperature at 56°C. with a final extension at 72°C for 10 minutes. PCR products were separated on a 1.0 % agarose gel and visualized with ethidium bromide staining (Figure 2). A 1 kb ladder (Gibco-BRL) was used as a size marker, and the plasmid pRSV-pol was used as a positive control. The ~750 bp PCR products are indicated by an arrow in Figure 2.

As shown in Figure 2, all cell lines capable of H5ts36 plaque formation at 38.5°C contained the Ad pol DNA sequences, whereas the LP-293 cells did not yield any amplification product with these primers. This result demonstrates that each of the selected cell lines stably co-integrated not only the hygromycin resistance plasmid pCEP4, but also pRSV-pol.

□ Complementation Of The Replication Defect Of H5ts36 By Ad Polymerase Expressing Cell Lines

The C to T transition at position 7623 of the H5ts36 genome alters the DNA binding affinity of the Ad polymerase protein, rendering it defective for viral replication at non-permissive temperatures [Chen *et al.* (1994) *Virology* 205:364; Miller and Williams (1987) *J. Virol.* 61:3630; and Wilkie *et al.* (1973) *Virology* 51:499]. To analyze the functional activity of the Ad polymerase protein expressed by each of the packaging cell lines, a viral replication-complementation assay was performed. LP-293 cells or the hygromycin resistant cell lines were seeded onto 60 mM dishes at densities of 2.5-3.0 x 10⁶ per dish, infected with H5ts36 at a multiplicity of infection (MOI) of 10, and incubated for 24 hours at 38.5°C, or 48 hours at 32°C. Total DNA was harvested from each plate, then 2 µg of each sample were digested with *Hind*III, separated on a 1.0% agarose gel, transferred to a nylon membrane, and hybridized with ³²P-labeled H5ts36 virion DNA. Densitometric analysis of the 8.010 bp *Hind*III fragment in each lane was performed on a phosphorimager (Molecular Dynamics) utilizing a gel image processing system (IP Lab Version 1.5, Sunnyvale, CA).

The resulting autoradiograph is shown in Figure 3. In Figure 3, the lane marked "Std." (standard) contains 1 µg of *Hind*III-digested H5ts36 virion DNA. The 8.010 bp *Hind*III fragments analyzed by densitometry are indicated by an arrow.

As shown in Figure 3, H5ts36 had a diminished ability to replicate in LP-293 cells at 5 the non-permissive temperature. In contrast, all seven of the previously selected cell lines were able to support replication of H5ts36 virion DNA at 38.5°C to levels approaching those occurring in LP-293 cells at 32°C.

A densitometric analysis of the amount of H5ts36 viral DNA replicated in each of the 10 cell lines at permissive and nonpermissive temperatures is presented in Table 2 below. For this assay, the relative amounts of the 8.010 bp *Hind*III fragment were compared. The 15 relative levels of H5ts36 virion DNA replication determined by densitometric analysis of the 8.010 bp *Hind*III fragment isolated from each of the cell line DNA samples. The surface area of the 8.010 bp fragment in 293 cells incubated at 38.5°C was designated as 1, and includes some replicated H5ts36 virion DNA. The numbers in each column represent the ratio between the densities of the 8.010 bp fragment isolated in the indicated cell line and the density of the same band present in LP-293 cells at 38.5°C.

As shown in Table 2, the levels of replication at the permissive temperature were all 20 within four-fold of each other, regardless of which cell line was analyzed, but at the non-permissive temperature LP-293 cells reveal the H5ts36 replication defect. The viral bands that were present in the LP-293 DNA sample at 38.5°C represented input virion DNA as well as low level replication of H5ts36 DNA, which is generated due to the leakiness of the ts mutation at the high MOI utilized in this experiment. The Ad polymerase-expressing cell lines were all found to be capable of augmenting

TABLE 2

Densitometric Analysis Of H5ts36 Replication

Cell Line	Ratios Of 8.010 bp HindIII Fragment Generated At:	
	32.0°C	38.5°C
LP-293	42.6	1.0
B-6	27.3	57.2
B-9	69.0	15.8
C-1	113.6	34.1
C-4	100.2	65.5
C-7	114.9	75.0
C-13	43.1	42.2
C-14	46.7	27.8

H5ts36 genome replication. Although one cell line (B-9) allowed H5ts36 replication to levels only 16 fold greater than LP-293 cells, this was the same cell line that was observed to display poor growth properties. Each of the remaining Ad polymerase-expressing cell lines allowed substantially greater replication of H5ts36 at non-permissive temperatures, compared to LP-293 cells (Table 2). An enhancement of replication up to 75 fold above that of LP-293 cells was observed with the cell line C-7 at 38.5°C. A substantially more rapid onset of viral cytopathic effect in Ad polymerase-expressing cell lines was observed at either temperature. These estimates of H5ts36 replication-complementation are conservative, since they have not been adjusted for the low level replication of H5ts36 at 38.5°C [Miller and Williams (1987), *supra*]. The leakiness of the H5ts36 mutation could potentially be overcome with the use of a virus deleted for the Ad polymerase gene.

25

g) RNA Analysis Of Ad Polymerase-Expressing Cell Lines

Total RNA was extracted from each of the cell lines using the RNAzol method (Teltest, Inc., Friendswood, TX 77546; Chomczynski and Sacchi (1987) Anal. Biochem. 162:156]. Fifteen micrograms of RNA from each cell line was electrophoresed on a 0.8% agarose-formaldehyde gel, and transferred to a Nytran membrane (Schleicher & Schuell) by blotting. The filter was UV crosslinked, and analyzed by probing with the two ³²P-labeled 1 kb *Scal* subfragments of Ad which span positions 6095-8105 of the Ad5 genome (see Figure 1A). These two *Scal* subfragments of the Ad genome are complimentary to the 5' end of the Ad polymerase mRNA. The resulting autoradiograph is shown in Figure 4. In Figure 4, the

location of the smaller and larger species of Ad polymerase mRNA are indicated relative to the 28S and 18S ribosomal RNAs. The aberrant transcript expressed by the B-9 cell line is indicated by an arrow.

The results shown in Figure 4 revealed that the RNA derived from cell lines B-6 and 5 C-7 contained two species of RNA, estimated to be ~4800 and ~7000 nt in length, while LP-293 derived RNA had no detectable hybridization signal. The presence of two polymerase RNA species suggests that the polyadenylation signal of the Ad IVa2 gene (present in the Ad-pol construct, see Fig. 1A) is being utilized by the cell RNA processing machinery, in addition to the SV-40 polyadenylation signal. Similar analysis of RNA derived from the cell lines C-1, 10 C-4, C-13, and C-14 also detected the same two transcripts as those detected in the RNA of cell lines B-6 and C-7, but at decreased levels, suggesting that even low levels of Ad polymerase mRNA expression can allow for the efficient replication of polymerase mutants such as H5ts36. The cell line B-6 expressed high levels of polymerase transcript and can plaque H5ts36 one day earlier than the other cell lines at 38.5°C, suggesting a causal 15 relationship. It is interesting to note that the two polymerase transcripts are also detected in RNA isolated from cell line B-9, but substantial amounts of a larger RNA transcript (size > 10 kb) is also present (see Figure 4). The high level production of the aberrant message may be related to the increased doubling time previously noted in this cell line.

20

h) Transfectability Of Ad Polymerase-Expressing Cell Lines

The ability of Ad polymerase-expressing 293 cell lines to support production of H5ts36 virions after transfection with H5ts36 genome DNA was examined as follows. 293 cells as well as hygromycin resistant cell lines were grown to near confluence on 60 mm dishes and transfected with either 3 µg of purified H5ts36 virion DNA, or with 3.5 µg of the 25 plasmid pFG140 (Microbix Biosystems), using the cationic lipid Lipofectamine (Gibco-BRL). Cells that received the H5ts36 virion DNA were incubated at 32°C for 14 days, or 38.5°C for 10 days. The pFG140 transfected cells were incubated at 37.5°C for 10 days. All plates were then stained with the neutral red agar overlay and plaques were counted the next day. The results are shown in Table 3.

TABLE 3

Transfection Efficiency Of Ad pol-Expressing Cell Lines

Cell line	Number Of Plaques At:	
	32.0°C	38.5°C
LP-293	>500	0
B-6	>500	~500
B-9	n.d.*	n.d.
C-1	n.d.	>500
C-4	n.d.	>500
C-7	n.d.	>500
C-13	n.d.	100
C-14	n.d.	>500

n.d. = not determined.

The results shown in Table 3 demonstrated that transfection of H5ts36 DNA at the non-permissive temperature allows for ample plaque production in all of the Ad polymerase-expressing cell lines tested, unlike the parental LP-293 cells. Cell line C-13 was at passage number 29, and demonstrated a somewhat decreased ability to generate plaques at this extended passage number. These same cell lines are also capable of producing plaques when transfected with the plasmid pFG140, a plasmid capable of producing infectious, E1 dependent Ad upon transfection of the parental 293 cells [Ghosh-Choudhury (1986) Gene 50:161]. These observations suggest that the Ad polymerase expressing cell lines should be useful for the production of second generation Ad vectors deleted not only for the E1 genes, but also for the polymerase gene. As shown below in Examples 2 and 3, this is indeed the case.

EXAMPLE 2

Isolation And Characterization Of Packaging Cell Lines That
Coexpress The Adenovirus E1, DNA Polymerase And Preterminal Proteins

30

In Example 1, packaging cell lines coexpressing Ad E1 and polymerase proteins were described. These cell lines were shown to support the replication and growth of H5ts36, an Ad with a temperature-sensitive mutation of the Ad polymerase protein. These polymerase-

expressing packaging cell lines can be used to prepare Ad vectors deleted for the E1 and polymerase functions. In this example, 293 cells cotransfected with both Ad polymerase and preterminal protein expression plasmids are characterized. Cell lines co-expressing the Ad E1, polymerase and preterminal proteins can be used to prepare Ad vectors deleted for the E1, polymerase and preterminal protein (pTP) functions.

5 **a) Tissue Culture And Virus Propagation**

The use of LP-293 cells (Microbix Biosystems Inc., Toronto), Ad-polymerase expressing cell lines, and plaque efficiency assays of Ad viruses was conducted as described 10 in Example 1. All cells were maintained in 10% fetal bovine serum supplemented DMEM media (GIBCO) in the presence of antibiotics. The virus H5sub100 [Freimuth and Ginsberg (1986) Proc. Natl. Acad. Sci. USA 83:7816] has a temperature sensitive (ts) mutation caused by a three base pair insertion within the amino terminus of the preterminal protein, in addition to a deletion of the E1 sequences (see Figure 1B). H5sub100 was propagated and titred at 15 32.0°C in LP-293 cells; the leakiness of this stock was less than 1 per 1000 plaque-forming units (pfu) at the nonpermissive temperature of 38.5°C. A lower titer cell lysate containing the virus H5in190 (which contains a 12 base-pair insertion within the carboxy-terminus of the preterminal protein as well as a deletion of the E1 region, see Figure 1B) was provided by Dr. P. Freimuth [Freimuth and Ginsberg (1986), *supra*]. The polymerase and preterminal protein 20 expressing cell lines were always maintained in media supplemented with hygromycin (Sigma) at 100 µg/mL.

25 **b) Isolation Of Ad Polymerase And Preterminal Protein Expressing 293 Cells**

The C-1, C-4, C-7, C-13, and C-14 cell lines (Ex. 1), which had been cotransfected with pRSV-pol, pRSV-pTP and CEP4, were screened for presence of pTP sequences and for the ability to support the growth of H5ts36 (ts for the Ad-polymerase), H5in190, and H5sub100 using plaque assays as described in Example 1.

i) Analysis Of Genomic DNA And Cellular RNA

Cell lines that had received the preterminal protein expression plasmid were screen for the presence of pRSV-pTP sequences and E1 sequences. Total DNA was isolated from the LP-293, B-6 (transfected with pRSV-pol only) or C-7 (cotransfected with pRSV-pol and pRSV-pTP) cell lines. two micrograms (μ g) of each DNA was codigested with the restriction enzymes *Xba*I and *Bam*HI, electrophoretically separated in a 0.6% agarose gel, and transferred onto a nylon membrane. The membrane was UV crosslinked, probed with both a 1.8 kb *Blnl-Xba*I fragment (spans the E1 coding region) isolated from the plasmid pFG140, and a 1.8kb *EcoRV* subfragment of Ad serotype 5 (spans the preterminal protein coding sequences; see Fig. 1B), both of which were random-primer radiolabeled with 32 P to a specific activity greater than 3.0×10^8 cpm/ μ g. The membrane was subsequently exposed to X-ray film with enhancement by a fluorescent screen. The resulting autoradiograph is shown in Figure 5.

In Figure 5, the preterminal specific sequences migrated as an ~11.0 kb DNA fragment while the E1 containing band migrated as a 2.3 kb DNA fragment. No hybridization of either probe to DNA isolated from either the LP-293 or B-6 cell lines was observed. As shown in Figure 5, only the C-7 cell line genomic DNA had preterminal coding sequences, unlike the parental LP-293 cells, or the Ad-polymerase expressing B-6 cells. In addition, all cell lines had E1 specific sequences present at nearly equivalent amounts, demonstrating that the selection design has not caused the loss of the E1 sequences originally present in the LP-293 cells. The results presented in Example 1 demonstrated that both the B-6 and C-7 cell lines contain polymerase specific sequences within their genomes, unlike the parental LP-293 cells.

To confirm that transcription of preterminal protein was occurring, total RNA was isolated from each of the cell lines, transferred to nylon membranes, and probed to detect preterminal protein-specific mRNA transcripts as follows. Total cellular RNA was isolated from the respective cell lines and 15 μ g of total RNA from each cell line was transferred to nylon membranes. The membranes were probed with the 1.8 kb *EcoRV* radiolabeled subfragment of Ad5 (see Fig. 1B) complementary to the preterminal protein coding region. The resulting autoradiograph is shown in Figure 6.

As shown in Figure 6, a single mRNA of the expected size (~3 kb in length) is detected only in RNA derived from the C-7 cell line. No hybridization was detected in lanes containing RNA derived from the LP-293 or B-6 cell lines. In Example 1, it was demonstrated that the C-7 cell line also expresses high levels of the Ad polymerase mRNA.

Thus, the C-7 cell line constitutively expresses both the Ad polymerase and preterminal protein mRNAs along with E1 transcripts.

5 ii) Plaquing Efficiency Of pTP Mutants On pTP-Expressing Cell Lines

The C-7 cell line was screened for the ability to transcomplement the growth of preterminal mutant viruses. The virus H5in190 (contains a 12 base pair insertion located within the carboxy-terminus of the preterminal protein) has been shown to have a severe growth and replication defect, producing less than 10 plaque-forming units per cell [Freimuth and Ginsberg (1986) Proc. Natl. Acad. Sci. USA 83:7816]. The results are summarized in Table 4 below. For the results shown in Table 4, LP-293, B-6, or C-7 cells were seeded at a density of $2.0\text{-}2.5 \times 10^6$ cells per plate. The cells were infected with limiting dilutions of lysates derived from the preterminal protein-mutant viruses H5in190 or H5sub100, incubated at 38.5°C, and plaques counted after six days. As shown in Table 4, only the C-7 cell line could allow efficient plaque formation of H5in190 at 38.5°C (the H5in190 lysate used to infect the cells was of a low titer, relative to the high titer H5sub100 stock), while both the B-6 and C-7 cell lines had nearly equivalent plaquing efficiencies when H5sub100 was utilized as the infecting virus.

20 TABLE 4
Plaquing Efficiency Of Preterminal Protein-Mutant Viruses

Virus	Mutation Location	Plaque Titres (pfu/ml)		
		LP-293	B-6	C-7
H5in190	carboxy-terminus	$\leq 1 \times 10^2$	$\leq 1 \times 10^2$	1.4×10^5
H5sub100	amino-terminus	$\leq 1 \times 10^4$	9.0×10^3	4.5×10^5

25 As shown in Table 4, when equivalent dilutions of H5in190 were utilized, the plaquing efficiency of the C-7 cell line was at least 100-fold greater than that of the B-6 or LP-293 cells. This result demonstrated that the C-7 cell line produces a functional preterminal protein, capable of trans-complementing the defect of the H5in190 derived preterminal protein.

30 The cell lines were next screened for the ability to trans-complement with the temperature-sensitive virus, H5sub100, at nonpermissive temperatures. H5sub100 has a codon insertion mutation within the amino-terminus of the preterminal protein, as well as an E1 deletion. The mutation is responsible both for a temperature sensitive growth defect, as well

as a replication defect [Freimuth and Ginsberg (1986), *supra* and Schaack *et al.* (1995) J. Virol. 69:4079]. The plaquing efficiency of the cell line C-7 was found to be at least 1000 fold greater than that of the LP-293 cells (at non-permissive temperatures) (see Table 4). Interestingly, the cell line B-6 was also capable of producing large numbers of H5sub100 derived plaques at 38.5°C, even though it does not express any preterminal protein. This result suggested that the high level expression of the polymerase protein was allowing plaque formation of H5sub100 in the B-6 cell line. To examine this possibility, the nature of H5sub100 growth in the various cell lines was examined.

10

c) Complementation Of The Replication And Growth Defects Of H5sub100

15

The cell lines B-6 and C-7 were shown to overcome the replication defect of H5ts36 (Ex. 1). Since the preterminal and polymerase proteins are known to physically interact with each other [Zhao and Padmanabhan (1988) Cell 55:1005], we investigated whether the expression of the Ad-polymerase could overcome the replication defect of H5sub100 at non-permissive temperatures using the following replication-complementation assay.

20

LP-293, B-6, or C-7 cells were seeded onto 60 mM dishes at a density of 2×10^6 cells per dish and infected the next day with H5sub100 at a multiplicity of infection (MOI) of 0.25, and incubated at 38.5°C for 16 hours or 32.0°C for 40 hours. The cells from each infected plate were then harvested and total DNA extracted as described in Example 1. Four micrograms of each DNA sample was digested with *Hind*III, electrophoresed through a 0.7% agarose gel, transferred to a nylon membrane, and probed with ^{32}P -labeled H5ts36 virion DNA. The resulting autoradiograph is shown in Figure 7. As seen in Figure 7, the H5sub100 replication defect when grown in LP-293 cells at 38.5°C is seen; this defect is not present when the virus is grown at the same temperature in either B-6 or C-7 cells.

25

The results depicted in Figure 7 demonstrates that both cell lines B-6 and C-7 could trans-complement the replication defect of H5sub100. This result demonstrated that the expression of the Ad polymerase in B-6 cells was able to overcome the preterminal protein-mediated replication defect of H5sub100. While not limiting the present invention to any particular mechanism, the ability of Ad polymerase to overcome the preterminal protein-mediated replication defect of H5sub100 may be due to a direct physical interaction of the polymerase with the amino-terminus of the H5sub100-derived preterminal protein.

In support of this hypothesis, it has also been demonstrated that the H5sub100 replication defect can be overcome when LP-293 cells were infected with a 100-fold greater amount of H5sub100. However, complementation of the H5sub100 replication defect is not sufficient to overcome the growth defect of H5sub100, since temperature shift-up experiments have demonstrated that the H5sub100 growth defect is not dependent upon viral replication [Schaack *et al.* (1995), *supra*]. Therefore, the overexpression of the Ad-polymerase must have allowed a very low level but detectable production of infectious H5sub100 particles in the B-6 cell line. The reduced growth of H5sub100 is therefore not due to a replication defect, but rather some other critical activity that the preterminal protein has a role in, such as augmentation of viral transcription by association with the nuclear matrix [Schaack and Shenk (1989) Curr. Top. Microbiol. Immunol. 144:185 and Hauser and Chamberlain (1996) J. Endo. 149:373]. This was confirmed by assessing the ability of the C-7 cell line to overcome the growth defect of H5sub100 utilizing one-step growth assays performed as follows.

Each of the cell lines (LP-293, B-6 and C-7) were seeded onto 60 mm dishes at 2.0 x 10⁵ cells/dish. The cell lines were infected at an MOI of 4 with each of the appropriate viruses (wtAd5, H5ts36, or H5sub100), and incubated at 38.5°C for 40 hours. The total amount of infectious virions produced in each 60 mm dish was released from the cell lysates by three cycles of freeze-thawing, and the titer was then determined by limiting dilution and plaque assay on B-6 cells at 38.5°C. The results are summarized in Figure 8.

The results shown in Figure 8, demonstrated that even though the B-6 cell line allowed normal replication and plaque formation of H5sub100 at 38.5°C (in fact, B-6 cells were utilized to determine the plaque titres depicted in Figure 8) they could not allow high level growth of H5sub100 and only produced titres of H5sub100 equivalent to that produced by the LP-293 cells. The C-7 cell line produced 100 fold more virus than the LP-293 or B-6 cells, see Figure 8. Encouragingly, the titre of H5sub100 produced by the C-7 cells approached titres produced by LP-293 cells infected with wild-type virus, Ad5. When the H5sub100 virions produced from infection of the C-7 cells were used to infect LP-293 cells at 38.5°C, all virus produced retained the *rs* mutation (*i.e.*, at least a 1000 fold drop in pfu was detected when LP-293 cells were respectively infected at 38.5°C vs. 32.0°C). This finding effectively rules out the theoretical possibility that the H5sub100 input virus genomes recombined with the preterminal protein sequences present in the C-7 cells.

In addition, the C-7 cell line allowed the high level growth of H5ts36, demonstrating that adequate amounts of the Ad-polymerase protein were also being expressed. The C-7 cell

line was capable of trans-complementing the growth of both H5ts36 and H5sub100 after 4 months of serial passaging, demonstrating that the coexpression of the E1, preterminal, and polymerase proteins was not toxic.

These results demonstrate that the constitutive expression of both the polymerase and preterminal proteins is not detrimental to normal virus production, which might have occurred if one or both of the proteins had to be expressed only during a narrow time period during the Ad life cycle. In summary, these results demonstrated that the C-7 cell line can be used as a packaging cell line to allow the high level growth of E1, preterminal, and polymerase deleted Ad vectors.

10

EXAMPLE 3

Production Of Adenovirus Vectors Deleted For E1 And Polymerase Functions

In order to produce an Ad vectors deleted for E1 and polymerase functions, a small, frame-shifting deletion was introduced into the Ad-pol gene contained within an E1-deleted Ad genome. The plasmid pBHG11 (Microbix) was used as the source of an E1-deleted Ad genome. pBHG11 contains a deletion of Ad5 sequences from bp 188 to bp 1339 (0.5-3.7 m.u.); this deletion removes the packaging signals as well as E1 sequences. pBHG11 also contains a large deletion within the E3 region (bp 27865 to bp 30995; 77.5-86.2 m.u.). The nucleotide sequence of pBHG11 is listed in SEQ ID NO:4 [for cross-correlation between the pBHG11 sequence and the Ad5 genome (SEQ ID NO:1), it is noted that nucleotide 8.773 in pBHG11 is equivalent to nucleotide 7.269 in Ad5].

pBHG11 was chosen to provide the Ad backbone because this plasmid contains a large deletion within the E3 region (77.5 to 86.2 m.u.) and therefore vectors derived from this plasmid permit the insertion of large pieces of foreign DNA. A large cloning capacity is important when the pol⁻ vectors is to be used to transfer a large gene such as the dystrophin gene (cDNA = 13.6 kb). However, the majority of genes are not this large and therefore other Ad backbones containing smaller deletions within the E3 region (e.g., pBHG10 which contains a deletion between 78.3 to 85.8 m.u.; Microbix) may be employed for the construction of pol⁻ vectors using the strategy outlined below.

a) **Construction Of A Plasmid Containing A Portion Of The Adenovirus Genome Containing The Polymerase Gene**

A fragment of the Ad genome containing the pol gene located on pBHG11 was subcloned to create pBSA-XB. Due to the large size of the Ad genome, this intermediate plasmid was constructed to facilitate the introduction of a deletion within the pol gene the pol deletion. pBSA-XB was constructed as follows. The polylinker region of pBluescript (Stratagene) was modified to include additional restriction enzyme recognition sites (the sequence of the modified polylinker is provided in SEQ ID NO:5; the remainder of pBluescript was not altered); the resulting plasmid was termed pBSX. pBHG11 was digested with *Xba*I and *Bam*HI and the 20.223 kb fragment containing the pol and pTP coding regions (E2b region) was inserted into pBSX digested with *Xba*I and *Bam*HI to generate pBSA-XB.

b) **Construction Of pBHG11Δpol**

A deletion was introduced into the pol coding region contained within pBSA-XB in such a manner that other key viral elements were not disturbed (e.g., the major late promoter, the tripartite leader sequences, the pTP gene and other leader sequences critical for normal virus viability). The deletion of the pol sequences was carried out as follows. pBSA-XB was digested with *Bsp*EI and the ends were filled in using T4 DNA polymerase. The *Bsp*EI-digested, T4 polymerase filled DNA was then digested with *Bam*HI and the 8809 bp *Bam*HI/*Bsp*EI(filled) fragment was isolated as follows. The treated DNA was run on a 0.6% agarose gel (TAE buffer) and the 8809 bp fragment was excised from the gel and purified using a QIAEX Gel Extraction Kit according to the manufacturer's instructions (QIAGEN, Chatsworth, CA).

A second aliquot of pBSA-XB DNA was digested with *Bsp*HI and the ends were filled in with T4 DNA polymerase. The *Bsp*HI-digested, T4 polymerase filled DNA was then digested with *Bam*HI and the 13.679 bp *Bam*HI/*Bsp*HI(filled) fragment was isolated as described above.

The purified 8809 bp *Bam*HI/*Bsp*EI(filled) fragment and the purified 13.679 bp *Bam*HI/*Bsp*HI(filled) fragment were ligated to generate p Δ pol. p Δ pol contains a 612 bp deletion within the pol gene (bp 8772 to 9385; numbering relative to that of pBHG11) and lacks the 11.4 kb *Bam*HI fragment containing the right arm of the Ad genome found within pBHG11.

To provide the right arm of the Ad genome, pΔpol was digested with *Bam*HI followed by treatment with calf intestinal alkaline phosphatase. pBHG11 was digested with *Bam*HI and the 11.4 kb fragment was isolated and purified using a QIAEX Gel Extraction Kit as described above. The purified 11.4 kb *Bam*HI fragment was ligated to the 5 *Bam*HI/phosphatased pΔpol to generate pBHG11Δpol. Proper construction of pBHG11Δpol was confirmed restriction digestion (*Hind*III).

c) **Rescue And Propagation Of Ad5Δpol Virus**

The Ad genome contained within pBHG11Δpol lacks the packaging signals. 10 Therefore, in order to recover virus containing the 612 bp deletion within the pol gene from pBHG11Δpol, this plasmid must be cotransfected into packaging cells along with DNA that provides a source of the Ad packaging signals. The Ad packaging signals may be provided by wild-type or mutant Ad viral DNA or alternatively may be provided using a shuttle vector which contains the left-end Ad5 sequences including the packaging signals such as 15 pΔE1sp1A, pΔE1sp1B (Microbix) or pAdBgII (pAdBgII is a standard shuttle vector which contains 0-1 m.u. and 9-16 m.u. of the adenovirus genome).

To rescue virus, pBHG11Δpol was co-transfected with Ad5d_l/7001 viral DNA. Ad5d_l/7001 contains a deletion in the E3 region; the E3 deletion contained within Ad5d_l/7001 is smaller than the deletion contained within the Ad genome contained within pBHG11. It is 20 not necessary that Ad5d_l/7001 be used to recover virus; other adenoviruses, including wild-type adenoviruses, may be used to rescue of virus from pBHG11Δpol.

It has been reported that the generation of recombinant Ads is more efficient if Ad 25 DNA-terminal protein complex (TPC) is employed in conjunction with a plasmid containing the desired deletion [Miyake *et al.* (1996) Proc. Natl. Acad. Sci. USA 93:1320]. Accordingly, Ad5d_l/7001-TPC were prepared as described [Miyake *et al.* (1996), *supra*]. Briefly, purified Ad5d_l/7001 virions (purified through an isopycnic CsCl gradient centered at 1.34 g/ml) were lysed by the addition of an equal volume of 8 M guanidine hydrochloride. The released Ad5d_l/7001 DNA-TPC was then purified through a buoyant density gradient of 2.8 M CsCl/4 M guanidine hydrochloride by centrifugation for 16 hr at 55,000 rpm in a VTi65 rotor 30 (Beckman). Gradient fractions containing Ad5d_l/7001 DNA-TPC were identified using an ethidium bromide spot test and then pooled, dialyzed extensively against TE buffer. BSA was then added to a final concentration of 0.5 mg/ml and aliquots were stored at -80°C. The

Ad5d/7001 DNA-TPC was then digested with *Sca*I and then gel-filtered through a Sephadex G-50 spin column.

One hundred nanograms of the digested Ad5d/7001 DNA-TPC was mixed with 5 µg of pBHG11Δpol and used to transfect pol-expressing 293 cells (*i.e.*, C-7). Approximately 10 days post-transfection, plaques were picked. The recombinant viruses were plaque purified and propagated using standard techniques (Graham and Prevac, *supra*). Viral DNA was isolated, digested with restriction enzymes and subjected to Southern blotting analysis to determine the organization of the recovered viruses. Two forms of virus containing the 612 bp pol deletion were recovered and termed Ad5ΔpolΔE3I and Ad5ΔpolΔE3II. One form of recombinant pol⁻ virus recovered, Ad5ΔpolΔE3I, underwent a double recombination event with the Ad5d/7001 sequences and contains the E3 deletion contained within Ad5d/7001 at the right end of the genome. The second form of recombinant pol⁻ virus, Ad5ΔpolΔE3II, retained pBHG11 sequences at the right end of the genome (*i.e.*, contained the E3 deletion found within pBHG11). These results demonstrate the production of a recombinant Ad vector containing a deletion within the pol gene.

d) Characterization Of The E1+, pol- Viruses

To demonstrate that the deletion contained within these two pol⁻ viruses renders the virus incapable of producing functional polymerase, Ad5ΔpolΔE3I was used to infect 293 cells and pol-expressing 293 cells (B-6 and C-7 cell lines) and a viral replication-complementation assay was performed as described in Example 1e. Briefly, 293, B-6 and C-7 cells were seeded onto 60 mm dishes at a density of 2 x 10⁶ cells/dish and infected with H5sub100 or Ad5ΔpolΔE3I at an MOI of 0.25. The infected cells were then incubated at 37°C or 38.5°C for 16 hours, or at 32.0°C for 40 hours. Cells from each infected plate were then harvested and total DNA was extracted. Four micrograms of each DNA sample was digested with *Hind*III, electrophoresised through an agarose gel, transferred to a nylon membrane and probed with ³²P-labeled adenoviral DNA. The resulting autograph is shown in Figure 9. In Figure 9, each panel shows, from left to right, DNA extracted from 293, B-6 and C-7 cells, respectively infected with either H5sub100 or Ad5ΔpolΔE3I (labeled Ad5ΔPOL in Fig. 9).

As shown in Figure 9, the recombinant pol⁻ virus was found to be viable on pol-expressing 293 cells but not on 293 cells. These results demonstrates that recombinant Ad viruses containing the 612 bp deletion found within pΔpol lack the ability to express Ad

polymerase. These results also demonstrate that B-6 and C-7 cells efficiently complement the Δpol found within Ad5ΔpolΔE3I and Ad5ΔpolΔE3II. In addition, these results show that replication of the ts pTP mutant H5sub100 can be complemented by high level expression of the Ad polymerase with or without co-expression of pTP.

Because the expression of early genes is required for the expression of the late gene products, the ability of recombinant viruses containing the Δpol deletion to direct the expression of late gene products was examined. 293 and C-7 cells were infected with Ad5ΔpolΔE3I and 24 hours after infection cell extracts were prepared. The cell extracts were serially diluted and examined for the expression of the fiber protein (a late gene product) by immunoblot analysis. The immunoblot was performed as described in Example 3C with the exception that the primary antibody used was an anti-fiber antibody (FIBER-KNOB obtained from Robert Gerard, University of Texas Southwestern Medical School). The results of this immunoblotting analysis revealed that no fiber protein was detected from 293 cells infected with Ad5ΔpolΔE3I (at any dilution of the cell extract). In contrast, even a 1:1000 dilution of cell extract prepared from C-7 cells infected with Ad5ΔpolΔE3I produced a visible band on the immunoblot. Therefore, the pol deletion contained within Ad5ΔpolΔE3I resulted in a greater than 1000-fold decrease in fiber production.

The above results demonstrate that polymerase gene sequences can be deleted from the virus and that the resulting deleted virus will only grow on cells producing Ad-polymerase *in trans*. Using the pol-expressing cell lines described herein (e.g., B-6 and C-7), large quantities of the pol⁻ viruses can be prepared. A dramatic shut-down in growth and late gene expression is seen when cells which do not express Ad polymerase are infected with the pol⁻ viruses.

25 e) **Generation Of E1⁻, Pol⁻ Ad Vectors**

Ad5d/7001 used above to rescue virus containing the polymerase deletion is an E1-containing virus. The presence of E1 sequences on the recombinant pol⁻ viruses is undesirable when the recombinant virus is to be used to transfer genes into the tissues of animals: the E1 region encodes the transforming genes and such viruses replicate extremely well *in vivo* leading to an immune response directed against cells infected with the E1-containing virus.

E1⁻ viruses containing the above-described polymerase deletion are generated as follows. pBHG11Δpol is cotransfected into pol-expressing 293 cells (e.g., B-6 or C-7) along

with a shuttle vector containing the left-end Ad5 sequences including the packaging signals. Suitable shuttle vectors include pΔE1sp1A (Microbix), pΔE1sp1B (Microbix) or pAdBgIII. The gene of interest is inserted into the polylinker region of the shuttle vector and this plasmid is then cotransfected into B-6 or C-7 cells along with pBHG11Δpol to generate a recombinant E1⁻, pol⁻ Ad vector containing the gene of interest.

EXAMPLE 4
Production Of Adenovirus Vectors
Deleted For E1 And Preterminal Protein Functions

10

In order to produce an Ad vectors deleted for E1 and preterminal protein functions, a small deletion was introduced into the Ad preterminal protein (pTP) gene contained within an E1-deleted Ad genome. The plasmid pBHG11 (Microbix) was used as the source of an E1-deleted Ad genome to maximize the cloning capacity of the resulting pTP⁻ vector. However, 15 other Ad backbones containing smaller deletions within the E3 region (e.g., pBHG10 which contains a deletion between 78.3 to 85.8 m.u.; Microbix) may be employed for the construction of pTP⁻ vectors using the strategy outlined below.

a) Construction Of pΔpTP

20

A deletion was introduced into the pTP coding region contained within pBSA-XB (Ex. 3) in such a manner that other key viral elements were not disturbed (e.g., the tripartite leader sequences, the i-leader sequences, the VA-RNA I and II genes, the 55 kD gene and the pol gene). The deletion of the pTP sequences was carried out as follows. pBSA-XB was digested with *Xba*I and EcoRV and the 7.875 kb fragment was isolated as described (Ex. 3).

25

Another aliquot of pBSA-XB was digested with *Mun*I and the ends were filled in using T4 DNA polymerase. The *Mun*I-digested, T4 polymerase filled DNA was then digested with *Xba*I and the 14.894 kb *Xba*I/*Mun*I(filled) fragment was isolated as described (Ex. 3). The 7.875 kb *Mun*I fragment and the 14.894 kb *Xba*I/*Mun*I(filled) fragment were ligated together to generate pΔpTP.

30

b) **Construction Of pBHG11ΔpTP**

p Δ pol contains a 429 bp deletion within the pTP gene (bp 10.705 to 11.134; numbering relative to that of pBHG11) and lacks the 11.4 kb *Bam*HI fragment containing the right arm of the Ad genome found within pBHG11.

To provide the right arm of the Ad genome, p Δ pTP was digested with *Bam*HI followed by treatment with shrimp alkaline phosphatase (SAP; U.S. Biochemicals, Cleveland, OH). pBHG11 was digested with *Bam*HI and the 11.4 kb fragment was isolated and purified using a QIAEX Gel Extraction Kit as described (Ex. 3). The purified 11.4 kb *Bam*HI fragment was ligated to the *Bam*HI/phosphatased p Δ pTP to generate pBHG11ΔpTP. Proper construction of pBHG11ΔpTP was confirmed restriction digestion.

c) **Rescue And Propagation Of Ad Vectors Containing The pTP Deletion**

The Ad genome contained within pBHG11ΔpTP lacks the Ad packaging signals. Therefore, in order to recover virus containing the 612 bp deletion within the pol gene from pBHG11Δpol, this plasmid must be cotransfected into packaging cells along with DNA that provides a source of the Ad packaging signals. The Ad packaging signals may be provided by wild-type or mutant Ad viral DNA or alternatively may be provided using a shuttle vector which contains the left-end Ad5 sequences including the packaging signals such as p Δ E1sp1A, p Δ E1sp1B (Microbix) or pAdBglII.

Recombinant Ad vectors containing the pTP deletion which contain a deletion within the E3 region are generated by cotransfection of pBHG11ΔpTP (the gene of interest is inserted into the unique *Pac*I site of pBHG11ΔpTP) with a E3-deleted Ad virus such as Ad5dl700 into pTP-expressing 293 cells (e.g., C-7); viral DNA-TPC are utilized as described above in Example 3.

Recombinant vectors containing the pTP deletion which also contain deletions within the E1 and E3 regions are generated by cotransfection of pBHG11ΔpTP into pTP-expressing 293 cells (e.g., C-7) along with a shuttle vector containing the left-end Ad5 sequences including the packaging signals. Suitable shuttle vectors include p Δ E1sp1A (Microbix), p Δ E1sp1B (Microbix) or pAdBglII. The gene of interest is inserted into the polylinker region of the shuttle vector and this plasmid is then cotransfected into B-6 or C-7 cells along with pBHG11ΔpTP to generate a recombinant E1 $^+$, pTP $^-$ Ad vector containing the gene of interest.

EXAMPLE 5**Production Of Adenovirus Vectors Deleted For
E1. Polymerase And Preterminal Protein Functions**

5 In order to produce an Ad vectors deleted for E1. polymerase and preterminal protein functions. a deletion encompassing pol and pTP gene sequences was introduced into the Ad sequences contained within an E1-deleted Ad genome. The plasmid pBHG11ΔE4 was used as the source of an E1-deleted Ad genome to maximize the cloning capacity of the resulting pol⁻. pTP⁻ vector. pBHG11ΔE4 is a modified form of BHG11 which contains a deletion of 10 all E4 genes except for the E4 ORF 6; the E4 region was deleted to create more room for the insertion of a gene of interest and to further disable the virus. However, other E1⁻ Ad backbones, such as pBHG11 and pBHG1 (Microbix; pBHG10 contains a smaller deletion within the E3 region as compared to pBHG11), may be employed for the construction of pol⁻. pTP⁻ vectors using the strategy outlined below.

15 Due to the complexity of the cloning steps required to introduce a 2.3 kb deletion that removes portions of both the pTP and pol genes, this deletion was generated using several steps as detailed below.

a) Construction Of pAXBΔpolΔpTPVARNA+t13

20 In order to create a plasmid containing Ad sequences that have a deletion within the pol and pTP genes, pAXBΔpolΔpTPVARNA+t13 was constructed as follows.

25 pBSA-XB was digested with *Bsp*E1 and the 18 kb fragment was isolated and recircularized to create pAXBΔpolΔpTP; this plasmid contains a deletion of the sequences contained between the *Bsp*E1 sites located at 8.773 and 12.513 (numbering relative to pBHG11).

30 A fragment encoding the VA-RNA3 sequence and the third leader of the tri-partite leader sequence was prepared using the PCR as follows. The PCR was carried out in a solution containing H5ts36 virion DNA (any Ad DNA, including wild-type Ad, may be used), 2 ng/mL of primers 4005E and 4006E, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin and *Pfu* polymerase. The forward primer, 4005E, [5'-TGCCGCAGCACCGGATGCATC-3' (SEQ ID NO:6)] contains sequences complementary to residues 12.551 to 12.571 of pBHG11 (SEQ ID NO:4). The reverse primer, 4006E, [5'-GCGTCCGGAGGCTGCCATG CGGCAGGG-3' (SEQ ID NO:7)] is complementary to

residues 11.091 to 11.108 of pBHG11 (SEQ ID NO:4) as well as a *Bsp*EI site (underlined).

The predicted sequence of the ~1.6 kb PCR product is listed in SEQ ID NO:8.

PCR was performed with a Perkin Elmer 9600 Thermocycler utilizing the following cycling parameters: initial denaturation at 94°C for 3 min. 3 cycles of denaturation at 94°C for 30 sec. annealing at 50°C for 30 sec. and extension at 72°C for 60 sec. followed by another 27 cycles with an increased annealing temperature at 56°C. with a final extension at 72°C for 10 minutes. The ~1.6 kb PCR product was purified using a QIAEX Gel Extraction Kit as described (Ex. 3).

The purified PCR fragment was then digested with *Bsp*EI. pAXBΔpolΔpTP was 10 digested with *Bsp*EI followed by treatment with SAP. The *Bsp*EI-digested PCR fragment and the *Bsp*EI-SAP-treated pAXBΔpolΔpTP were ligated together to create pAXBΔpolΔpTPVARNA+t13.

15 b) **Construction Of pBHG11ΔpolΔpTPVARNA+t13**

pAXBΔpolΔpTPVARNA+t13 contains a 2.3 kb deletion within the pol and pTP genes (bp 8.773 to 11.091; numbering relative to that of pBHG11) and lacks the 11.4 kb *Bam*HI fragment containing the right arm of the Ad genome.

To provide the right arm of the Ad genome, pAXBΔpolΔpTPVARNA+t13 was digested with *Bam*HI followed by treatment with SAP. pBHG11ΔE4 (pBHG11 or pBHG10 20 may be used in place of pBHG11ΔE4) was digested with *Bam*HI and the 11.4 kb fragment was isolated and purified using a QIAEX Gel Extraction Kit as described (Ex. 3). The purified 11.4 kb *Bam*HI fragment was ligated to the *Bam*HI/phosphatased pAXBΔpolΔpTPVARNA+t13 to generate pBHG11ΔpolΔpTPVARNA+t13. Proper construction of pBHG11ΔpolΔpTPVARNA+t13 was confirmed restriction digestion.

25

c) **Rescue And Propagation Of Ad Vectors Containing The pol, pTP Double Deletion**

The Ad genome contained within pBHG11ΔpolΔpTPVARNA+t13 lacks the Ad 30 packaging signals. Therefore, in order to recover virus containing the 2.3 kb deletion within the pol and pTP genes from pBHG11ΔpolΔpTPVARNA+t13, this plasmid must be cotransfected into packaging cells along with DNA that provides a source of the Ad packaging signals. The Ad packaging signals may be provided by wild-type or mutant Ad viral DNA or alternatively may be provided using a shuttle vector which contains the left-end

Ad5 sequences including the packaging signals such as pΔE1sp1A, pΔE1sp1B (Microbix) or pAdBgIII.

Recombinant vAd vectors containing the pol, pTP double deletion which also contain a deletion within the E3 region are generated by cotransfection of

5 pBHG11ΔpolΔpTPVARNA+t13 (the gene of interest is inserted into the unique *Pac*I site of pBHG11ΔpolΔpTPVARNA+t13) with a E3-deleted Ad virus such as Ad5d17001 into pol- and pTP-expressing 293 cells (e.g., C-7); viral DNA-TPC are utilized as described (Ex. 3).

Recombinant vectors containing the pol, pTP double deletion which also contain deletions within the E1 and E3 regions are generated by cotransfection of

10 pBHG11ΔpolΔpTPVARNA+t13 into pol- and pTP-expressing 293 cells (e.g., C-7) along with a shuttle vector containing the left-end Ad5 sequences including the packaging signals.

Suitable shuttle vectors include pΔE1sp1A (Microbix), pΔE1sp1B (Microbix) or pAdBgIII.

The gene of interest is inserted into the polylinker region of the shuttle vector and this plasmid is then cotransfected into B-6 or C-7 cells along with

15 pBHG11ΔpolΔpTPVARNA+t13 to generate a recombinant E1⁻, pol⁻, pTP⁻ Ad vector containing the gene of interest.

EXAMPLE 6

Encapsidated Adenovirus Minichromosomes

Containing A Full Length Dystrophin cDNA

In this Example, the construction of an encapsidated adenovirus minichromosome (EAM) consisting of an infectious encapsidated linear genome containing Ad origins of replication, packaging signal elements, a β-galactosidase reporter gene cassette and a full length (14 kb) dystrophin cDNA regulated by a muscle specific enhancer/promoter is described. EAMs are generated by cotransfecting 293 cells with supercoiled plasmid DNA (pAd5βdys) containing an embedded inverted origin of replication (and the remaining above elements) together with linear DNA from E1-deleted virions expressing human placental alkaline phosphatase (hpAP). All proteins necessary for the generation of EAMs are provided *in trans* from the hpAP virions and the two can be separated from each other on equilibrium CsCl gradients. These EAMs are useful for gene transfer to a variety of cell types both *in vitro* and *in vivo*.

a) **Generation And Propagation Of Encapsidated Adenovirus Minichromosomes**

To establish a vector system capable of delivering full length dystrophin cDNA clones, the minimal region of Ad5 needed for replication and packaging was combined with a conventional plasmid carrying both dystrophin and a β -galactosidase reporter gene. In the first vector constructed, these elements were arranged such that the viral ITRs flanked (ITRs facing outward) the reporter gene and the dystrophin gene [i.e., the vector contained from 5' to 3' the right or 3' ITR (mu 100 to 99), the dystrophin gene and the reporter gene and the left or 5' ITR and packaging sequence (mu 1 to 0)]. Upon introduction of this vector along with helper virus into 293 cells, no encapsidated adenovirus minichromosomes were recovered.

The second and successful vector, pAd5 β dys (Fig. 10) contains 2.1 kb of adenovirus DNA, together with a 14 kb murine dystrophin cDNA under the control of the mouse muscle creatine kinase enhancer/promoter, as well as a β -galactosidase gene regulated by the human cytomegalovirus enhancer/promoter.

Figure 10 shows the structure of pAd5 β dys (27.8 kb). The two inverted adenovirus origins of replication are represented by a left and right inverted terminal repeat (LITR/RITR). Replication from these ITRs generates a linear genome whose termini correspond to the 0 and 100 map unit (mu) locations. Orientation of the origin with respect to wild type adenovirus serotype 5 sequences in mu is indicated above the figure (1 mu=360 bp). Encapsidation of the mature linear genome is enabled by five (AI-AV) packaging signals (Ψ). The *E. coli* β -galactosidase and *mus musculus* dystrophin cDNAs are regulated by cytomegalovirus (CMV) and muscle creatine kinase (MCK) enhancer/promoter elements, respectively. Both expression cassettes contain the SV40 polyadenylation (pA) signal. Since the E1A enhancer/promoter overlaps with the packaging signals, pAd5 β dys was engineered such that RNA polymerase transcribing from the E1A enhancer/promoter will encounter the SV40 late polyadenylation signal. Pertinent restriction sites used in constructing pAd5 β dys are indicated below the figure. An adenovirus fragment corresponding to mu 6.97 to 7.77 was introduced into pAd5 β dys during the cloning procedure (described below). P1 and P2 represent location of probes used for Southern blot analysis. Restriction sites destroyed during the cloning of the Ad5 origin of replication and packaging signal are indicated in parentheses.

pAd5 β dys was constructed as follows. pBSX (Ex. 3a) was used as the backbone for construction of pAd5 β dys. The inverted fused Ad5 origin of replication and five encapsidation signals were excised as a *Pst*I/*Xba*I fragment from pAd5ori, a plasmid containing the 6 kb *Hind*III fragment from pFG140 (Microbix Biosystems). This strategy also introduced a 290 bp fragment from Ad5 corresponding to map units 6.97 to 7.77 adjacent to the right inverted repeat (see Fig. 10). The *E. coli* β -galactosidase gene regulated by the human CMV immediate early (IE) promoter/enhancer expression cassette was derived as an *Eco*RI/*Hind*III fragment from pCMV β [MacGregor and Caskey (1989) Nucleic Acids Res. 17:2365]; the CMV IE enhancer/promoter is available from a number of suppliers as is the *E. coli* β -galactosidase gene]. The murine dystrophin expression cassette was derived as a *Bss*HII fragment from pCVAA, and contains a 3.3 kb MCK promoter/enhancer element [Phelps *et al.* (1995) Hum. Mol. Genet. 4:1251 and Jaynes *et al.* (1986) Mol. Cell. Biol. 6:2855]. The sequence of the ~3.3 kb MCK promoter/enhancer element is provided in SEQ ID NO:9 (in SEQ ID NO:9, the last nucleotide of SEQ ID NO:9 corresponds to nucleotide +7 of the MCK gene). The enhancer element is contained within a 206 bp fragment located -1256 and -1050 upstream of the transcription start site in the MCK gene.

It was hoped that the pAd5 β dys plasmid would be packageable into an encapsidated minichromosome when grown in parallel with an E1-deleted virus due to the inclusion of both inverted terminal repeats (ITR) and the major Ad packaging signals in the plasmid. The ITRs and packaging signals were derived from pFG140 (Microbix), a plasmid that generates E1-defective Ad particles upon transfection of human 293 cells.

hpAP is an E1 deleted Ad5 containing the human placental alkaline phosphatase gene [Muller *et al.* (1994) Circ. Res. 75:1039]. This virus was chosen to provide the helper functions so that it would be possible to monitor the titer of the helper virus throughout serial passages by quantitative alkaline phosphatase assays.

293 cells were cotransfected with pAd5 β dys and hpAP DNA as follows. Low passage 293 cells (Microbix Biosystems) were grown and passaged as suggested by the supplier. Five pAd5 β dys and hpAP DNA (5 and 0.5 μ g, respectively) were dissolved in 70 μ l of 20 mM HEPES buffer (pH 7.4) and incubated with 30 μ l of DOTAP (BMB) for 15 min. at room temperature. This mixture was resuspended in 2 mls of DMEM supplemented with 2% fetal calf serum (FCS) and added dropwise to a 60 mm plate of 293 cells at 80% confluency. Four hours post-transfection the media was replaced by DMEM with 10% FCS. Cytopathic effect was observed 6-12 days post-transfection.

Cotransfection of 293 cells with supercoiled pAd5 β dys and linear hpAP DNA produced Ad5 β dys EAMs (the encapsidated version of pAd5 β dys) approximately 6 to 12 days post transfection, as evidenced by the appearance of a cytopathic effect (CPE). Initially, the amount of Ad5 β dys EAMs produced was significantly lower than that of hpAP virions so the viral suspension was used to re-infect fresh cultures, from which virus was isolated and used for serial infection of additional cultures (Fig. 11). Infection and serial passaging of 293 cells was carried out as follows.

Lysate from one 60 mm plate of transfected 293 cells was prepared by vigorously washing the cells from the plate and centrifuging at 1 K rpm in a clinical centrifuge. Cells were resuspended in DMEM and 2% FCS, freeze-thawed in a dry ice-ethanol bath, cell debris removed by centrifugation, and approximately 75% of the crude lysate was used to infect 293 cells in DMEM supplemented with 2% FCS for 1 hour and then supplemented with 10% FCS thereafter. Infection was allowed to proceed for 18-20 hrs before harvesting the virus. The total number of cells infected in each serial passage is indicated in Figure 11.

In Figure 11, the total number of transducing adenovirus particles produced (output) per serial passage on 293 cells, total input virus of either the helper (hpAP) or Ad5 β dys, and the total number of cells used in each infection is presented. The total number of input/output transducing particles were determined by infection of 293 cells plated in 6-well microtiter plates. Twenty four hours post-infection the cells were assayed for alkaline phosphatase or β -galactosidase activity (described below) to determine the number of cells transduced with either Ad5 β dys or hpAP. The number of transducing particles were estimated by extrapolation of the mean calculated from 31 randomly chosen 2.5 mm² sectors of a 961 mm² plate. The intra-sector differences in total output of each type of virus are presented as the standard deviations, σ , in Figure 11. For each serial passage, 75% of the total output virus from the previous passage was used for infection.

Alkaline phosphatase or β -galactosidase activity was determined as follows. For detection of alkaline phosphatase, infected 293 cells on Petri dishes were rinsed twice with phosphate buffered saline (PBS) and fixed for 10 minutes in 0.5% glutaraldehyde in PBS. Cells were again rinsed twice with PBS for ten minutes followed by inactivation of endogenous alkaline phosphatase activity at 65°C for 1 hr. in PBS prior to the addition of the chromogenic substrate BCIP (5-bromo-4-chloro-3-indolyl phosphate) at 0.15 mg/ml and nitro blue tetrazolium at 0.3 mg/ml. Cells were incubated at 37°C in darkness for 3- 24 hrs. For β -galactosidase assays, the cells were fixed and washed as above, then assayed using standard

methods [MacGregor *et al.* (1991) In Murray (ed.), *Methods in Molecular Biology: Vol. 7: Gene Transfer and Expression Protocols*, Human Press Inc., Clifton, NJ, pp. 217-225].

As shown in Figure 11, the rate of increase in titer of Ad5 β dys EAMs between transfection and serial passage 6 was approximately 100 times greater than that for hpAP virions. This result indicated that Ad5 β dys has a replication advantage over the helper virus, probably due to the shorter genome length (a difference of approximately 8 kb) and hence an increased rate of packaging.

Interestingly, after serial passage 6 there was a rapid decrease in the total titer of hpAP virions whereas the titer of Ad5 β dys EAMs continued to rise. While not limiting the present invention to any particular mechanism, at least two possible mechanisms could be responsible for this observation. Firstly, a buildup of defective hpAP virions due to infections at high multiplicities may slowly out-compete their full length counterparts, a phenomenon that has been previously observed upon serial propagation of adenovirus [Daniell (1976) J. Virol. 19:685; Rosenwirth *et al.* (1974) Virology 60:431; and Burlingham *et al.* (1974) Virology 60:419]. Secondly, the emergence of replication competent virions due to recombination events between E1 sequences in cellular DNA and the hpAP genome could lead to a buildup of virus particles defective in expressing alkaline phosphatase [Lochmüller *et al.* (1994) Hum. Gene Ther. 5:1485].

Southern analysis of DNA prepared from serial lysates 3, 6, 9 and 12 indicated that full length dystrophin sequences were present in each of these lysates (Fig. 12A). In addition, the correct size restriction fragments were detected using both dystrophin and β -galactosidase probes against lysate DNA digested with several enzymes (Figs. 12A-B).

Figure 12 shows a Southern blot analysis of viral DNA from lysates 3, 6, 9 and 12, digested with the restriction enzymes *BssHII*, *NruI* and *EcoRV*, indicating the presence of a full length dystrophin cDNA in all lysates. Fragments from the C terminus of *mus musculus* dystrophin cDNA (A) or the N terminus of *E. coli* β -galactosidase (B) were labeled with dCTP³² and used as probes [Sambrook *et al.*, *supra*]. The position of these probes and the predicted fragments for each digest is indicated in Figure 10. Note that one end of each fragment (except the 17.8 kb *BssHII* dystrophin fragment) detected is derived from the end of the linearized Ad5 β dys genome (see Fig. 10). Low levels of shorter products, presumably derived from defective virions, become detectable only at high serial passage number.

At the later passages (9 and 12) there appeared to be an emergence of truncated Ad5 β dys sequences, suggesting that deletions and/or rearrangements may be occurring at later

passages. Hence, most experiments were performed with Ad5 β dys EAMs derived from the earlier passages. The possibility of the emergence of replication competent (E1-containing) viruses was also examined by infection of HeLa cells by purified and crude serial lysates, none of which produced any detectable CPE.

5

b) **Purification Of Encapsidated Adenovirus Minichromosomes On CsCl Gradients**

The ability to separate Ad5 β dys EAMs from hpAP virions based on their buoyancy difference (due presumably to their different genome lengths) on CsCl gradients was 10 examined. Repeated fractionation of the viral lysate allows small differences in buoyancy to be resolved. CsCl purification of encapsidated adenovirus minichromosomes was performed as follows. Approximately 25% of the lysate prepared from various passages during serial infections was used to purify virions. Freeze-thawed lysate was centrifuged to remove the cell debris. The cleared lysate was extracted twice with 1,1,2 tricholorotrifluoroethane 15 (Sigma) and applied to CsCl step and self forming gradients.

Purification of virus was initially achieved by passing it twice through CsCl step gradients with densities of $\rho=1.45$ and $\rho=1.20$ in a SW28 rotor (Beckman). After isolation of the major band in the lower gradient, the virus was passed through a self forming gradient (initial $\rho=1.334$) at 37,000 rpm for 24 hrs followed by a relaxation of the gradient by 20 reducing the speed to 10,000 rpm for 10 hrs. in a SW41 rotor (Beckman) at 12°C [Anet and Strayer (1969) Biochem. Biophys. Res. Commun. 34:328]. The upper band from the gradient (composed mainly of Ad5 β dys virions) was isolated using an 18 gauge needle, reloaded on a fourth CsCl gradient ($\rho=1.334$) and purified at 37,000 rpm for 24 hrs followed by 10,000 rpm for 10 hrs at 12°C.

25 The Ad5 β dys-containing CsCl band was removed in 100 μ l fractions from the top of the centrifugation tube and CsCl was removed by chromatography on Sephadex G-50 (Pharmacia). Aliquots from each fraction were used to infect 293 cells followed by β -galactosidase and alkaline phosphatase assays to quantitate the level of contamination by hpAP virions in the final viral isolate.

30 Results of the physical separation between Ad5 β dys EAMs and hpAP virions are shown in Figure 13. Figure 13 shows the physical separation of Ad5 β dys from hpAP virions at the third (A) and final (B) stages of CsCl purification (initial $\rho=1.334$) in a SW41 tube. Aliquots of Ad5 β dys EAMs from the final stage were drawn through the top of the

centrifugation tube and assayed for β -galactosidase and alkaline phosphatase expression.

Results of these assays are presented in Figure 14.

In Figure 14. shows the level of contamination of Ad5 β dys EAMs by hpAP virions obtained from passage 6. Following four cycles of CsCl purification, aliquots were removed from the top of the centrifugation tube and used for infection of 293 cells, which were fixed 24 hrs later and assayed for β -galactosidase or alkaline phosphatase activity (described below). The number of transducing particles are an underestimation of the actual totals as in some cases a positive cell may have been infected by more than one transducing particle. The ratio of the two types of virions - Ad5 β dys EAMs (LacZ) or hpAP (AP) in each fraction is indicated in the lower graph.

The maximum ratio of transducing Ad5 β dys EAMs to hpAP virions reproducibly achieved in this study was 24.8 -- a contamination with helper virus corresponding to approximately 4% of the final viral isolate.

15 c) **Dystrophin And β -galactosidase Expression By Encapsidated
Adenovirus Minichromosomes In Muscle Cells**

To determine if the Ad5 β dys EAMs were able to express β -galactosidase and dystrophin in muscle cells. mouse *mdx* myogenic cultures were infected with CsCl purified EAMs.

20 i) **Propagation And Infection Of Muscle Cells**

MM14 and *mdx* myogenic cell lines were kindly provided by S. Hauschka (University of Washington) and were cultured as previously described [Linkhart *et al.* (1981) Dev. Biol. 86:19 and Clegg *et al.* (1987) J. Cell Biol. 105:949]. Briefly, myoblasts were grown on plastic tissue culture plates coated with a 0.1% gelatin in Ham's F-10 medium containing 15% (v/v) horse serum, 0.8 mM CaCl₂, 200 ng/ml recombinant human basic fibroblast growth factor (b-FGF) and 60 μ g/ml genitimidin (proliferation medium). Cultures were induced to differentiate by switching to growth in the presence of growth medium lacking b-FGF and containing 10% horse serum (differentiation medium). Myoblasts or differentiated myotubes (three days post switching) were infected at a multiplicity of infection of 2.2 Ad5 β dys EAMs per cell. Fractions containing minimal contamination with hpAP virions (3, 4 and 5 of passage 6) were used for western and immunofluorescence analysis. Infection was allowed to proceed for 3 days for both the myoblasts and myotubes before harvesting cells.

ii) Total Protein Extraction And Immunoblot Analysis

For protein extraction, muscle cells were briefly trypsinized, transferred to a microcentrifuge tube, centrifuged at 14 K for 3 min at room temp and resuspended two times in PBS. After an additional centrifugation, the cell pellet was resuspended in 80 µl of RIPA buffer (50 mM Tris-Cl, pH 7.5; 150 mM NaCl; 1% Nonidet P-40; 0.5% sodium deoxycholate; 0.1% SDS) (Sambrook *et al.*, *supra*). The sample was briefly sheared using a 22 gauge needle to reduce viscosity and total protein concentration assayed using the bicinchoninic acid protein assay reagent (Pierce, Rockford, IL). Expression of full length dystrophin or β-galactosidase in infected *mdx* and MM14 myoblasts or myotubes was analyzed by electrophoresis of 40 µg of total protein extract on a 6% SDS-PAGE gel (in 25 mM Tris, 192 mM glycine, 10 mM β-mercaptoethanol, 0.1% SDS). After transferring to Gelman Biotrace NT membrane (in 25 mM Tris, 192 mM glycine, 10 mM β-mercaptoethanol, 0.05% SDS, 20% methanol), the membrane was blocked with 5% non-fat milk and 1% goat-serum in Tris-buffered saline-Tween (TBS-T) for 12 hrs at 4°C. Immunostaining was done according to the protocol for the ECL western blotting detection reagents (Amersham Life Sciences, Buckingham, UK). The primary antibodies used were Dys-2 (Vector Laboratories) and anti-β-galactosidase (BMB, Indianapolis, IN) with a horseradish peroxidase-conjugated anti-mouse secondary antibody.

Western blot analysis of EAM-infected *mdx* myoblasts and myotubes (three days post-fusion) indicated that EAMs were able to infect both of these cell types (Figure 15). In Figure 15, immunoblots of protein extracts from *mdx* myoblasts and myotubes demonstrating the expression of β-galactosidase (A) and dystrophin (B) in cells infected with Ad5βdys EAMs. Total protein was extracted 3 days post infection in all cases. Myotubes were infected at three days following a switch to differentiation media. In Figure 15A, lane 1 contains total protein extract from 293 cells infected with a virus expressing β-galactosidase as a control (RSV-LacZ); lanes 2-5 contain total protein extracts from uninfected *mdx* myoblasts, *mdx* myoblasts infected with Ad5βdys EAMs, *mdx* myotubes and *mdx* myotubes derived from *mdx* myoblasts infected with Ad5βdys EAMs, respectively. In Figure 15B, lanes 1 and 7 contain total protein from mouse muscle ("C57") while lane 2 contains protein from wild type MM14 myotubes, as controls. Lanes 3-5 contain total protein extracts from uninfected *mdx* myoblasts, *mdx* myoblasts infected with Ad5βdys EAMs, *mdx* myotubes and *mdx* myotubes derived from *mdx* myoblasts infected with Ad5βdys EAMs, respectively.

As shown in Figure 15, expression of β -galactosidase was detected in both the infected *mdx* myoblasts and myotubes indicating that the CMV promoter was active at both these early stages of differentiation in muscle cells. However, only infected *mdx* myotubes produced protein detected by dys-2, an antibody recognizing the 17 C-terminal amino acids of dystrophin (Fig. 15). No dystrophin expression was detected in infected myoblasts by western analysis, indicating that the muscle creatine kinase promoter functions minimally, if at all, within the Ad5 β dys EAM prior to terminal differentiation of these cells.

Dystrophin expression in *mdx* cells infected with EAMs was confirmed by immunofluorescence studies using N-terminal dystrophin antibodies. In agreement with the western analysis, dystrophin expression from the MCK promoter was detected only in differentiated *mdx* myotubes infected by Ad5 β dys EAMs (Fig. 16). Figures 16A-C show immunofluorescence of dystrophin in wild type MM14 myotubes (A), uninfected *mdx* (B) and infected *mdx* myotubes (C), respectively. The results shown in Figure 16 demonstrate the transfer and expression of recombinant dystrophin to differentiated *mdx* cells by Ad5 β dys EAMs.

Immunofluorescence of myogenic cells was performed as follows. Approximately 1.5×10^6 MM14 or *mdx* myoblasts were plated on Poly-L-lysine (Sigma) coated glass slides (7 x 3 cm) which had been previously etched with a 0.05% chromium potassium sulfate and 0.1% gelatin solution. For myotube analysis, the cultures were switched to differentiation media [Clegg *et al.* (1987), *supra*] 48 hours after plating, immediately infected and then allowed to fuse for 3 days, whereas myoblasts were continuously propagated in proliferation media [Clegg *et al.* (1987), *supra*]. Cells were washed three times with PBS at room temperature and fixed in 3.7% formaldehyde. For immunostaining, cells were incubated in 0.5% Triton X-100, blocked with 1% normal goat serum and incubated with an affinity purified antibody against the N-terminus of murine dystrophin for 2 hrs, followed by extensive washing in PBS and 0.1% Tween-20 with gentle shaking. Cells were incubated with a 1:200 dilution of biotin conjugated anti-rabbit antibody (Pierce) for one hour and washed as above. Cells were further incubated with a 1:300 dilution of streptavidin-fluorescein isothiocyanate conjugate (Vectorlabs, Burlingam, CA) for one hour and washed as above, followed by extensive washing in PBS.

The above results show that embedded inverted Ad origins of replication coupled to an encapsidation signal can convert circular DNA molecules to linear forms in the presence of helper virus and that these genomes can be efficiently encapsidated and propagated to high

titors. Such viruses can be purified on a CsCl gradient and maintain their ability to transduce cells *in vitro*, and their increased cloning capacity allows the inclusion of large genes and tissue specific gene regulatory elements. The above results also show that the dystrophin gene was expressed in cells transduced by such viruses and that the protein product was correctly localized to the cell membrane. The above method for preparing EAMs theoretically enables virtually any gene of interest to be inserted into an infectious minichromosome by conventional cloning in plasmid vectors, followed by cotransfection with helper viral DNA in 293 cells. This approach is useful for a variety of gene transfer studies *in vitro*. The observation that vectors completely lacking viral genes can be used to transfer a full-length dystrophin cDNA into myogenic cells indicates that this method may be used for the treatment of DMD using gene therapy.

10
15
20
25
30

d) A Modified MCK Enhancer Increases Expression Of Linked Genes In Muscle

The DNA fragment containing enhancer/promoter of the MCK gene utilized in the Ad5 β dys EAM plasmid is quite large (~3.3 kb). In order to provide a smaller DNA fragment capable of directing high levels of expression of linked genes in muscle cells, portions of the 3.3 kb MCK enhancer/promoter were deleted and/or modified and inserted in front of a reporter gene (*lacZ*). The enhancer element of the MCK gene was modified to produce the 2RS5 enhancer; the sequence of the 2RS5 enhancer is provided in SEQ ID NO:10. The first 6 residues of SEQ ID NO:10 represent a *Kpn*I site added for ease of manipulation of the modified MCK enhancer element. Residue number 7 of SEQ ID NO:10 corresponds to residue number 2164 of the wild-type MCK enhancer sequence listed in SEQ ID NO:9 (position 2164 of SEQ ID NO:9 corresponds to position -1256 of the MCK gene). Residue number 174 of SEQ ID NO:10 corresponds to residue number 2266 of the wild-type MCK enhancer sequence listed in SEQ ID NO:9.

These MCK/*lacZ* constructs were used to transfet cells in culture (*i.e.*, myogenic cultures) or were injected as naked DNA into the muscle of mice and β -galactosidase activity was measured. Figure 17 provides a schematic of the MCK/*lacZ* constructs tested. The first construct shown in Figure 17 contains the 3.3 kb wild-type MCK enhancer/promoter fragment linked to the *E. coli lacZ* gene. The wild-type enhancer element (-1256 to -1056) is depicted by the box containing "E": the core promoter element (-358 to -80) is indicated by the light cross-hatching and the minimal promoter element (-80 to +7) is indicated by the dark

cross-hatching. The core promoter element is required in addition to the minimal promoter element (which is required for basal expression) in order to achieve increased muscle-specific expression in tissue culture [Shield *et al.* (1996) Mol. Cell. Biol. 16:5058]. The modified enhancer element, the 2RS5 enhancer, is indicated by the box labeled "E*." The box labeled "mi nx" contains a synthetic intron derived from adenovirus and is used to increase expression of the constructs (any intron may be utilized for this purpose). The box labeled "CMV" depicts the CMV IE enhancer/promoter which was used a positive control.

In figure 17, β -galactosidase activity is expressed relative to the activity of the wild-type MCK enhancer/promoter construct shown at the top of the figure. As shown in Figure 10 17, a construct containing the 2RS5 enhancer (SEQ ID NO:10) linked to either the minimal MCK promoter (a ~ 261 bp element) or the core and minimal MCK promoter elements (a ~539 bp element) directs higher levels of expression of the reporter gene in muscle cells as compared to the ~3.3 kb fragment containing the wild-type enhancer element. These modified enhancer/promoter elements are considerably smaller than the ~3.3 kb fragment used in the 15 Ad5 β dys EAM plasmid and are useful for directing the expression of foreign genes in muscle cells. These smaller elements are particularly useful for driving the expression of genes in the context of self-propagating adenoviral vectors which have more severe constraints on the amount of foreign DNA which can be inserted in comparison to the used of "gutted" adenoviruses such as the EAMs described above.

20

EXAMPLE 7

Generation Of High Titer Stocks Of Encapsidated Adenovirus Minichromosomes Containing Minimal Helper Virus Contamination

25 The results presented in Example 6 demonstrated that encapsidated adenovirus minichromosomes (EAMs) can be prepared that lack all viral genes and which can express full-length dystrophin cDNAs in a muscle specific manner. The propagation of these EAMs requires the presence of helper adenoviruses that contaminate the final EAM preparation with conventional adenoviruses (about 4% of the total preparation). In this example the EAM 30 system is modified to enable the generation of high titer stocks of EAMs with minimal helper virus contamination. Preferably the EAM stocks contain helper virus representing less than 1%, preferably less than 0.1% and most preferably less than 0.01% of the final viral isolate. Purified EAMs are then injected *in vivo* in muscles of dystrophin minus *mdx* mice to

determine whether these vectors lead to immune rejection and whether they can alleviate dystrophic symptoms in *mdx* muscles.

The amount of helper virus present in the EAM preparations is reduced in two ways. The first is by selectively controlling the relative packaging efficiency of the helper virus versus the EAM virus. The second is to improve physical methods for separating EAM from helper virus. These approaches enable the generation of dystrophin-expressing EAMs that are contaminated with minimal levels of helper virus.

10 a) **Development And Characterization Of Adenovirus Packaging
Cell Lines Expressing The Cre Recombinase From
Bacteriophage P1**

15 Cell lines expressing a range of *Cre* levels are used to optimize the amount of helper virus packaging that occurs during growth of the EAM vectors. The *Cre-loxP* system [Sauer and Henderson (1988) Proc. Natl. Acad. Sci. USA 85:5166] is employed to selectively disable helper virus packaging during growth of EAMs. The bacterial *Cre* recombinase catalyzes efficient recombination between a 34 bp target sequence called *loxP*. To delete a desired sequence, *loxP* sites are placed at each end of the sequence to be deleted in the same orientation: in the presence of *Cre* recombinase the intervening DNA segment is efficiently excised.

20 Cell lines expressing a range of *Cre* recombinase levels are generated. The expression of too little *Cre* protein may result in high levels of helper virus being generated, which leads to unacceptably high levels of helper virus contaminating the final EAM preparation. If very high levels of *Cre* expression are present in a cell line, excision of the packaging signal from the helper virus would be 100% efficient (*i.e.*, it would completely prevent helper virus packaging). As shown in Example 6, serial passage of EAM preparations containing low levels of helper virus increased the titer of the EAM. Therefore, it is desirable, at least in the initial passages of a serial passage that some helper virus capable of being packaged is present. A low level of packagable helper virus may be provided by using a cell line expressing levels of *Cre* recombinase which are not high enough to achieve excision of the packaging signals from 100% of the helper virus: these cell lines would be used early in the serial passaging of the EAM stock and a cell line expressing high enough levels of *Cre* recombinase to completely prevent helper virus packaging would be used for the final passage.

Alternatively, EAMs may be prepared using a packaging cell line that supports high efficiency *Cre* recombinase-mediated excision of the packaging signals from the helper virus by transfection of the *Cre*-expressing cell line with the EAM plasmid followed by infection of these cells with *loxP*-containing helper virus using an MOI of ≥ 1.0 .

5 Human 293 cell lines that express a variety of levels of *Cre* recombinase are generated as follows. An expression vector containing the *Cre* coding region, pOG231, was cotransfected into 293 cells along with pcDNA3 (Invitrogen); pcDNA3 contains the *neo* gene under the control of the SV40 promoter. pOG231 uses the human CMV enhancer/promoter [derived from CDM8 (Invitrogen)] to express a modified *Cre* gene [pOG231 was obtained 10 from S. O'Gorman]. The modified *Cre* gene contained within pOG231 has had a nuclear localization signal inserted into the coding region to increase the efficiency of recombination.

pOG231 was constructed as follows. A *Bgl*/II site was introduced into the 5' *Xba*I site of the synthetic intron of pMLSISCAT [Haung and Gorman (1990) Nucleic Acids Res. 18:937] by linker tailing. A *Bgl*/II site in the synthetic intron of pMLSISCAT was destroyed 15 and a *Bam*HI linker was inserted into the *Pst*I site at the 3' end of the synthetic intron in pMLSISCAT. *Bgl*/II and *Sma*I sites and a nuclear localization signal were introduced into the 5' end of pMC-Cre [Gu *et al.* (1993) Cell 73:1155] using a PCR fragment that extended from the novel *Bgl*/II and *Sma*I sites to the *Bam*HI site in the *Cre* coding region. This PCR 20 fragment was ligated to a *Bam*HI/*Sall* fragment containing a portion of the *Cre* coding region derived from pIC-Cre (Gu *et al.*, *supra*) and the intron plus *Cre* coding sequence was inserted into a modified form of pOG44 [O'Gorman *et al.* (1991) Science 251:1351] to generate pOG231. The predicted sequence of pOG231 from the *Bgl*/II site to the *Bam*HI site located in the middle of the *Cre* coding sequence is listed in SEQ ID NO:11.

One 60 mm dish of 293 cells (Microbix) were transfected with 10 μ g of *Pvu*II-linearized pOG231 and 1 μ g of *Not*I-linearized pcDNA3 using a standard calcium phosphate precipitation protocol. Two days after the addition of DNA, the transfected cells were split 25 into three 100 mm dishes and 1000 μ g/ml of active G418 was added to the medium. The cells were fed periodically with G418-containing medium and three weeks later, 24 G418-resistant clones were isolated.

30 The isolated clones were expanded for testing. Aliquots were frozen in liquid nitrogen at the earliest possible passage. The neomycin resistant cell lines were examined for the expression of *Cre* recombinase using following transfection assay. The neomycin resistant cells were transfected with PGK-1-GFP-lacZ (obtained from Sally Camper, Univ. of

Michigan, Ann Arbor, MI), which contains a green fluorescent protein (GFP) expression cassette that can be excised by *Cre* recombinase to allow expression of β -galactosidase; transfection was accomplished using standard calcium phosphate precipitation. Figure 18 provides a schematic of a GFP/ β -gal reporter construct suitable for assaying the expression of *Cre* recombinase in mammalian cells: GFP sequences and β -gal (*i.e.*, *lacZ*) sequences are available from commercial sources (*e.g.*, Clontech, Palo Alto, CA and Pharmacia Biotech, Piscataway, NJ, respectively).

Control experiments verified that 293 cells transfected with PGK-1-GFP-lacZ expressed significant amounts of β -galactosidase only if these cells also expressed *Cre* recombinase. β -galactosidase assays were performed as described in Example 6. Neomycin resistant cells expressing *Cre* recombinase were grouped as high, medium or low expressors based upon the amount of β -galactosidase activity produced (estimated by direct counting of β -galactosidase-positive cells per high-power field and by observing the level of staining and the rapidity with which the blue stain was apparent) when these cell lines were transfected with the GFP/ β -gal reporter construct. Thirteen positive (*i.e.*, *Cre*-expressing) lines, D608#12, #7, #22, #18, #17, #4, #8, #2, #2/2, #13, #5, #15 and #21 were retained for further use.

The results of this transfection analysis revealed that cultures of 293 cells expressing medium to high levels of *Cre* recombinase could be generated without apparent toxicity.

20

b) Generation Of Helper Adenovirus Strains That Contain *loxP* Sites Flanking The Adenovirus Packaging Signals

Studies of EAM production demonstrated that the EAM vector has a packaging advantage over the helper adenovirus (Ex. 6). While not limiting the present invention to a particular mechanism, it is hypothesized that this packaging and replication advantage can be greatly increased by using helper viruses that approach the packaging size limits of Ad5 [Bett *et al.* (1993) J. Virol. 67:5911], by using viruses with mutations in E4 and/or E2 genes [Yeh *et al.* (1996) J. Virol. 70:559; Gorziglia *et al.* (1996) J. Virol. 70:4173; and Amalfitano *et al.* (1996) Proc. Natl. Acad. Sci. USA 93:3352], by inclusion of mutations or alterations in the packaging signals of the helper virus [Imler *et al.* (1995) Hum. Gene Ther. 6:711] and by combining these strategies.

The *Cre-loxP* excision method is used to disable the packaging signals from the helper virus genomes. The Ad5 packaging domain extends from nucleotide 194 to 358 and is composed of five distinct elements that are functionally redundant [Hearing *et al.* (1987) J.

Virol. 61:2555]. Theoretically, any molecule containing the Ad5 origin of replication and packaging elements should replicate and be packaged into mature virions in the presence of non-defective helper virus. Disabling the packaging signals should allow replication and gene expression to proceed, but will prevent packaging of viral DNA into infectious particles. This in turn should allow the ratio of EAM to helper virus to be increased greatly.

To disable the packaging signals within the helper virus used to encapsidate the EAMs, the *loxP* sequences are incorporated into a helper virus that has a genome approaching the maximal packaging size for Ad [~105 map units: Bett *et al.* (1993), *supra*] which further decreases the efficiency of helper virus packaging. Final virus size can be adjusted by the choice of introns inserted into the reporter gene, by the choice of reporter genes, or by including a variety of DNA fragments of various sizes to act as "stuffer" fragments. A convenient reporter gene is the alkaline phosphatase gene (see Ex. 6). The optimized *Cre-loxP* system is also incorporated into a helper viral backbone containing disruptions of any or all of the E1-E4 genes. Use of such deleted genomes requires viral growth on appropriate complementing cell lines, such as 293 cells expressing E2, and/or E4 gene products. The *loxP* sequences are incorporated into the helper virus by placing the *loxP* sequences on either side of the packaging signals on a shuttle vector. This modified shuttle vector is then used to recombine with the Ad DNA derived from a virus containing disruptions of any or all of the E1-E4 genes to produce the desired helper virus containing the packaging signals flanked by *loxP* sequences.

pAdBglII, an adenovirus shuttle plasmid containing Ad sequences from 0-1 and 9-16 map units (mu) was used as the starting material. Synthetic oligonucleotides were used to create a polylinker which was inserted at 1 mu within pAdBglII as follows. The BglII LoxP oligo [5'-GAAGATCTATAACTCGTATAATGTATGCTA
25 TACGAAGTTATTACCGAAGAAATGGCTCGAGATCTTC-3' (SEQ ID NO:12) and its reverse complement [5'-GAAGATCTCGAGCCATTCTTCGGTAATAACTTCGT
ATAGCATACATTACGAAGTTAGATCTTC-3' (SEQ ID NO:13)] were synthesized. The AflIII LoxP oligo [5'-CCACATGTATAACTTCGTATAGCATA
30 TTATACGAAGTTACATGTGG-3' (SEQ ID NO:14) and its reverse complement [5'-CCACATGTATAACTTCGTATAATGTATGCTATACGAAGTTACATG TGG-3' (SEQ ID NO:15)] were synthesized. The double stranded form of each *loxP* oligonucleotide was digested with the appropriate restriction enzyme (*e.g.*, *Bg*/II or *Af*/III) and inserted into pAdBglII which had been digested with *Bg*/II and *Af*/III. This resulted in the insertion of

5 *LoxP* sequences into the shuttle vector flanking the packaging signals that are located between 0.5 and 1 mu of Ad5 (one mu equals 360 bp in the Ad5 genome; the sequence of the Ad5 genome is listed in SEQ ID NO:1). The 3' *loxP* sequence was inserted into the *Bg*/II site within pAdBglIII. The 5' *loxP* sequence was inserted into the *Xba*/II site located at base 143 (~0.8 mu) (numbering relative to Ad5).

10 DNA sequencing was used to verify the final structure of the modified shuttle plasmid between 0-1 mu. If *Cre* recombinase-mediated excision of the packaging signals is found to be too efficient (as judged by the production of too little helper virus), alternate sites for the insertion of the *loxP* sequences are used that would result in deletion of 2, 3 or 4 packaging sequences rather than all 5 [Grable and Hearing (1990) J. Virol. 64:2047]. The insertion of *loxP* sequences at sites along the Ad genome contained within the shuttle vector which would result in the deletion 2, 3 or 4 packaging sequences are easily made using the technique of recombinant PCR [Higuchi (1990) In: *PCR Protocols: A Guide to Methods and Applications*. Innis *et al.* (eds.) Academic Press, San Diego, CA, pp. 177-183]. The optimal amount of *Cre* recombinase-mediated excision of the packaging signals is that amount which permits the production of enough packaged helper virus to permit the slow spread of virus on the first plate of cells co-transfected with helper virus DNA (containing the *loxP* sequences) and the EAM vector. This permits serial passage of the EAM preparation onto a subsequent lawn of cells to increase the titer of the EAM preparation. Alternatively, if *Cre* recombinase-mediated excision of the packaging signals is essentially 100% efficient in all *Cre*-expressing cells lines (*i.e.*, regardless of the level of *Cre*-expression, that is even a cell line expressing a low level of *Cre* as judged by the GFP/ β -gal assay described above), the packaged EAMs may be used along with helper virus (used at a MOI of ~1.0) to infect the second or subsequent lawn of cells to permit serial passaging to increase the titer of the EAM preparation.

15 Following introduction of the *loxP* sequences into the shuttle vector, the human placental alkaline phosphatase (HpAp) cDNA under control of the RSV promoter was inserted into the polylinker to provide a reporter gene for the helper virus. This is the same reporter used previously during EAM generation (Ex. 6). The HpAp sequences were inserted as follows. The *loxP*-containing shuttle vector was linearized with *Xba*I and the hpAp cassette was ligated into the *Xba*I site (a *Xba*I site was inserted into pAdBglIII during the insertion of the *loxP* sequences as a *Xba*I site was located on the 3' end of the *loxP* sequences inserted into the *Bg*/II site of pAdBglIII). The HpAp cassette was constructed as follows.

pRSVh.APT40 (obtained from Gary Nabel, Univ. of Michigan, Ann Arbor, MI) was digested with *Eco*RI to generate an *Eco*RI fragment containing the HpAP cDNA and the SV40 intron and polyadenylation sequences. pRc/RSV (Invitrogen) was digested with *Hind*III, then partially digested with *Eco*RI. A 5.208 bp fragment was then size selected on an agarose gel, 5 treated with calf alkaline phosphatase, and ligated to the *Eco*RI fragment derived from pRSVhAPT40 to generate pRc/RSVAP. pRc/RSVAP was then digested with *Sal*I and *Xba*I to liberate the RSV promoter linked to the HpAP cDNA cassette (including the SV40 intron and polyadenylation sequences). This *Sal*I-*Xba*I fragment was inserted into the *loxP*-containing shuttle vector which had been digested with *Sal*I and *Xba*I to generate pADLoxP-RSVAP.

10 Helper virus containing *loxP* sites flanking the Ad packaging signals is generated by co-transfection of the *LoxP* shuttle plasmid (pADLoxP-RSVAP) and *Cla*I-digested Ad5dI7001 DNA into 293 cells [Graham and Prevec (1991) Manipulation of Adenovirus Vectors. In *Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols*. Murray (ed.). Humana Press Inc., Clifton, NJ, pp. 109-128]. Figure 19 provides a schematic 15 showing the recombination event between the *loxP* shuttle vector and the Ad5dI7001 genome. Co-transfection is carried out as described in Example 3c.

20 Alternatively, the reporter gene may be inserted into the E3 region of pBHG10 or pBHG11 (using the unique *Pac*I site) rather than into the polylinker located in the E1 region of the shuttle vector. The reporter gene-containing pBHG10 or 11 is then used in place of Ad5dI7001 for cotransfection of 293 cells along with the *loxP*-containing pAdBglII.

25 Following cotransfection, recombinant plaques are picked, plaque purified, and tested for incorporation of both hpAp and *loxP* sequences by PCR and Southern analysis (Ex. 3). Viruses which contain *loxP* sites flanking the packaging signals and the marker gene (hpAp) are retained, propagated and purified.

The isolated helper virus containing *loxP* sites flanking the packaging signals and the marker gene is then used to infect both 293 cells and the 293 cell lines that express *Cre* (section a. above). *Cre* recombinase-expressing cell lines that produce optimal levels of *Cre* recombinase when infected with the *loxP*-containing helper virus are then used for the generation of EAMs as described below.

c) **Generation Of Encapsidated Adenovirus Minichromosomes
That Express Dystrophin**

The growth of EAMs is optimized using the following methods. In the first method, plasmid DNA from the EAM vector (Ex. 6) are co-transfected into 293 cells with purified viral DNA from the helper virus, and viruses are harvested 10-14 days later after appearance of a viral cytopathic effect (CPE) as described in Example 6. This approach is simple, yet potentially increases helper virus levels by allowing viral spread throughout the culture dishes.

In the second method, the co-transfected 293 cells are overlaid with agar and single plaques are picked and tested for EAM activity by the ability to express β -galactosidase activity following infection of HeLa cells (Ex. 6). This second approach is more time consuming, but will result in less contamination by helper.

The ability of these two methods to generate EAMs are directly compared. The preferred method is that which produces the highest titer of EAM with the lowest contamination of helper virus. The efficiency of EAM generation may also be increased by using helper virus DNA that retains the terminal protein (TP) (*i.e.*, the helper virus is used as a viral DNA-TPC as described in Ex. 3). The use of viral DNA-TPC has been shown to increase the efficiency of viral production following transfection of 293 cells by an order of magnitude [Miyake *et al.* (1996), *supra*].

The initial transfection will utilize 293 cells that do not express *Cre* recombinase, so that efficient spread of the helper can lead to large scale production of EAM. The method producing the highest ratio of EAM to helper virus is then employed to optimize conditions for the serial propagation of the EAM on 293 cells expressing *Cre* recombinase. This optimization is conducted using cell lines expressing different levels of *Cre* recombinase. The following variables are tested: 1) the ratio of input viral titer to cell number, 2) the number of serial passages to use for EAM generation, 3) the use of cell lines producing different levels of *Cre* to achieve the optimal ratio between high EAM titer and low helper titer, 4) continuous growth on *Cre*-producing 293 cells versus alternating between *Cre*-producing cells and the parental 293 cells, or to alternate between high and low *Cre*-producing cells and 5) CsCl purification of EAMs prior to re-infection of 293 cells increases the ratio of the final EAM/helper titers. The protocols that result in the highest yield of EAM with minimal helper virus are used to generate large volumes of crude viral lysates for purification by density gradient centrifugation (Ex. 6).

EAMs were purified from helper virus using standard CsCl density gradient centrifugation protocols in Example 6 and resulted in preparations containing ~4% helper virus. In order to improve the physical separation of EAMs and helper virus, a variety of different centrifugation conditions are possible, including changing the gradient shape, type of rotor and tube used, combinations of step and continuous gradients, and the number of gradients used. Materials with better resolving powers than CsCl can also be employed. These include rubidium chloride and potassium bromide [Reich and Zarybnicky (1979) *Annal. Biochem.* 94:193].

10 d) **Use Of EAMs Encoding Dystrophin For Long Term
Expression Of Dystrophin in Muscle**

To demonstrate the ability of the purified dystrophin expressing EAMs (prepared as described above) to deliver and express dystrophin in the muscle of an animal, the following experiment is conducted. First, purified dystrophin-EAMs are delivered to the muscle by direct intramuscular injection into newborn, 1 month, and adult (3 month) mouse quadriceps muscle. The dystrophin expressing EAM Ad5 β Dys are injected into *mdx* mice and into transgenic *mdx* mice that express β -galactosidase in the pituitary gland [Tripathy *et al.* (1996) *Nature Med.* 2:545]. These latter mice are used to avoid potential immune-rejection of cells expressing β -galactosidase from the Ad5 β Dys vector. An alternate EAM lacking the β -galactosidase reporter gene may also be employed; however, the presence of the β -Gal reporter simplifies EAM growth and purification (vectors lacking β -Gal have their purity estimated by PCR assays rather than by β -Gal assays).

Following intramuscular injection of EAM, animals are sacrificed at intervals between 1 week and 6 months to measure dystrophin expression [by western blot analysis and by immunofluorescence (Phelps *et al.* (1995) *Hum. Mol. Genet.* 4:1251 and Rafael *et al.* (1996) *J. Cell Biol.* 134:93] and muscle extracts will also be assayed for β -Gal activity [MacGregor *et al.* (1991), *supra*]. These results are compared with previous results obtained using current generation viral vectors (*i.e.*, containing deletions in E1 and E3 only) to demonstrate that EAMs improve the prospects for long term gene expression in muscle.

e) Use Of Dystrophin-EAMs To Prevent, Halt, Or Reverse The
Dystrophic Symptoms That Develop In The Muscles Of *mdx*
Mice

To demonstrate that beneficial effects on dystrophic muscle are achieved by delivery of dystrophin expressing EAMs to *mdx* mice, the following experiments are conducted. Central nuclei counts are performed on soleus muscle at intervals following injection of EAM into newborn, 1 month, and 3 month (adult) mice (Phelps *et al.*, 1995). Central nuclei arise in mouse muscle only after a myofiber has undergone dystrophic necrosis followed by regeneration, and is a quantitative measure of the degree of dystrophy that has occurred in a muscle group (Phelps *et al.*, 1995).

More informative assays are also contemplated. These assays require administration of EAMs to mouse diaphragm muscles.

The diaphragm is severely affected in *mdx* mice (Stedman *et al.*, 1991; Cox *et al.*, 1993), and displays dramatic decreases in both force and power generation. Administration of virus to the diaphragm will allow the strength of the muscles to be measured at intervals following dystrophin delivery. The force and power generating assays developed by the Faulkner lab are used to measure the effect of dystrophin transgenes (Shrager *et al.*, 1992; Rafael *et al.*, 1994; Lynch *et al.*, 1996).

To determine whether dystrophin delivery to dystrophic muscle reverses dystrophy or stabilizes muscle, varying amounts of the dystrophin EAM are delivered to the diaphragm at different stages of the dystrophic process and then strength is measured at intervals following EAM administration. First, various titers of EAM are tested to determine the minimal amount of virus needed to transduce the majority of muscle fibers in the diaphragm. It has been shown that conventional adenovirus vectors can transduce the majority of diaphragm fibers when 10^8 pfu are administrated by direct injection into the intraperitoneal cavity [Huard *et al.* (1995) Gene Therapy 2:107]. In addition, it has been shown that transduction of a simple majority of fibers in a muscle group is sufficient to prevent virtually all the dystrophic symptoms in mice [Rafael *et al.* (1994) Hum. Mol. Genet. 3:1725 and Phelps *et al.* (1995) Hum. Mol. Genet. 4:1251]. Virus is administered to *mdx* animals at three different ages (neonatal, 1 month, and 3 months). Animals are sacrificed for physiological analysis of diaphragm muscle at two different times post infection (1 month and 3 months). Error control is achieved by performing these experiments in sextuplicate. Control animals consist of mock injected wild-type (C57Bl/10) and dystrophic (*mdx*) mice. Three month old

mdx mice display a 40% reduction in force and power generation compared with wild-type mice, while 6 month animals display a greater than 50% reduction (Cox *et al.* (1993) *Nature* 364:725; Rafael *et al.* (1994). *supra*; Phelps *et al.* (1995). *supra*; and Corrado *et al.* (1996) *J. Cell. Biol.* 134:873].

5

EXAMPLE 8

Improved Shuttle Vectors For The Production Of Helper Virus Containing *LoxP* Sites

10 In the previous example, a shuttle vector containing adenoviral sequences extending from 9 mu to 16 mu of the Ad5 genome was modified to contain *loxP* sequences surrounding the packaging signals (the *LoxP* shuttle vector). This modified shuttle vector was then recombined with an Ad virus to produce a helper virus containing the *loxP* sequences. This helper virus was then used to infect cells expressing *Cre* recombinase along with DNA comprising a minichromosome containing the dystrophin gene, a reporter gene and the packaging signals and ITRs of Ad in order to preferentially package the minichromosomes. Using this approach the helper virus, which has had the packaging signals removed by *Cre-loxP* recombination, contains the majority of the Ad genome (only a portion of the E3 region is deleted). Thus, if low levels of helper virus are packaged and appear in the EAM preparation, the EAM preparation has the potential of passing on helper virus capable of directing the expression of Ad proteins in cells which are exposed to the EAM preparation. The expression of Ad proteins may lead to an immune response directed against the infected cells.

20

Another approach to reducing the possibility that the EAM preparation contains helper virus capable of provoking an immune response is to use helper viruses containing deletions and/or mutations within the pol and pTP genes. Helper virus containing a deletion in the pol and/or pTP genes is cotransfected with the EAM construct into 293-derived cell lines expressing pol or pol and pTP to produce EAMs. Any helper virus present in the purified EAM preparation will be replication defective due to the deletion in the pol and/or pTP genes. As shown in Example 3, viruses containing a deletion in the pol gene are incapable of directing the expression of viral late genes; therefore, helper viruses containing a deletion in the pol gene or the pol and pTP genes should not be capable of provoking an immune response (*i.e.*, a CTL response) against late viral proteins synthesized *de novo*. Shuttle

25

30

vectors contain deletions within the Ad pol and/or pTP genes are constructed as described below.

5 **a) Construction Of A Shuttle Vector Containing The Δpol
Deletion**

pAdBglIII was modified to contain sequences corresponding to 9 to 40 mu of the Ad5 genome as follows. pAdBglIII was digested with *Bg*/II and a linker/adapter containing an *Ascl* site was added to create pAdBglIIAsc. pAdBglIIAsc was then digested with *Bst*1107I. Ad5~~d~~l7001 viral DNA was digested with *Ascl* and the ends were filled in using T4 DNA polymerase. The *Ascl*-digested, T4 DNA polymerase filled Ad5~~d~~l7001 viral DNA was then digested with *Bst*1107I and the ~9.9 kb *Ascl-Bst*1107I(filled) fragment containing the pol and pTP genes was isolated (as described in Ex. 3) and ligated to the *Bst*1107I-digested pAdBglIIAsc to generate pAdAsc. pAdAsc is a shuttle vector which contains the genes encoding the DNA polymerase and preterminal protein (the inserted *Ascl-Bst*1107I fragment corresponds to nucleotides 5767 to 15,671 of the Ad5 genome).

10 A shuttle vector, pAdAscΔpol, which contains the 612 bp deletion in the pol gene (described in Ex. 3) was constructed as follows. Ad5ΔpolΔE3I viral DNA (Ex. 3) was digested with *Ascl* and the ends were filled in using T4 DNA polymerase. The *Ascl*-digested, T4 DNA polymerase filled Ad5ΔpolΔE3I viral DNA was then digested with *Bst*1107I and the ~9.3 kb *Ascl-Bst*1107I(filled) fragment containing the deleted pol gene and the pTP gene was 15 isolated (as described in Ex. 3) and ligated to *Bst*1107I-digested pAdBglIIAsc to generate pAdAscΔpol.

20 **b) Construction Of A Shuttle Vector Containing The ΔpolΔpTP
Deletion**

A shuttle vector, pAdAscΔpolΔpTP, which contains a 2.3 kb deletion within the pol 25 and pTP genes (described in Ex. 5) was constructed as follows. pAXBΔpolΔpTPVARNA+t13 (Ex. 5b) was digested with *Ascl* and the ends were filled in using T4 DNA polymerase. The *Ascl*-digested, T4 DNA polymerase filled pAXBΔpolΔpTPVARNA+t13 DNA was then digested with *Bst*1107I and the ~7.6 kb *Ascl-Bst*1107I(filled) fragment containing the deleted pol gene and the pTP gene was isolated (as 30 described in Ex. 3) and ligated to *Bst*1107I-digested pAdBglIIAsc to generate pAdAscΔpolΔpTP.

In order to reduce the packaging of the above helper viruses, the pol⁻ or pol⁻, pTP⁻ helper viruses can be modified to incorporate *loxP* sequences on either side of the packaging

signals as outlined in Example 7. The *loxP*-containing pol⁻ or pol⁺, pTP⁻ shuttle vectors (pTP⁻ shuttle vectors may also be employed) are cotransfected into 293 cells expressing *Cre* recombinase and pol or *Cre* recombinase, pol and pTP, respectively along with an appropriate E1⁺ viral DNA-TPC (the E1⁻ viral DNA may also contain deletions elsewhere in the genome such as in the E4 genes or in the E2a gene as packaging cell lines expressing the E4 ORF 6 or 6/7 and lines expressing E2a genes are available) to generate helper virus containing *loxP* sites flanking the packaging signals as well as a deletion in the pol gene or the pol and pTP genes. The resulting helper virus(es) is used to cotransfect 293 cells expressing pol or pol and pTP along with the desired EAM construct. The resulting EAM preparation should contain little if any helper virus and any contaminating helper virus present would be replication defective and incapable of expressing viral late gene products. Helper viruses containing *loxP* sequences and deletions in all essential early genes may be employed in conjunction with *Cre* recombinase-expressing cell lines expressing *in trans* the E1, E4 ORF 6, E2a, and E2b (e.g., Ad polymerase and pTP) proteins (the E3 proteins are dispensable for growth in culture). Cell lines coexpressing E1, polymerase and pTP are provided herein.

Cell lines expressing E1 and E4 proteins have been recently described [Krougliak and Graham (1995) Hum. Gene Ther. 6:1575 and Wang *et al.* (1995) Gene Ther. 2:775] and cell lines expressing E1 and E2a proteins have been recently described [Zhou *et al.* (1996) J. Virol. 70:7030]. Therefore, a cell line co-expressing E1, E2a, E2b, and E4 is constructed by introduction of expression plasmids containing the E2a and E4 coding regions into the E1-, Ad polymerase- and pTP-expressing cell lines of the present invention. These packaging cell lines are used in conjunction with helper viruses containing deletions in the E1, E2a, E2b and E4 regions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Chamberlain, Jeffrey S.
 Amalfitano, Andrea
 Hauser, Michael A.
 Kumar-Singh, Rajendra
 Hartigan-O'Connor, Dennis J.

(ii) TITLE OF INVENTION: IMPROVED ADENOVIRUS VECTORS

(iii) NUMBER OF SEQUENCES: 15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Medlen & Carroll, LLP
 (B) STREET: 220 Montgomery Street, Suite 2200
 (C) CITY: San Francisco
 (D) STATE: California
 (E) COUNTRY: United States Of America
 (F) ZIP: 94104

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US
 (B) FILING DATE:
 (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ingolia, Diane E.
 (B) REGISTRATION NUMBER: 40,027
 (C) REFERENCE/DOCKET NUMBER: UM-02484

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 705-8410
 (B) TELEFAX: (415) 397-8338

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35935 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CATCATCAAT AATATAACCTT ATTTTGGATT GAAGCCAATA TGATAATGAG GGGGTGGAGT	60
TTGTGACGTG CGCGGGGCG TGGGAACGGG GCGGGTGACG TAGTAGTGTG GCGGAAGTGT	120
GATGTTGCAA GTGTGGCGGA ACACATGTAA GCGACGGATG TGGCAAAAGT GACGTTTTG	180
GTGTGCGCCG GTGTACACAG GAAGTGACAA TTTTCGGCG GTTTTAGGCG GATGTTGTAG	240
TAAATTTGGG CGTAACCGAG TAAGATTGG CCATTTCGC GGGAAAAGT AATAAGAGGA	300
AGTGAAATCT GAATAATTCT GTGTTACTCA TAGCGCGTAA TATTGTCTA GGGCCGCGGG	360
GACTTTGACC GTTTACGTGG AGACTCGCCC AGGTGTTTT CTCAGGTGTT TTCCGCGTTC	420
CGGGTCAAAG TTGGCGTTTT ATTATTATAG TCAGCTGACG TGTAGTGTAT TTATAACCCGG	480

TGAGTTCCTC	AAGAGGCCAC	TCTTGAGTGC	CAGCGAGTAG	AGTTTTCTCC	TCCGAGCCGC	540
TCCGACACCG	GGACTGAAAA	TGAGACATAT	TATCTGCCAC	GGAGGTGTTA	TTACCGAAGA	600
AATGGCCGCC	AGTCTTTGG	ACCAGCTGAT	CGAAGAGGTA	CTGGCTGATA	ATCTTCCACC	660
TCCTAGCCAT	TTTGAACCAC	CTACCCCTCA	CGAACTGTAT	GATTTAGACG	TGACGGCCCC	720
CGAAGATCCC	AACGAGGAGG	CGGTTTCGCA	GATTTTCCC	GAECTCTGAA	TGTTGGCGGT	780
GCAGGAAGGG	ATTGACTTAC	TCACTTTCC	GCCGGCGCCC	GGTTCTCCGG	AGCCGCCTCA	840
CCTTCCCAGG	CAGCCCGAGC	AGCCGGAGCA	GAGAGCCTTG	GGTCCGGTTT	CTATGCCAAA	900
CCTTGTACCG	GAGGTGATCG	ATCTTACCTG	CCACGAGGCT	GGCTTCCAC	CCAGTGACGA	960
CGAGGATGAA	GAGGGTGAGG	AGTTTGTTG	AGATTATGTG	GAGCACCCCG	GGCACGGTTG	1020
CAGGTCTTGT	CATTATCACC	GGAGGAATAC	GGGGGACCCA	GATATTATGT	GTTCGCTTTG	1080
CTATATGAGG	ACCTGTGGCA	TGTTTGTCTA	CAGTAAGTGA	AAATTATGGG	CAGTGGGTGA	1140
TAGAGTGGTG	GGTTTGGTGT	GGTAATTTTT	TTTTTAATT	TTACAGTTT	GTGGTTAAA	1200
GAATTTGTA	TTGTGATTT	TTTAAAGGT	CCTGTGTCTG	AACCTGAGCC	TGAGCCCGAG	1260
CCAGAACCGG	AGCCTGCAAG	ACCTACCCGC	CGTCCTAAAA	TGGCGCCTGC	TATCCTGAGA	1320
CGCCCGACAT	CACCTGTGTC	TAGAGAATGC	AATAGTAGTA	CGGATAGCTG	TGACTCCGGT	1380
CCTTCTAACCA	CACCTCCTGA	GATAACCCCG	GTGGTCCCAG	TGTGCCCAT	TAAACCAGTT	1440
CCCGTGAGAG	TTGGTGGCG	TCGCCAGGCT	GTGGAATGTA	TCGAGGACTT	GCTTAACGAG	1500
CCTGGCAAC	CTTTGGACTT	GAGCTGTAAA	CGCCCCAGGC	CATAAGGTGT	AAACCTGTGA	1560
TTGCGTGTGT	GGTTAACGCC	TTTGTGCTG	GAATGAGTTG	ATGTAAGTTT	AATAAAGGGT	1620
GAGATAATGT	TTAACTTGCA	TGGCGTGTAA	AATGGGGCGG	GGCTTAAAGG	GTATATAATG	1680
CGCCGTGGGC	TAATCTTGGT	TACATCTGAC	CTCATGGAGG	CTTGGGAGTG	TTTGGAAAGAT	1740
TTTCTGCTG	TGCGTAACCT	GCTGGAACAG	AGCTCTAACCA	GTACCTCTTG	GTGTTGGAGG	1800
TTTCTGTGGG	GCTCATCCCA	GGCAAAGTTA	GTCTGCAGAA	TTAAGGAGGA	TTACAAGTGG	1860
GAATTTGAAG	AGCTTTGAA	ATCCTGTGGT	GAGCTGTTG	ATTCTTGAA	TCTGGTCAC	1920
CAGGCGCTTT	TCCAAGAGAA	GGTCATCAAG	ACTTTGGATT	TTTCCACACC	GGGGCGCGCT	1980
CGGGCTGCTG	TTGCTTTTTT	GAGTTTATA	AAGGATAAAAT	GGAGCGAAGA	AAACCCATCTG	2040
AGCGGGGGGT	ACCTGCTGGA	TTTTCTGGCC	ATGCATCTGT	GGAGAGCGGT	TGTGAGACAC	2100
AAGAATCGCC	TGCTACTGTT	GTCTTCCGTC	CGCCCCGGCGA	TAATACCGAC	GGAGGAGCAG	2160
CAGCAGCAGC	AGGAGGAAGC	CAGGCCGGCG	CGGCAGGAGC	AGAGCCCAG	GAACCCGAGA	2220
GCCGGCTGG	ACCCTCGGGA	ATGAATGTTG	TACAGGTGGC	TGAACTGTAT	CCAGAACTGA	2280
GACGCATTT	GACAATTACA	GAGGATGGGC	AGGGGCTAAA	GGGGTAAAG	AGGGAGCGGG	2340
GGGCTTGTGA	GGCTACAGAG	GAGGCTAGGA	ATCTAGCTTT	TAGCTTAATG	ACCAGACACC	2400
GTCCTGAGTG	TATTACTTTT	CAACAGATCA	AGGATAATTG	CGCTAATGAG	CTTGATCTGC	2460
TGGCGCAGAA	GTATTCCATA	GAGCAGCTGA	CCACTTACTG	GCTGCAGCCA	GGGGATGATT	2520
TTGAGGAGGC	TATTAGGGTA	TATGCAAAGG	TGGCACTTAG	GCCAGATTGC	AACTACAAGA	2580

TCAGCAACT	TGTAAATATC	AGGAATTGTT	GCTACATTC	TGGGAACGGG	GCCGAGGTGG	2640
AGATAGATAC	GGAGGATAGG	GTGGCCTTA	GATGTAGCAT	GATAAATATG	TGGCCGGGG	2700
TGCTTGGCAT	GGACGGGGTG	GTTATTATGA	ATGTAAGGTT	TACTGGCCCC	AATTTAGCG	2760
GTACGGTTT	CCTGCCAAT	ACCAACCTTA	TCCTACACGG	TGTAAGCTTC	TATGGGTTA	2820
ACAATACCTG	TGTGGAAGCC	TGGACCGATG	TAAGGGTTCG	GGGCTGTGCC	TTTTACTGCT	2880
GCTGGAAGGG	GGTGGTGTGT	CGCCCCAAA	GCAGGGCTTC	AATTAAGAAA	TGCCTCTTG	2940
AAAGGTGTAC	CTTGGGTATC	CTGTCTGAGG	GTAACTCCAG	GGTGCGCCAC	AATGTGGCCT	3000
CCGACTGTGG	TTGCTTCATG	CTAGTGAAAA	GCGTGGCTGT	GATTAAGCAT	AACATGGTAT	3060
GTGGCAACTG	CGAGGACAGG	GCCTCTCAGA	TGCTGACCTG	CTCGGACGGC	AACTGTCA	3120
TGCTGAAGAC	CATTACCGTA	GCCAGCCACT	CTCGCAAGGC	CTGGCCAGTG	TTTGAGCATA	3180
ACATACTGAC	CCGCTGTTCC	TTGCATTGG	GTAACAGGAG	GGGGGTGTT	CTACCTTACC	3240
AATGCAATT	GAGTCACACT	AAGATATTGC	TTGAGCCGA	GAGCATGTCC	AAGGTGAACC	3300
TGAACGGGGT	GTGGACATG	ACCATGAAGA	TCTGGAAGGT	GCTGAGGTAC	GATGAGACCC	3360
GCACCAGGTG	CAGACCCCTGC	GAGTGTGGCG	GTAAACATAT	TAGGAACCAG	CCTGTGATGC	3420
TGGATGTGAC	CGAGGAGCTG	AGGCCCGATC	ACTTGGTGCT	GGCCTGCACC	CGCGCTGAGT	3480
TTGGCTCTAG	CGATGAAGAT	ACAGATTGAG	GTACTGAAAT	GTGTGGCGT	GGCTTAAGGG	3540
TGGGAAAGAA	TATATAAGGT	GGGGGTCTTA	TGTAGTTTG	TATCTGTTT	GCAGCAGCCG	3600
CCGCCGCCAT	GAGCACCAAC	TCGTTTGATG	GAAGCATTGT	GAGCTCATAT	TTGACAACGC	3660
GCATGCCCCC	ATGGGCCGGG	GTGCGTCAGA	ATGTGATGGG	CTCCAGCATT	GATGGTCGCC	3720
CCGTCCCTGCC	CGCAAACCT	ACTACCTTGA	CCTACGAGAC	CGTGTCTGGA	ACGCCGTTGG	3780
AGACTGCAGC	CTCCGCCGCC	GCTTCAGCCG	CTGCAGCCAC	CGCCCGCGGG	ATTGTGACTG	3840
ACTTTGCTT	CCTGAGCCCG	CTTGCAAGCA	GTGCAGCTTC	CCGTTCATCC	GCCCGCGATG	3900
ACAAGTTGAC	GGCTCTTTG	GCACAATTGG	ATTCTTGAC	CCGGGAACCT	AATGTCGTT	3960
CTCAGCAGCT	GTTGGATCTG	CGCCAGCAGG	TTTCTGCCCT	GAAGGCTTCC	TCCCCCTCCCA	4020
ATGCGGTTA	AAACATAAAT	AAAAAACAG	ACTCTGTTG	GATTGGATC	AAGCAAGTGT	4080
CTTGCTGTCT	TTATTAGGG	GTGGCGCG	CGCGGTAGGC	CCGGGACCAG	CGGTCTCGGT	4140
CGTTGAGGGT	CCTGTGTATT	TTTCCAGGA	CGTGGTAAAG	GTGACTCTGG	ATGTTCAGAT	4200
ACATGGGCAT	AAGCCCGTCT	CTGGGGTGG	GGTAGCACCA	CTGCAGAGCT	TCATGCTGCG	4260
GGGTGGGTGTT	GTAGATGATC	CAGTCGTAGC	AGGAGCGCTG	GGCGTGGTGC	CTAAAAATGT	4320
CTTTCAGTAG	CAAGCTGATT	GCCAGGGCA	GGCCCTTGGT	GTAAGTGT	ACAAAGCGGT	4380
TAAGCTGGGA	TGGGTGCATA	CGTGGGGATA	TGAGATGCAT	CTTGGACTGT	ATTTTTAGGT	4440
TGGCTATGTT	CCCAGCCATA	TCCCTCCGGG	GATTCAATGTT	GTGCAGAAC	ACCAGCACAG	4500
TGTATCCGGT	GCACCTGGGA	AATTTGTAT	GTAGCTTAGA	AGGAAATGCG	TGGAAGAACT	4560
TGGAGACGCC	CTTGTGACCT	CCAAGATTT	CCATGCATTC	GTCCATAATG	ATGGCAATGG	4620
CCCCACGGGC	GGCGGGCTGG	GCGAAGATAT	TTCTGGGATC	ACTAACGTCA	TAGTTGTGTT	4680

CCAGGATGAG ATCGTCATAG GCCATTTTA CAAAGCGCG GCGGAGGGTG CCAGACTGCG	4740
GTATAATGGT TCCATCCGGC CCAGGGCGT AGTTACCTC ACAGATTGC ATTTCCCACG	4800
CTTGAGTTA AGATGGGGG ATCATGTCTA CCTGCGGGC GATGAAGAAA ACGGTTCCG	4860
GGGTAGGGGA GATCAGCTGG GAAGAAAGCA GGTCCTGAG CAGCTGCGAC TTACCGCAGC	4920
CGGTGGGCC GTAAATCACA CCTATTACCG GGTGCAACTG GTAGTTAAGA GAGCTGCAGC	4980
TGCCGTACATC CCTGAGCAGG GGGGCCACTT CGTTAACAT GTCCCTGACT CGCATGTTT	5040
CCCTGACCRA ATCCGCCAGA AGCGCTCGC CGCCCAAGCGA TAGCAGTTCT TGCAAGGAAG	5100
CAAAGTTTT CAACGGTTT AGACCGTCCG CCGTAGGCAT GCTTTGAGC GTTTGACCAA	5160
GCAGTTCCAG GCGGTCCCAC AGCTCGGTCA CCTGCTCTAC GGCACTCTCGA TCCAGCATAT	5220
CTCCTCGTT CGCGGGTTGG GGCGGCTTTC GCTGTACGGC AGTAGTCGGT GCTCGTCCAG	5280
ACGGGCCAGG GTCATGTCTT TCCACGGCG CAGGGTCCTC GTCAAGCGTAG TCTGGGTAC	5340
GGTGAAGGGG TGCGCTCCGG GCTGCGCGT GGCCAGGGTG CGCTTGAGGC TGGTCCTGCT	5400
GGTGCTGAAG CGCTGCCGGT CTTCGCCCTG CGCGTCGGCC AGGTAGCATT TGACCATGGT	5460
GTCATAGTCC AGCCCCCTCG CGCGTGGCC CTTGGCGCG AGCTTGCCT TGAGGAGGC	5520
GCCGCACGAG GGGCAGTGCA GACTTTGAG GGCGTAGAGC TTGGGCGCGA GAAATACCGA	5580
TTCCGGGGAG TAGGCATCCG CGCCGCAGGC CCCGCAGACG GTCTCGCATT CCACGAGCCA	5640
GGTGAGCTCT GGCGTTCGG GGTAAAAAAC CAGGTTCCC CCATGCTTT TGATGCGTTT	5700
CTTACCTCTG GTTTCCATGA GCCGGTGTCC ACGCTCGGTG ACCAAAAGGC TGTCCGTGTC	5760
CCCGTATACA GACTTGAGAG GCCTGTCTC GAGCGGTGTT CCGCGGTCT CCTCGTATAG	5820
AAACTCGGAC CACTCTGAGA CAAAGGCTCG CGTCCAGGCC AGCACGAAGG AGGCTAAGTG	5880
GGAGGGGTAG CGGTGTTGT CCACTAGGGG GTCCACTCGC TCCAGGGTGT GAAGACACAT	5940
GTCGCCCTCT TCGGCATCAA GGAAGGTGAT TGGTTGTAG GTGTAGGCCA CGTGACCGGG	6000
TGTTCCCTGAA GGGGGCTAT AAAAGGGGGT GGGGGCGCGT TCGTCCTCAC TCTCTTCCGC	6060
ATCGCTGTCT GCGAGGGCCA GCTGTTGGGG TGAGTACTCC CTCTGAAAAG CGGGCATGAC	6120
TTCTGCGCTA AGATTGTCAG TTTCCAAAAA CGAGGAGGAT TTGATATTCA CCTGGCCCAG	6180
GGTGATGCCT TTGAGGGTGG CCGCATCCAT CTGGTCAGAA AAGACAATCT TTTTGTGTC	6240
AAGCTTGGTG GCAAACGACC CGTAGAGGGC GTTGGACAGC AACTTGGCGA TGGAGGCCAG	6300
GGTTTGGTTT TTGTCGCGAT CGGCGCGCTC CTTGGCCGCG ATGTTAGCT GCACGTATTC	6360
GCGCGCAACG CACCGCCATT CGGGAAAGAC GGTGGTGCAGC TCGTCGGGCA CCAGGTGCAC	6420
GCGCCAACCG CGGTTGTGCA GGGTGACAAG GTCAACGCTG GTGGCTACCT CTCCCGTAG	6480
GCGCTCGTTG GTCCAGCAGA GGCGGCCGCC CTTGCGCGAG CAGAATGGCG GTAGGGGTC	6540
TAGCTGCGTC TCGTCGGGG GGTCTGCGTC CACGGTAAAG ACCCCGGGCA GCAGGGCGCG	6600
GTCGAAGTAG TCTATCTTGC ATCCTTGCAA GTCTAGCGCC TGCTGCCATG CGCGGGCGGC	6660
AAGCGCGCGC TCGTATGGGT TGAGTGGGG ACCCCATGGC ATGGGGTGGG TGAGCCCGGA	6720
GGCGTACATG CCGCAAATGT CGTAAACGTA GAGGGCTCT CTGAGTATTC CAAGATATGT	6780

AGGGTAGCAT CTTCCACCGC GGATGCTGGC GCGCACGTA TCGTATAGTT CGTGCAGGG	6840
AGCGAGGAGG TCGGGACCGA GGTGCTACG GGCGGGCTGC TCTGCTCGGA AGACTATCTG	6900
CCTGAAGATG GCATGTGAGT TGGATGATAT GGTTGGACGC TGGAAGACGT TGAAGCTGGC	6960
GTCTGTGAGA CCTACCGCGT CACGCACGAA GGAGGCGTAG GAGTCGCGCA GCTTGTGAC	7020
CAGCTCGCG GTGACCTGCA CGTCTAGGGC GCAGTAGTCC AGGGTTTCCT TGATGATGTC	7080
ATACTTATCC TGTCCCCTTT TTTTCCACAG CTCGCGTTG AGGACAAACT CTTCGGGTC	7140
TTTCCAGTAC TCTTGGATCG GAAACCCGTC GGCCCTCGAA CGGTAAGAGC CTAGCATGTA	7200
GAACCTGGTTG ACGGCCTGGT AGGCGCAGCA TCCCTTTCT ACGGGTAGCG CGTATGCCG	7260
CGCGGGCTTC CGGAGCGAGG TGTGGGTGAG CGCAAAGGTG TCCCTGACCA TGACTTGAG	7320
GTACTGGTAT TTGAAGTCAG TGTGTCGCA TCCGCCCTGC TCCCAGAGCA AAAAGTCCGT	7380
GCGCTTTTG GAACGCGGAT TTGGCAGGGC GAAGGTGACA TCGTTGAAGA GTATCTTCC	7440
CGCGCGAGGC ATAAAGTTGC GTGTGATGCG GAAGGGTCCC GGCACCTCGG AACGGTTGTT	7500
AATTACCTGG GCGCGAGCA CGATCTCGTC AAAGCCGTTG ATGTTGTGGC CCACAATGTA	7560
AAGTTCCAAG AAGCGGGGA TGCCCTTGAT GGAAGGCAAT TTTTAAGTT CCTCGTAGGT	7620
GAGCTCTTCA GGGGAGCTGA GCCCGTGCTC TGAAAGGGCC CAGTCTGCAA GATGAGGGTT	7680
GGAAGCGCAGC AATGAGCTCC ACAGGTCACG GCCCATTAGC ATTTGCAGGT GGTCGCGAAA	7740
GGTCCTAAC TGGCGACCTA TGGCCATTTC TTCTGGGTG ATGCAGTAGA AGGTAAGCGG	7800
GTCTTGTTC CAGCGGTCCC ATCCAAGGTT CGCGGCTAGG TCTCGCGCGG CAGTCACTAG	7860
AGGCTCATCT CCGCCGAAC TCACTGACCAG CATGAAGGGC ACGAGCTGCT TCCCAAAGGC	7920
CCCCATCCAA GTATAGGTCT CTACATCGTA GGTGACAAAG AGACGCTCGG TGCGAGGATG	7980
CGAGCCGATC GGGAAAGAACT GGATCTCCCG CCACCAATTG GAGGAGTGGC TATTGATGTG	8040
GTGAAAGTAG AAGTCCCTGC GACGGGCCGA ACACTCGTGC TGGTTTTGT AAAAAACGTGC	8100
GCAGTACTGG CAGCGGTGCA CGGGCTGTAC ATCCTGCACG AGGTTGACCT GACGACCGCG	8160
CACAAGGAAG CAGAGTGGGA ATTGAGCCC CTCGCCTGGC GGGTTTGGCT GGTGGTCTTC	8220
TACTTCGGCT GCTTGTCTT GACCGTCTGG CTGCTCGAGG GGAGTTACGG TGGATCGGAC	8280
CACCACGCCG CGCGAGCCCA AAGTCCAGAT GTCCGCGCGC GGCGGTGGA GCTTGATGAC	8340
AACATCGCGC AGATGGGAGC TGTCCATGGT CTGGAGCTCC CGCGCGTCA GGTCAAGGGGG	8400
GAGCTCCTGC AGGTTACCT CGCATAGACG GGTCAGGGCG CGGGCTAGAT CCAGGTGATA	8460
CCTAATTCC AGGGGCTGGT TGGTGGCGGC GTCGATGGCT TGCAAGAGGC CGCATCCCCG	8520
CGCGCGACT ACGGTACCGC GCGGCAGGCG GTGGGCCCG GGGGTGTCCCT TGGATGATGC	8580
ATCTAAAGC GGTGACGCCG GCGAGCCCCC GGAGGTAGGG GGGGCTCCGG ACCCGCCGGG	8640
AGAGGGGGCA GGGGCACGTC GGCAGCGCGC GCGGGCAGGA GCTGGTGCTG CGCGCGTAGG	8700
TTGCTGGCGA ACGCGACGAC GCGCGGGTTG ATCTCCTGAA TCTGGCGCCT CTGCGTGAAG	8760
ACGACGGGCC CGGTGAGCTT GAGCCTGAAA GAGAGTCGA CAGAATCAAT TTCGGTGTG	8820
TTGACGGCGG CCTGGCGCAA AATCTCCTGC ACGTCTCCTG AGTTGTCTTG ATAGGCGATC	8880

TCGGCCATGA	ACTGCTCGAT	CTCTTCCCTCC	TGGAGATCTC	CGCGTCCGGC	TCGCTCCACG	8940
GTGGCGGCGA	GGTCGTTGGA	AATGCGGGCC	ATGAGCTGCG	AGAAGGCAGT	GAGGCCTCCC	9000
TCGTTCCAGA	CGCGGCTGTA	GACCACGCC	CCTTCGGCAT	CGCGGGCGCG	CATGACCACC	9060
TGCGCGAGAT	TGAGCTCCAC	GTGCCGGCG	AAGACGGCGT	AGTTTCGCAG	GCGCTGAAAG	9120
AGGTAGTTGA	GGGTGGTGGC	GGTGTGTTCT	GCCACGAAGA	AGTACATAAC	CCAGCGTCGC	9180
AACGTGGATT	CGTTGATATC	CCCCAAGGCC	TCAAGGCAGT	CCATGGCCTC	GTAGAAGTCC	9240
ACGGCGAAGT	TGAAAAACTG	GGAGTTGCAG	GCCGACACGG	TTAACTCCTC	CTCCAGAAGA	9300
CGGATGAGCT	CGGGCACAGT	GTCGCGCACC	TCGCGCTCAA	AGGCTACAGG	GGCCTCTTCT	9360
TCTTCTTCAA	TCTCCTCTTC	CATAAGGCC	TCCCCTCTT	CTTCTTCTGG	CGGCGGTGGG	9420
GGAGGGGGGA	CACGGCGGCG	ACGACGGCGC	ACCGGGAGGC	GGTCGACAAA	GCGCTCGATC	9480
ATCTCCCCGC	GGCGACGGCG	CATGGTCTCG	GTGACGGCGC	GGCCGTTCTC	GCGGGGGCGC	9540
AGTTGGAAGA	CGCCGCCCCGT	CATGTCCCGG	TTATGGGTTG	GCGGGGGGCT	GCCATGCGGC	9600
AGGGATAACGG	CGCTAACGAT	GCATCTCAAC	AATTGTTGTG	TAGGTACTCC	GCCGCCGAGG	9660
GACCTGAGCG	AGTCGCATC	GACCGGATCG	GAAAACCTCT	CGAGAAAGGC	GTCTAACAG	9720
TCACAGTCGC	AAGGTAGGCT	GAGCACCGTG	GCGGGCGGCA	GCAGGGCGCG	GTGGGGTTG	9780
TTTCTGGCGG	AGGTGCTGCT	GATGATGTAA	TTAAAGTAGG	CGGTCTTGAG	ACGGCGGATG	9840
GTCGACAGAA	GCACCATGTC	CTTGGGTCCG	GCCTGCTGAA	TGCGCAGGCG	GTGGCCATG	9900
CCCCAGGCTT	CGTTTGACA	TCGGCGCAGG	TCTTTGAGT	AGTCTTGAT	GAGCCTTTCT	9960
ACCGGCACCTT	CTTCTTCTCC	TTCTCTTGT	CCTGCATCTC	TTGCATCTAT	CGCTGGCG	10020
GCGGCGGAGT	TTGGCCGTAG	GTGGCGCCCT	CTTCCTCCCA	TGCGTGTGAC	CCCGAAGCCC	10080
CTCATCGGCT	GAAGCAGGGC	TAGGTCGGCG	ACAACCGCCT	CGGCTAATAT	GGCCTGCTGC	10140
ACCTGCGTGA	GGGTAGACTG	GAAGTCATCC	ATGTCCACAA	AGCGGTGGTA	TGCGCCCGTG	10200
TTGATGGTGT	AAAGTGCAGTT	GGCCATAACG	GACCAGTTAA	CGGTCTGGTG	ACCCGGCTGC	10260
GAGAGCTCGG	TGTACCTGAG	ACCGAGTAA	GCCCTCGAGT	CAAATACGTA	GTGTTGCAA	10320
GTCCGCACCA	GGTACTGGTA	TCCCACAAA	AAAGTGGCGC	GCGGCTGGCG	GTAGAGGGC	10380
CAGCGTAGGG	TGGCGGGGGC	TCCGGGGCG	AGATCTCCA	ACATAAGGC	ATGATATCCG	10440
TAGATGTACC	TGGACATCCA	GGTGATGCCG	GCGGCGGTGG	TGGAGGCGCG	CGGAAAGTCG	10500
CGGACGCGGT	TCCAGATGTT	GCGCAGCGGC	AAAAAGTGCT	CCATGGTCGG	GACGCTCTGG	10560
CCGGTCAGGC	GCGCGCAATC	GTTGACGCTC	TAGACCGTGC	AAAAGGAGAG	CCTGTAAGCG	10620
GGCACTCTTC	CGTGGCTGG	TGGATAAATT	CGCAAGGGTA	TCATGGCGGA	CGACCGGGGT	10680
TCGAGCCCCG	TATCCGGCCG	TCCGCCGTGA	TCCATGCGGT	TACCGCCCGC	GTGTCGAACC	10740
CAGGTGTGCG	ACGTCAGACA	ACGGGGGAGT	GCTCCTTTG	GCTTCCTTCC	AGGCGCGCG	10800
GCTGCTGCGC	TAGCTTTTT	GGCCACTGGC	CGCGCGCAGC	GTAAGCGGTT	AGGCTGGAAA	10860
GCGAAAGCAT	TAAGTGGCTC	GCTCCCTGTA	GCCGGAGGGT	TATTTCCAA	GGGTTGAGTC	10920
GCGGGACCCC	CGGTCGAGT	CTCGGACCGG	CCGGACTGCG	GCGAACGGGG	GTTCGCCTCC	10980

CCGTCATCCA AGACCCCGCT TGCAAATTCC TCCGGAAACA GGGACGAGCC CCTTTTTTGC 11040
 TTTTCCCAGA TGCATCCGGT GCTGCGGCAG ATGCGCCCCC CTCTCAGCA GCGGCAAGAG 11100
 CAAGAGCAGC GGCAGACATG CAGGGCACCC TCCCCTCCTC CTACCGCGTC AGGAGGGGCG 11160
 ACATCCGCGG TTGACGCGGC AGCAGATGGT GATTACGAAC CCCCGCGGCC CGGGGCCCGG 11220
 CACTACCTGG ACTTGGAGGA GGGCGAGGGC CTGGCGCGGC TAGGAGGCC CTCTCCTGAG 11280
 CGGTACCCAA GGGTGCAGCT GAAGCGTGAT ACGCGTGAGG CGTACGTGCC GCGGCAGAAC 11340
 CTGTTTCGCG ACCCGGAGGG AGAGGAGCCC GAGGAGATGC GGGATCGAAA GTTCCACGCA 11400
 GGGCGCGAGC TGCGGCATGG CCTGAATCGC GAGCGGTTGC TGCGCGAGGA GGACTTGAG 11460
 CCCGACGCGC GAACCGGGAT TAGTCCCAGG CGCGCACACG TGGCGGCCGC CGACCTGGTA 11520
 ACCGCATAACG AGCAGACGGT GAACCAGGAG ATTAACCTTC AAAAAAGCTT TAACAACCAC 11580
 GTGCGTACGC TTGTGGCGCG CGAGGAGGTG GCTATAGGAC TGATGCATCT GTGGGACTTT 11640
 GTAAAGCGCGC TGGAGCAAAA CCCAAATAGC AAGCCGCTCA TGGCGCAGCT GTTCCTTATA 11700
 GTGCAGCACA GCAGGGACAA CGAGGCATTG AGGGATGCGC TGCTAAACAT AGTAGAGCCC 11760
 GAGGGCCGCT GGCTGCTCGA TTTGATAAAC ATCCTGCAGA GCATAGTGGT GCAGGAGCGC 11820
 AGCTTGAGCC TGGCTGACAA GGTGGCCGCC ATCAACTATT CCATGCTTAG CCTGGGCAAG 11880
 TTTTACGCCG GCAAGATATA CCATACCCCT TACGTTCCCA TAGACAAGGA GGTAAAGATC 11940
 GAGGGGTTCT ACATGCGCAT GGCGCTGAAG GTGCTTACCT TGAGCGACGA CCTGGCGTT 12000
 TATCGCAACG AGCGCATCCA CAAGGCCGTG AGCGTGAGCC GGCGGCCGCA GCTCAGCGAC 12060
 CGCGAGCTGA TGCACAGCCT GCAAAGGGCC CTGGCTGGCA CGGGCAGCGG CGATAGAGAG 12120
 GCCGAGCTCCT ACTTTGACGC GGGCGCTGAC CTGCGCTGGG CCCCAGGCC ACAGCCTG 12180
 GAGGCAGCTG GGGCCGGACC TGGGCTGGCG GTGGCACCCG CGCGCGCTGG CAACGTCGGC 12240
 GGCCTGGAGG AATATGACGA GGACGATGAG TACGAGCCAG AGGACGGCGA GTACTAAGCG 12300
 GTGATGTTTC TGATCAGATG ATGCAAGACG CAACGGACCC GGCGGTGCGG GCGCGCTGC 12360
 AGAGCCAGCC GTCCGGCCTT AACTCCACGG ACGACTGGCG CCAGGTCAATG GACCGCATCA 12420
 TGTCGCTGAC TGCGCGCAAT CCTGACCGTG TCCGGCAGCA GCCGCAGGCC AACCGGCTCT 12480
 CCGCAATTCT GGAAGCGGTG GTCCCGCGC GCGCAAACCC CACGCACGAG AAGGTGCTGG 12540
 CGATCGTAAA CGCGCTGGCC GAAAACAGGG CCATCCGGCC CGACGAGGCC GGCGTGGTCT 12600
 ACGACGCGCT GCTTCAGCGC GTGGCTCGTT ACAACAGCGG CAACGTGCAG ACCAACCTGG 12660
 ACCGGCTGGT GGGGGATGTG CGCGAGGCCG TGGCGCAGCG TGAGCGCGC CAGCAGCAGG 12720
 GCAACCTGGG CTCCATGGTT GCACTAAACG CCTTCCTGAG TACACAGCCC GCAAACGTGC 12780
 CGCGGGGACA GGAGGACTAC ACCAACTTTG TGAGCGCACT GCGGCTAATG GTGACTGAGA 12840
 CACCGCAAAG TGAGGTGTAC CAGTCTGGC CAGACTATTT TTTCCAGACC AGTAGACAAG 12900
 GCCTGCAGAC CGTAAACCTG AGCCAGGCTT TCAAAAACCTT GCAGGGGCTG TGGGGGGTGC 12960
 GGGCTCCAC AGGCGACCGC GCGACCGTGT CTAGCTTGCT GACGCCAAC TCGCGCCTGT 13020
 TGCTGCTGCT AATAGCGCCC TTCACGGACA GTGGCAGCGT GTCCCGGGAC ACATACCTAG 13080

GTCACTTGCT	GACACTGTAC	CGCGAGGCCA	TAGGTCAGGC	GCATGTGGAC	GAGCATACTT	13140
TCCAGGAGAT	TACAAGTGTC	AGCCGCGCGC	TGGGGCAGGA	GGACACGGGC	AGCCTGGAGG	13200
CAACCCCTAAA	CTACCTGCTG	ACCAACCGGC	GGCAGAAAGAT	CCCCTCGTTG	CACAGTTAA	13260
ACAGCGAGGA	GGAGCGCATT	TTGCGCTACG	TGCAGCAGAG	CGTGAGCCTT	AACCTGATGC	13320
GCGACGGGGT	AACGCCAGC	GTGGCGCTGG	ACATGACCCG	GCGAACATG	GAACCGGGCA	13380
TGTATGCCTC	AAACCGGCCG	TTTATCAACC	GCCTAATGGA	CTACTTGCAT	CGCGCGGCCG	13440
CCGTGAACCC	CGAGTATTTC	ACCAATGCCA	TCTTGAACCC	GCACTGGCTA	CCGCCCCCTG	13500
GTTTCTACAC	CGGGGGATTTC	GAGGTGCCCG	AGGGTAACGA	TGGATTCCCTC	TGGGACGACA	13560
TAGACGACAG	CGTGTTC	CCGCAACCGC	AGACCTGCT	AGAGTTGCAA	CAGCGCGAGC	13620
AGGCAGAGGC	GGCGCTGCGA	AAGGAAAGCT	TCCGCAGGCC	AAGCAGCTT	TCCGATCTAG	13680
GCGCTGCGGC	CCCGCGGTCA	GATGCTAGTA	GCCCATTCC	AAGCTTGATA	GGGTCTCTTA	13740
CCAGCACTCG	CACCACCCGC	CCGCGCCTGC	TGGCGAGGA	GGAGTACCTA	AACAACCTGC	13800
TGCTGCAGCC	GCAGCGC	AAAAACCTGC	CTCCGGCATT	TCCCAACAAAC	GGGATAGAGA	13860
GCCTAGTGG	CAAGATGAGT	AGATGGAAGA	CGTACGCGA	GGAGCACAGG	GACGTGCCAG	13920
GCCC CGGCC	GCCCACCCGT	CGTCAAAGGC	ACGACCGTCA	GCGGGGTCTG	GTGTGGGAGG	13980
ACGATGACTC	GGCAGACGAC	ACGACCGTCC	TGGATTGGG	AGGGAGTGGC	AACCCGTTG	14040
CGCACCTTCG	CCCCAGGCTG	GGGAGAATGT	TTTAAAAAAA	AAAAAGCATG	ATGAAAATA	14100
AAAAACTCAC	CAAGGCCATG	GCACCGAGCG	TTGGTTTCT	TGTATTCCCC	TTAGTATGCG	14160
GCGCGCGGCC	ATGTATGAGG	AAGGT CCTCC	TCCCTCCTAC	GAGAGTGTGG	TGAGCGCGGC	14220
GCCAGTGGCG	GC GGCGCTGG	GT TCTCC	CGATGCTCCC	CTGGACCCGC	CGTTTG GCC	14280
TCCCGGGTAC	CTGCGCCTA	CCGGGGGGAG	AAACAGC ATC	CGTTACTCTG	AGTTGGCACC	14340
CCTATTGAC	ACCACCGTG	TGTACCTGGT	GGACAACAAG	TCAACGGATG	TGGCATCCCT	14400
GAACTACCAG	AACGACCACA	GCAACTTCT	GACCACGGTC	ATTCAAAACA	ATGACTACAG	14460
CCCGGGGGAG	GCAAGCACAC	AGACCATCAA	TCTTGACGAC	CGT CCGCACT	GGGGCGGCCGA	14520
CCTGAAAACC	ATCCTGCATA	CCAACATGCC	AAATGTGAAC	GAGTTCATGT	TTACCAATAA	14580
GT TTAAGGG	CGGGTGATGG	TGTCGCGCTT	GCCTACTAAG	GACAATCAGG	TGGAGCTGAA	14640
ATACGAGTGG	GTGGAGTTCA	CGCTGCCGA	GGGCAACTAC	TCCGAGACCA	TGACCATAGA	14700
CCTTATGAAC	AACCGC GATCG	TGGAGCACTA	CTTGAAAGTG	GGCAGACAGA	ACGGGGTTCT	14760
GGAAAGCGAC	ATCGGGGTA	AGTTTGACAC	CCGCAACTTC	AGACTGGGGT	TTGACCCCGT	14820
CACTGGTCTT	GTCATGCCTG	GGGTATATAC	AAACGAAGCC	TTCCATCCAG	ACATCATT	14880
GCTGCCAGGA	TGCGGGGTGG	ACTTCACCC	CAGCCGCCTG	AGCAACTTGT	TGGGCATCCG	14940
CAAGCGGCAA	CCCTTCCAGG	AGGGCTTAG	GATCACCTAC	GATGATCTGG	AGGGTGGTAA	15000
CATTCCCGCA	CTGTTGGATG	TGGACGCCTA	CCAGGGCAGC	TTGAAAGATG	ACACCGAAC	15060
GGCGGGGGT	GGCGCAGGCG	GCAGCAACAG	CAGTGGCAGC	GGCGCGGAAG	AGAACTCCAA	15120
CGCGGCAGCC	CGGGCAATGC	AGCCGGTGG	GGACATGAAC	GATCATGCCA	TTCGCGGCCGA	15180

CACCTTGCC ACACGGGCTG AGGAGAAGCG CGCTGAGGCC GAAGCAGCGG CCGAAGCTGC	15240
CGCCCCCCT GCGCAACCCG AGGTGAGAA GCCTCAGAAG AAACCGGTGA TCAAACCCCT	15300
GACAGAGGAC AGCAAGAAC GCAGTTACAA CCTAATAAGC AATGACAGCA CCTTCACCCA	15360
GTACCGCAGC TGGTACCTTG CATAACA CCGCGACCC CAGACCGGAA TCCGCTCATG	15420
GACCTGCTT TGCACCTCTG ACGTAACCTG CGGCTGGAG CAGGTCTACT GGTGTTGCC	15480
AGACATGATG CAAGACCCCG TGACCTTCCG CTCCACGCGC CAGATCAGCA ACTTTCCGGT	15540
GGTGGGCCCG GAGCTGTTGC CCGTGCACTC CAAGAGCTTC TACAACGACC AGGCCGTCTA	15600
CTCCCAACTC ATCCGCCAGT TTACCTCTCT GACCCACGTG TTCAATCGCT TTCCCGAGAA	15660
CCAGATTTG GCGCGCCCG CAGCCCCCAC CATCACCACC GTCAAGTAAA ACGTTCTGC	15720
TCTCACAGAT CACGGGACGC TACCGCTCGG CAACAGCATC GGAGGAGTCC AGCGAGTGAC	15780
CATTACTGAC GCCAGACGCC GCACCTGCCCT ACAGTTTAC AAGGCCCTGG GCATAGTCTC	15840
GCCGCGCGTC CTATCGAGCC GCACCTTTTG AGCAAGCATG TCCATCCTTA TATCGCCCAG	15900
CAATAACACA GGCTGGGCC TGCGCTTCCC AAGCAAGATG TTTGGCGGGG CCAAGAAGCG	15960
CTCCGACCAA CACCCAGTGC GCGTGCACGG GCACTACCCG GCGCCCTGGG GCGCGCACAA	16020
ACGCGGCCGC ACTGGGCGCA CCACCGTCGA TGACGCCATC GACGCGGTGG TGGAGGAGGC	16080
GCGCAACTAC ACGCCACGC CGCCACCAGT GTCCACAGTG GACGCGGCCA TTCAGACCGT	16140
GGTGCACCGA GCGCCGGCCT ATGCTAAAT GAAGAGACGG CGGAGGCGCG TAGCACGTCG	16200
CCACCGCCGC CGACCCGGCA CTGCCGCCA ACGCGCGCG GCGCCCTGC TTAACCGCGC	16260
ACGTCGACCC GCGCGACGGG CGGCCATGCG GGCGCTCGA AGGCTGGCCG CGGGTATTGT	16320
CACTGTGCCCG CCCAGGTCCA GCGACGAGC GGCGCCCGCA GCAGCCCGGG CCATTAGTGC	16380
TATGACTCAG GGTGCGAGGG GCAACGTGA TTGGGTGCGC GACTCGTTA GCGGCCTGCG	16440
CGTGCCTGT CGCACCCGCC CCCCACGCAA CTAGATTGCA AGAAAAAAACT ACTTAGACTC	16500
GTACTGTTGT ATGTATCCAG CGCGGGCGGC GCGCAACGAA GCTATGTCCA AGCGCAAAAT	16560
CAAAGAAGAG ATGCTCCAGG TCATCGCGCC GGAGATCTAT GGCCCCCGA AGAAGGAAGA	16620
GCAGGATTAC AAGCCCCGAA AGCTAAAGCG GGTCAAAAG AAAAGAAAG ATGATGATGA	16680
TGAACCTGAC GACGAGGTGG AACTGCTGCA CGCTACCGCG CCCAGGCAC GGGTACAGTG	16740
GAAAGGTGCA CGCGTAAAC GTGTTTGCG ACCCGGCACC ACCGTAGTCT TTACGCCCG	16800
TGAGCGCTCC ACCCGCACCT ACAAGCGCGT GTATGATGAG GTGTACGGCG ACGAGGACCT	16860
GCTTGAGCAG GCCAACGAGC GCCTCGGGGA GTTGCTAC GGAAAGCGGC ATAAGGACAT	16920
GCTGGCGTTG CCGCTGGACG AGGGCAACCC AACACCTAGC CTAAAGCCCG TAACACTGCA	16980
GCAGGTGCTG CCCCGCTTG CACCGTCCGA AGAAAAGCGC GGCTAAAGC GCGAGTCTGG	17040
TGACTTGGCA CCCACCGTGC AGCTGATGGT ACCCAAGCGC CAGCGACTGG AAGATGTCTT	17100
GGAAAAAAATG ACCGTGGAAC CTGGGCTGGA GCGCGAGGTC CGCGTGCACGC CAATCAAGCA	17160
GGTGGCGCCG GGACTGGCGC TGCAGACCGT GGACGTCAG ATACCCACTA CCAGTAGCAC	17220
CAGTATTGCC ACCGCCACAG AGGGCATGGA GACACAAACG TCCCCGGTTG CCTCAGCGGT	17280

GGCGGATGCC	GCGGTGCAGG	CGGTCGCTGC	GGCCGCGTCC	AAGACCTCTA	CGGAGGTGCA	17340
AACGGACCCG	TGGATGTTTC	GCCTTCAGC	CCCCCGGCCG	CCGCGCGGTT	CGAGGAAGTA	17400
CGCGCGCGC	AGCGCGCTAC	TGCCCGAATA	TGCCCTACAT	CCTTCCATTG	CGCCTACCCC	17460
CGGCTATCGT	GGCTACACCT	ACCGCCCCAG	AAGACGAGCA	ACTACCCGAC	GCCGAACCAC	17520
CACTGGAACC	CGCCGGCGCC	GTCGCCGTG	CCAGCCCCGTG	CTGGCCCCGA	TTTCCGTGCG	17580
CAGGGTGGCT	CGCGAAGGAG	GCAGGACCCCT	GGTGCTGCCA	ACAGCGCGCT	ACCACCCAG	17640
CATCGTTAA	AAGCCGGTCT	TTGTGGTTCT	TGCAGATATG	GCCCTCACCT	GCCGCCTCCG	17700
TTTCCCGGTG	CCGGGATTCC	GAGGAAGAAT	GCACCGTAGG	AGGGGCATGG	CCGGCCACGG	17760
CCTGACGGGC	GGCATGCGTC	GTGCGCACCA	CCGGCGGCCG	CGCGCGTCGC	ACCGTCGCAT	17820
GCGCGCGGT	ATCCTGCC	TCCTTATTCC	ACTGATCGCC	GCGCGATTG	GCGCCGTGCC	17880
CGGAATTGCA	TCCGTGGCCT	TGCAGGCGCA	GAGACACTGA	TTAAAAACAA	GTTGCATGTG	17940
GAAAATCAA	AATAAAAAGT	CTGGACTCTC	ACGCTCGCTT	GGTCCTGTAA	CTATTTGTA	18000
GAATGGAAGA	CATCAACTTT	GCGTCTCTGG	CCCCGCGACA	CGGCTCGCGC	CCGTTCATGG	18060
GAAACTGGCA	AGATATCGGC	ACCAGCAATA	TGAGCGGTGG	CGCCTTCAGC	TGGGGCTCGC	18120
TGTGGAGCGG	CATTAAAAT	TCGGTTCCA	CCGTTAAGAA	CTATGGCAGC	AAGGCCTGGA	18180
ACAGCAGCAC	AGGCCAGATG	CTGAGGGATA	AGTTGAAAGA	GCAAAATTTC	CAACAAAAGG	18240
TGGTAGATGG	CCTGGCCTCT	GGCATTAGCG	GGGTGGTGG	CCTGGCCAAC	CAGGCAGTGC	18300
AAAATAAGAT	TAACAGTAAG	CTTGATCCCC	GCCCTCCCGT	AGAGGAGCCT	CCACCGGCCG	18360
TGGAGACAGT	GTCTCCAGAG	GGGCGTGGCG	AAAAGCGTCC	GCGCCCCGAC	AGGGAAGAAA	18420
CTCTGGTGAC	GCAAATAGAC	GAGCCTCCCT	CGTACGAGGA	GGCACTAAAG	CAAGGCCTGC	18480
CCACCACCCG	TCCCATCGCG	CCCATGGCTA	CCGGAGTGCT	GGGCCAGCAC	ACACCCGTAA	18540
CGCTGGACCT	GCCTCCCCCC	GCCGACACCC	AGCAGAAACC	TGTGCTGCCA	GGCCCGACCG	18600
CCGTTGTTGT	AACCGTCCT	AGCCGCGCGT	CCCTGCGCCG	CGCCGCCAGC	GGTCCCGCAT	18660
CGTTGCGGCC	CGTAGCCAGT	GGCAACTGGC	AAAGCACACT	GAACAGCATC	GTGGGTCTGG	18720
GGGTGCAATC	CCTGAAGCGC	CGACGATGCT	TCTGAATAGC	TAACGTGTG	TATGTGTGTC	18780
ATGTATGCGT	CCATGTCGCC	GCCAGAGGAG	CTGCTGAGCC	GCCGCGCGCC	CGCTTTCCAA	18840
GATGGCTACC	CCTTCGATGA	TGCCGAGTGT	GTCTTACATG	CACATCTCGG	GCCAGGACGC	18900
CTCGGAGTAC	CTGAGCCCCG	GGCTGGTGCA	GTTCGCCCCG	GCCACCGAGA	CGTACTTCAG	18960
CCTGAATAAC	AAGTTTAGAA	ACCCCACGGT	GGCGCTACG	CACGACGTGA	CCACAGACCG	19020
GTCCCAGCGT	TTGACGCTGC	GGTCATCCC	TGTGGACCGT	GAGGATACTG	CGTACTCGTA	19080
CAAGGCGCGG	TTCACCCCTAG	CTGTGGGTGA	TAACCGTGTG	CTGGACATGG	CTTCCACGTA	19140
CTTTGACATC	CGCGCGGTGC	TGGACAGGGG	CCCTACTTT	AAGCCCTACT	CTGGCACTGC	19200
CTACAACGCC	CTGGCTCCCA	AGGGTGCC	AAATCCTTGC	GAATGGGATG	AAGCTGCTAC	19260
TGCTCTTGAA	ATAAACCTAG	AAGAAGAGGA	CGATGACAAC	GAAGACGAAG	TAGACGAGCA	19320
AGCTGAGCAG	CAAAAAACTC	ACGTATTG	GCAGGGCCT	TATTCTGGTA	TAAATATTAC	19380

AAAGGAGGGT ATTCAAATAG GTGTCGAAGG TCAAACACCT AAATATGCCG ATAAAACATT	19440
TCAACCTGAA CCTCAAATAG GAGAATCTCA GTGGTACGAA ACTGAAATT AATCATGCAGC	19500
TGGGAGAGTC CTTAAAAGA CTACCCCAAT GAAACCATGT TACGGTTCAT ATGCAAACCC	19560
CACAAATGAA AATGGAGGGC AAGGCATTCT TGTAAGCAA CAAAATGGAA AGCTAGAAAG	19620
TCAAGTGGAA ATGCAATTT TCTCAACTAC TGAGGCGACC GCAGGCAATG GTGATAACTT	19680
GACTCCTAAA GTGGTATTGT ACAGTGAAGA TGTAGATATA GAAACCCAG ACACCTCATAT	19740
TTCTTACATG CCCACTATTA AGGAAGGTAA CTCACGAGAA CTAATGGGCC ACAATCTAT	19800
GCCCAACAGG CCTAATTACA TTGCTTTAG GGACAATTT ATTGGTCTAA TGTATTACAA	19860
CAGCACGGGT AATATGGGTG TTCTGGCGGG CCAAGCATCG CAGTTGAATG CTGTTGTAGA	19920
TTTGCAAGAC AGAAACACAG AGCTTTCATA CCAGCTTTG CTTGATTCCA TTGGTGATAG	19980
AACCAGGTAC TTTCTATGT GGAATCAGGC TGTTGACAGC TATGATCCAG ATGTTAGAAT	20040
TATTGAAAAT CATGGAACGT AAGATGAAC TCCAAATTAC TGCTTTCCAC TGGGAGGTGT	20100
GATTAATACA GAGACTCTTA CCAAGGTAAA ACCTAAAACA GGTCAGGAAA ATGGATGGGA	20160
AAAAGATGCT ACAGAATTTT CAGATAAAAA TGAAAATAAGA GTTGGAAATA ATTTGCCAT	20220
GGAAATCAAT CTAAATGCCA ACCTGTGGAG AAATTCCTG TACTCCAACA TAGCGCTGTA	20280
TTTGCCCGAC AAGCTAAAGT ACAGTCCTTC CAACGTAAAA ATTCTGATA ACCCAAACAC	20340
CTACGACTAC ATGAACAAAGC GAGTGGTGGC TCCCAGGTTA GTGGACTGCT ACATTAACCT	20400
TGGAGCACGC TGGTCCCTTG ACTATATGGA CAACGTCAAC CCATTTAAC ACCACCGCAA	20460
TGCTGGCCTG CGCTACCGCT CAATGTTGCT GGGCAATGGT CGCTATGTGC CCTTCCACAT	20520
CCAGGTGCCT CAGAAGTTCT TTGCCATTAA AAACCTCCTT CTCCCTGCCGG GCTCATACAC	20580
CTACGAGTGG AACTTCAGGA AGGATGTTAA CATGGTTCTG CAGAGCTCCC TAGGAAATGA	20640
CCTAAGGGTT GACGGAGCCA GCATTAAGTT TGATAGCATT TGCCCTTACG CCACCTTCTT	20700
CCCCATGGCC CACAAACACCG CCTCCACGCT TGAGGCCATG CTTAGAAACG ACACCAACGA	20760
CCAGTCCTT AACGACTATC TCTCCGCCGC CAACATGCTC TACCTATAC CCGCCAACGC	20820
TACCAACGTG CCCATATCCA TCCCCTCCCG CAACTGGCG GCTTCCCGCG GCTGGGCCTT	20880
CACGCGCCTT AAGACTAAGG AAACCCCATC ACTGGGCTCG GGCTACGACC CTTATTACAC	20940
CTACTCTGGC TCTATACCT ACCTAGATGG AACCTTTAC CTCAACCACA CCTTTAAGAA	21000
GGTGGCCATT ACCTTGACT CTTCTGTCAG CTGGCCTGGC AATGACCGCC TGCTTACCCC	21060
CAACGAGTTT GAAATTAAGC GCTCAGTTGA CGGGGAGGGT TACAACGTTG CCCAGTGTAA	21120
CATGACCAAA GACTGGITCC TGGTACAAAT GCTAGCTAAC TACAACATTG GCTACCAGGG	21180
CTTCTATATC CCAGAGAGCT ACAAGGACCG CATGTACTCC TTCTTAGAA ACTTCCAGCC	21240
CATGAGCCGT CAGGTGGTGG ATGATACTAA ATACAAGGAC TACCAACAGG TGGGCATCCT	21300
ACACCAACAC AACAACTCTG GATTTGTTGG CTACCTTGCC CCCACCATGC GCGAAGGACA	21360
GGCCTACCCCT GCTAACTTCC CCTATCCGCT TATAGGCAAG ACCGCAGTTG ACAGCATTAC	21420
CCAGAAAAAG TTTCTTGCG ATCGCACCCCT TTGGCGCATC CCATTCTCCA GTAACTTTAT	21480

GTCCATGGC	GCACTCACAG	ACCTGGCCA	AAACCTCTC	TACGCCA	ACT CCGCCCACGC	21540
GCTAGACATG	ACTTTGAGG	TGGATCCC	AT GGACGAGCCC	ACCCTTCTT	ATGTTTGTT	21600
TGAAGTCTT	GACGTGGTCC	GTGTGCACCG	GCCGCACCGC	GGCGTCATCG	AAACCGTGT	21660
CCTGCGCACG	CCCTTCTCGG	CCGGCAACGC	CACAACATAA	AGAAGCAAGC	AACATCAACA	21720
ACAGCTGCCG	CCATGGGCTC	CACTGAGCAG	GAACTGAAAG	CCATTGTCAA	AGATCTTGGT	21780
TGTGGGCCAT	ATTTTTGGG	CACCTATGAC	AAGCGCTTC	CAGGCTTGT	TTCTCACAC	21840
AAGCTCGCCT	GCGCCATAGT	CAATACGGCC	GGTCGCGAGA	CTGGGGCGT	ACACTGGATG	21900
GCCTTGCGCT	GGAACCCGCA	CTCAAAAACA	TGCTACCTCT	TTGAGCC	TTGCTTTCT	21960
GACCAGCGAC	TCAAGCAGGT	TTACCAGTT	GAGTACGAGT	CACTCCTGCG	CCGTAGCGCC	22020
ATTGCTTCTT	CCCCCGACCG	CTGTATAACG	CTGGAAAAGT	CCACCCAAAG	CGTACAGGGG	22080
CCCAACTCGG	CCGCCTGTGG	ACTATTCTGC	TGCATGTTTC	TCCACGCCTT	TGCCAACTGG	22140
CCCCAAACTC	CCATGGATCA	CAACCCCACC	ATGAACCTTA	TTACCGGGT	ACCCAACCTCC	22200
ATGCTCAACA	GTCCCCAGGT	ACAGCCCACC	CTGCGTCGCA	ACCAGGAACA	GCTCTACAGC	22260
TTCCTGGAGC	GCCACTCGCC	CTACTTCCGC	AGCCACAGTG	CGCAGATTAG	GAGCGCCACT	22320
TCTTTTTGTC	ACTTGAAAAAA	CATGTAAAAAA	TAATGTACTA	GAGACACTTT	CAATAAAGGC	22380
AAATGCTTTT	ATTTGTACAC	TCTCGGGTGA	TTATTACCC	CCACCC	TTGC CGTGC	22440
GTTTAAAAT	CAAAGGGGTT	CTGCCGCGCA	TCGCTATGCG	CCACTGGCAG	GGACACGTTG	22500
CGATACTGGT	GTTTAGTGCT	CCACTTAAAC	TCAGGCACAA	CCATCCGCGG	CAGCTCGGTG	22560
AAGTTTCAC	TCCACAGGCT	GCGCACCATC	ACCAACGCGT	TTAGCAGGTC	GGGCGCCGAT	22620
ATCTTGAAGT	CGCAGTTGGG	GCCTCCGCC	TGCGCGCG	AGTTGCGATA	CACAGGGTTG	22680
CAGCACTGGA	ACACTATCAG	CGCCGGTGG	TGCACGCTGG	CCAGCACGCT	CTTGTGGAG	22740
ATCAGATCCG	CGTCCAGGTC	CTCCCGTTG	CTCAGGGCGA	ACGGAGTCAA	CTTTGGTAGC	22800
TGCCTTCCA	AAAAGGGCGC	GTGCCAGGC	TTTGAGTTGC	ACTCGCACCG	TAGTGGCATC	22860
AAAAGGTGAC	CGTCCCCGGT	CTGGCGTTA	GGATACAGCG	CCTGCATAAA	AGCCTTGATC	22920
TGCTTAAAG	CCACCTGAGC	CTTGCGCCT	TCAGAGAAGA	ACATGCCGCA	AGACTTGCG	22980
GAAAATGAT	TGGCCGGACA	GGCCGCGTCG	TGCACGCAGC	ACCTTGC	GGTGTGGAG	23040
ATCTGCACCA	CATTCGGCC	CCACCGGTT	TTCACGATCT	TGGCCTTGCT	AGACTGCTCC	23100
TTCAGCGCGC	GCTGCCCGTT	TTCGCTCGTC	ACATCCATT	CAATCACGTG	CTCCTTATTT	23160
ATCATAATGC	TTCCGTGTAG	ACACTTAAGC	TGCCCTCGA	TCTCAGCGCA	GCGGTGCAGC	23220
CACAACGCGC	AGCCCGTGGG	CTCGTGATGC	TTGTAGGTCA	CCTCTGCAA	CGACTGCAGG	23280
TACGCCTGCA	GGAATCGCCC	CATCATCGTC	ACAAAGGTCT	TGTTGCTGGT	GAAGGTCAGC	23340
TGCAACCCGC	GGTGCTCTC	GTTCAGCCAG	GTCTTGCA	CGGCCGCCAG	AGCTTCCACT	23400
TGGTCAGGCA	GTAGTTGAA	GTTCGCCTT	AGATCGTTAT	CCACGTGGTA	CTTGTCCATC	23460
AGCGCGCGCG	CAGCCTCCAT	GCCCTTCTCC	CACGCAGACA	CGATCGGCAC	ACTCAGCGGG	23520
TTCATCACCG	TAATTCACT	TTCCGCTTCG	CTGGGCTCTT	CCTCTCCTC	TTGCGTCCGC	23580

ATACCACGCG	CCACTGGTC	GTCTTCATT	AGCCGCCGCA	CTGTGCGCTT	ACCTCCTTG	23640
CCATGTTGA	TTAGCACCGG	TGGGTTGCTG	AAACCCACCA	TTTGTAGCGC	CACATCTTCT	23700
CTTTCTTCT	CGCTGTCCAC	GATTACCTCT	GGTGATGGCG	GGCGCTCGGG	CTTGGGAGAA	23760
GGGCGCTTCT	TTTTCTTCTT	GGCGCAATG	GCCAAATCCG	CCGCCGAGGT	CGATGGCCGC	23820
GGGCTGGGTG	TGCGCGGCAC	CAGCGCGTCT	TGTGATGAGT	CTTCCTCGTC	CTCGGACTCG	23880
ATACGCCGCC	TCATCCGCTT	TTTTGGGGGC	GCCCAGGGAG	CGGGCGGCAG	CGGGGACGGG	23940
GACGACACGT	CCTCCATGGT	TGGGGGACGT	CGCGCCGCAC	CGCGTCCGCG	CTCGGGGTG	24000
GTTCGCGCT	GTCCTCTTC	CCGACTGGCC	ATTCCTTCT	CCTATAGGCA	GAAAAAGATC	24060
ATGGAGTCAG	TCGAGAAGAA	GGACAGCCTA	ACCGCCCCCT	CTGAGTTCGC	CACCACCGCC	24120
TCCACCGATG	CCGCCAACGC	GCCTACCACC	TTCCCCGTCG	AGGCACCCCC	GCTTGAGGAG	24180
GAGGAAGTGA	TTATCGAGCA	GGACCCAGGT	TTTGTAAAGCG	AAGACGACGA	GGACCGCTCA	24240
GTACCAAACAG	AGGATAAAAAA	GCAAGACCAAG	GACAACGCAG	AGGCAAACGA	GGAAACAAGTC	24300
GGGCGGGGGGG	ACGAAAGGCA	TGGCGACTAC	CTAGATGTGG	GAGACGACGT	GCTGTTGAAG	24360
CATCTGCAGC	GCCAGTGCAGC	CATTATCTGC	GACGCGTTGC	AAGAGCGCAG	CGATGTGCC	24420
CTCGCCATAG	CGGATGTCAG	CCTTGCCTAC	GAACGCCACC	TATTCTCACC	GGCGTACCC	24480
CCCAAACGCC	AAGAAAACGG	CACATGCGAG	CCCAACCCGC	GCCTCAACTT	CTACCCCGTA	24540
TTTGCCGTGC	CAGAGGTGCT	TGCCACCTAT	CACATCTTTT	TCCAAAACGT	CAAGATAACCC	24600
CTATCCTGCC	GTGCCAACCG	CAGCCGAGCG	GACAAGCAGC	TGGCCTGCG	GCAGGGCGCT	24660
GTCATAACCTG	ATATCGCCTC	GCTCAACGAA	GTGCCAAAAAA	TCTTGAGGG	TCTTGGACGC	24720
GACGAGAAGC	GCGCGGCAA	CGCTCTGCAA	CAGGAAAACA	GCGAAAATGA	AAGTCACCT	24780
GGAGTGTGG	TGGAACTCGA	GGGTGACAAC	GCGCGCCTAG	CCGTACTAAA	ACGCAGCAGTC	24840
GAGGTACCCC	ACTTGCCTA	CCCGGCACCT	AACCTACCCC	CCAAGGTAT	GAGCACAGTC	24900
ATGAGTGAGC	TGATCGTGC	CCGTGCGCAG	CCCCTGAGA	GGGATGCAA	TTTGAAGAA	24960
CAAACAGAGG	AGGGCCTACC	CGCAGTTGGC	GACGAGCAGC	TAGCGCGCTG	GCTTCAAACG	25020
CGCGAGCCTG	CCGACTTGG	GGAGCGACGC	AAACTAATGA	TGGCCGCAGT	GCTCGTTACC	25080
GTGGAGCTTG	AGTGCATGCA	GCGGTTCTTT	GCTGACCCGG	AGATGCAGCG	CAAGCTAGAG	25140
GAAACATTGC	ACTACACCTT	TCGACAGGGC	TACGTACGCC	AGGCCGTCAA	GATCTCAAAC	25200
GTGGAGCTCT	GCAACCTGGT	CTCCTACCTT	GGAATTTCGC	ACGAAAACCG	CCTTGGCAA	25260
AACTGTCTTC	ATTCCACGCT	CAAGGGCGAG	GCGCGCCGCG	ACTACGTCCG	CGACTGCGTT	25320
TACTTATTC	TATGCTACAC	CTGGCAGACG	GCCATGGCG	TTTGGCAGCA	GTGCTTGGAG	25380
GAGTGCAACC	TCAAGGAGCT	GCAGAAAATG	CTAAAGCAA	ACTTGAAGGA	CCTATGGACG	25440
GCCTTCACG	AGCGCTCCGT	GGCCGCGCAC	CTGGCGGACA	TCATTTCCC	CGAACGCC	25500
CTTAAAACCC	TGCAACAGGG	TCTGCCAGAC	TTCACCAAGTC	AAAGCATGTT	GCAGAACTTT	25560
AGGAACCTTA	TCCTAGAGCG	CTCAGGAATC	TTGCGGCCA	CCTGCTGTGC	ACTTCCTAGC	25620
GAACCTTGTGC	CCATTAAGTA	CCGCGAATGC	CCTCCGCCGC	TTTGGGCCA	CTGCTACCTT	25680

CTGCAGCTAG CCAACTACCT TGCCTACCAC TCTGACATAA TGGAAGACGT GAGCGGTGAC	25740
GGTCTACTGG AGTGTCACTG TCGCTGCAAC CTATGCACCC CGCACCGCTC CCTGGTTGC	25800
AATTGCAGC TGCTTAACGA AAGTCAAATT ATCGGTACCT TTGAGCTGCA GGGTCCCTCG	25860
CCTGACGAAA AGTCCGCGGC TCCGGGGTTG AAACTCACTC CGGGGCTGTG GACGTCGGCT	25920
TACCTTCGCA AATTGTACC TGAGGACTAC CACGCCACG AGATTAGGTT CTACGAAGAC	25980
CAATCCCGCC CGCCAAATGC GGAGCTTACC GCCTGCGTCA TTACCCAGGG CCACATTCTT	26040
GGCCAATTGC AAGCCATCAA CAAAGCCCGC CAAGAGTTTC TGCTACGAAA GGGACGGGGG	26100
GTTTACTTGG ACCCCCAGTC CGGCGAGGAG CTCAACCCAA TCCCCCGCC GCCGAGCCC	26160
TATCAGCAGC AGCCGCGGGC CCTTGCTTCC CAGGATGGCA CCCAAAAAGA AGCTGCAGCT	26220
GCCGCCGCCA CCCACGGACG AGGAGGAATA CTGGGACAGT CAGGCAGAGG AGGTTTTGGA	26280
CGAGGAGGAG GAGGACATGA TGGAAGACTG GGAGAGCCTA GACGAGGAAG CTTCCGAGGT	26340
CGAAGAGGTG TCAGACGAAA CACCGTCACC CTCGGTCGA TTCCCCCTCGC CGGCGCCCCA	26400
GAAATCGGCA ACCGGTTCCA GCATGGCTAC AACCTCCGCT CCTCAGGCGC CGCCGGCACT	26460
GCCCGTTCGC CGACCCAACC GTAGATGGGA CACCACTGGA ACCAGGGCCG GTAAGTCCAA	26520
GCAGCCGCCG CCGTTAGCCC AAGAGCAACA ACAGCGCCAA GGCTACCGCT CATGGCGCGG	26580
GCACAAGAAC GCCATAGTTG CTTGCTTGCA AGACTGTGGG GGCAACATCT CCTTCGCCCCG	26640
CCGTTTCTT CTCTACCATC ACGGCGTGGC CTTCCCCGT AACATCCTGC ATTACTACCG	26700
TCATCTCTAC AGCCCATACT GCACCGGGCG CAGCGGCAGC GGCAAGCAACA GCAGGGCCA	26760
CACAGAAGCA AAGGCGACCG GATAGCAAGA CTCTGACAAA GCCCAAGAAA TCCACAGCGG	26820
CGGCAGCAGC AGGAGGAGGA GCGCTGCGTC TGGCGCCCAA CGAACCCGTA TCGACCCGCG	26880
AGCTTAGAAA CAGGATTTT CCCACTCTGT ATGCTATATT TCAACAGAGC AGGGGCCAAG	26940
AACAAGAGCT GAAAATAAAA AACAGGTCTC TCGGATCCCT CACCCGCAGC TGCCTGTATC	27000
ACAAAAGCGA AGATCAGCTT CGGCGCACGC TGGAAGACGC GGAGGCTCTC TTCAGTAAAT	27060
ACTGCGCGCT GACTCTTAAG GACTAGTTTC GCGCCCTTTC TCAAATTAA GCGGAAAC	27120
TACGTCATCT CCAGGGCCA CACCCGGCGC CAGCACCTGT CGTCAGCGCC ATTATGAGCA	27180
AGGAAATTCC CACGCCCTAC ATGTGGAGTT ACCAGCCACA AATGGGACTT GCGGCTGGAG	27240
CTGCCAAGA CTACTCAACC CGAATAAAACT ACATGAGCGC GGGACCCAC ATGATATCCC	27300
GGGTCAACGG AATCCCGGCC CACCGAAACC GAATTCTCTT GGAACAGGGCG GCTATTACCA	27360
CCACACCTCG TAATAACCTT AATCCCCGTA GTTGGCCCGC TGCCCTGGTG TACCAGGAA	27420
GTCCCGCTCC CACCACTGTG GTACTTCCA GAGACGCCA GGGCGAAGTT CAGATGACTA	27480
ACTCAGGGGC GCAGCTTGC GGGCGCTTTC GTCACAGGGT GCGGTGCGCC GGGCAGGGTA	27540
TAACTCACCT GACAATCAGA GGGCGAGGTA TTCAGCTAA CGACGAGTCG GTGAGCTCCT	27600
CGCTTGGTCT CCGTCCGGAC GGGACATTTC AGATGGCGG CGCCGGCCGT CCTTCATTCA	27660
CGCCTCGTCA GGCAATCCTA ACTCTGCAGA CCTCGTCCTC TGAGCCGCGC TCTGGAGGCA	27720
TTGGAACTCT GCAATTATT GAGGAGTTTG TGCCATCGGT CTACTTTAAC CCCTTCTCGG	27780

GACCTCCCCG CCACTATCCG GATCAATTAA TTCCCTAAGT TGACGCGGTAAAGGACTCGG 27840
 CGGACGGCTA CGACTGAATG TTAAGTGGAG AGGCAGAGCA ACTGCGCCTG AAACACCTGG 27900
 TCCACTGTGG CCGCCACAAG TGCTTTGCCG GCGACTCCGG TGAGTTTGCTACTTTGAAT 27960
 TGCCCGAGGA TCATATCGAG GGCCCAGGCC ACGGCGTCCG GCTTACCGCC CAGGGAGAGC 28020
 TTGCCCGTAG CCTGATTCCG GAGTTTACCC AGCGCCCCCT GCTAGTTGAG CGGGACAGGG 28080
 GACCCTGTGT TCTCACTGTG ATTTGCAACT GTCCTAACCT TGGATTACAT CAAGATCTTT 28140
 GTTGCCATCT CTGTGCTGAG TATAATAAAAT ACAGAAATTA AAATATAACTG GGGCTCCTAT 28200
 CGCCATCCTG TAAACGCCAC CGTCTTCACC CGCCCAAGCA AACCAAGGCG AACCTTACCT 28260
 GGTACTTTA ACATCTCTCC CTCTGTGATT TACAACAGTT TCAACCCAGA CGGAGTGAGT 28320
 CTACGAGAGA ACCTCTCCGA GCTCAGCTAC TCCATCAGAA AAAACACCAAC CCTCCTTACC 28380
 TGCCGGGAAAC GTACGAGTGC GTCACCGGCC GCTGCACCAC ACCTACCGCC TGACCGTAAA 28440
 CCAGACTTTT TCCGGACAGA CCTCAATAAC TCTGTTTACCA AGAACAGGAG GTGAGCTTAG 28500
 AAAACCCCTTA GGGTATTAGG CCAAAGGCGC AGCTACTGTG GGGTTTATGA ACAATTCAAG 28560
 CAACTCTACG GGCTATTCTA ATTCAAGGTTT CTCTAGAATC GGGGTTGGGG TTATTCTCTG 28620
 TCTTGTGATT CTCTTTATTC TTATACTAAC GCTTCTCTGC CTAAGGCTCG CCGCTGCTG 28680
 TGTGCACATT TGCATTATT GTCAGCTTT TAAACGCTGG GGTGCCACC CAAGATGATT 28740
 AGGTACATAA TCCTAGGTTT ACTCACCCCT GCGTCAGCCC ACGGTACCAAC CAAAAAGGTG 28800
 GATTTTAAGG AGCCAGCCTG TAATGTTACA TTCGAGCTG AAGCTAATGA GTGCACCACT 28860
 CTTATAAAT GCACCACAGA ACATGAAAAG CTGCTTATTC GCCACAAAAAA CAAAATTGGC 28920
 AAGTATGCTG TTTATGCTAT TTGGCAGCCA GGTGACACTA CAGAGTATAA TGTTACAGTT 28980
 TTCCAGGGTA AAAGTCATAA AACTTTATG TATACTTTTC CATTGTTATGA AATGTGCGAC 29040
 ATTACCATGT ACATGAGCAA ACAGTATAAG TTGTGGCCCC CACAAAATTG TGTGGAAAAC 29100
 ACTGGCACTT TCTGCTGCAC TGCTATGCTA ATTACAGTGC TCGCTTGGT CTGTACCCCTA 29160
 CTCTATATTA AATACAAAAG CAGACGCAGC TTTATTGAGG AAAAGAAAAT GCCTTAATTT 29220
 ACTAAGTTAC AAAGCTAATG TCACCACTAA CTGCTTACT CGCTGCTTGC AAAACAAATT 29280
 CAAAAAGTTA GCATTATAAT TAGAATAGGA TTTAAACCCC CCGGTCATTT CCTGCTCAAT 29340
 ACCATTCCCC TGAACAAATTG ACTCTATGTC GGATATGCTC CAGCGCTACA ACCTTGAAGT 29400
 CAGGCTTCCCT GGATGTCAGC ATCTGACTTT GGCCAGCACC TGTCGGCGGG ATTTGTTCCA 29460
 GTCCAACCTAC AGCGACCCAC CCTAACAGAG ATGACCAACA CAACCAACGC GGCGCCGCT 29520
 ACCGGACTTA CATCTACCAAC AAATACACCC CAAGTTCTG CCTTGTCAA TAACTGGGAT 29580
 AACTTGGGCA TGTGGTGGTT CTCCATAGCG CTTATGTTG TATGCCTTAT TATTATGTGG 29640
 CTCATCTCT GCCTAAAGCG CAAACCGGCC CGACCACCCA TCTATAGTCC CATCATTGTG 29700
 CTACACCCAA ACAATGATGG AATCCATAGA TTGGACGGAC TGAAACACAT GTTCTTTCT 29760
 CTTACAGTAT GATTAATGA GACATGATTC CTCGAGTTT TATATTACTG ACCCTTGTG 29820
 CGCTTTTTG TGCCTGCTCC ACATTGGCTG CGGTTCTCA CATCGAAGTA GACTGCATTC 29880

CAGCCTTCAC	AGTCTATTTG	CTTTACGGAT	TTGTCACCCCT	CACGCTCATC	TGCAGCCTCA	29940
TCACTGTGGT	CATGCCCTT	ATCCAGTGCA	TTGACTGGGT	CTGTGTGCGC	TTTGCATATC	30000
TCAGACACCCA	TCCCCAGTAC	AGGGACAGGA	CTATAGCTGA	GCTTCTTAGA	ATTCTTTAAT	30060
TATGAAATTT	ACTGTGACTT	TTCTGCTGAT	TATTCGACC	CTATCTGCGT	TTTGTCCCC	30120
GACCTCCAAG	CCTCAAAGAC	ATATATCATG	CAGATTCACT	CGTATATGGA	ATATTCCAAG	30180
TTGCTACAAT	GAAAAAAAGCG	ATCTTCCGA	AGCCTGGTTA	TATGCAATCA	TCTCTGTTAT	30240
GGTGTCTGC	AGTACCATCT	TAGCCCTAGC	TATATATCCC	TACCTTGACA	TTGGCTGGAA	30300
ACGAATAGAT	GCCATGAACC	ACCCAACHTT	CCCCCGCGCC	GCTATGCTTC	CACTGCAACA	30360
AGTTGTTGCC	GGCGGCTTTG	TCCCAGCCAA	TCAGCCTCGC	CCCACTTCTC	CCACCCCCAC	30420
TGAAATCAGC	TACTTTAAC	TAACAGGAGG	AGATGACTGA	CACCTAGAT	CTAGAAATGG	30480
ACGGAATTAT	TACAGAGCAG	CGCCTGCTAG	AAAGACGCAG	GGCAGCGGCC	GAGCAACAGC	30540
GCATGAATCA	AGAGCTCCAA	GACATGGTTA	ACTTGCACCA	GTGAAAAGG	GGTATCTTT	30600
GTCTGGTAAA	GCAGGCCAAA	GTCACCTACG	ACAGTAATAC	CACCGGACAC	CGCCTTAGCT	30660
ACAAGTTGCC	AACCAAGCGT	CAGAAATTGG	TGGTCATGGT	GGGAGAAAAG	CCCATTACCA	30720
TAACTCAGCA	CTCGGTAGAA	ACCGAAGGCT	GCATTCACTC	ACCTGTCAA	GGACCTGAGG	30780
ATCTCTGCAC	CCTTATTAAG	ACCCGTGCG	GTCTCAAAGA	TCTTATTCCC	TTTAACTAAT	30840
AAAAAAAAAAAT	AATAAAGCAT	CACTTACTTA	AAATCAGTTA	GCAAATTCT	GTCCAGTTA	30900
TTCAGCAGCA	CCTCCTTGCC	CTCCTCCAG	CTCTGGTATT	GCAGCTTCCT	CCTGGCTGCA	30960
AACTTCTCC	ACAATCTAAA	TGGAATGTCA	GTTTCCTCCT	GTTCTGTCC	ATCCGCACCC	31020
ACTATCTTCA	TGTTGTTGCA	GATGAAGCGC	GCAAGACCGT	CTGAAGATAAC	CTTCAACCCCC	31080
GTGTATCCAT	ATGACACGGA	AACCGGTCT	CCAACTGTGC	CTTTCTTAC	TCCTCCCTT	31140
GTATCCCCCA	ATGGGTTCA	AGAGAGTCCC	CCTGGGTAC	TCTCTTGCG	CCTATCCGAA	31200
CCTCTAGTTA	CCTCCAATGG	CATGCTTGCG	CTCAAAATGG	GCAACGGCCT	CTCTCTGGAC	31260
GAGGCCGGCA	ACCTTACCTC	CCAAAATGTA	ACCACTGTGA	GCCCACCTCT	CAAAAAAACC	31320
AAGTCAAACA	AAACCTGGA	AATATCTGCA	CCCCTCACAG	TTACCTCAGA	AGCCCTAACT	31380
GTGGCTGCCG	CCGCACCTCT	AATGGTCGCG	GGCAACACAC	TCACCATGCA	ATCACAGGCC	31440
CCGCTAACCG	TGCACGACTC	CAAACCTAGC	ATTGCCACCC	AAGGACCCCT	CACAGTGTCA	31500
GAAGGAAAGC	TAGCCCTGCA	AACATCAGGC	CCCCTCACCA	CCACCGATAG	CAGTACCCCT	31560
ACTATCACTG	CCTCACCCCC	TCTAACTACT	GCCACTGGTA	GCTTGGGCAT	TGACTTGAAA	31620
GAGCCCATT	ATACACAAAA	TGGAAAAC	GGACTAAAGT	ACGGGGCTCC	TTTGCATGTA	31680
ACAGACGACC	AAACACTTT	GACCGTAGCA	ACTGGTCCAG	GTGTGACTAT	TAATAACT	31740
TCCTTGCAAA	CTAAAGTTAC	TGGAGCCTTG	GGTTTGATT	CACAAGGCAA	TATGCAACTT	31800
AATGTAGCAG	GAGGACTAAG	GATTGATTCT	CAAAACAGAC	GCCTTATACT	TGATGTTAGT	31860
TATCCGTTG	ATGCTAAAAA	CCAACTAAAT	CTAAGACTAG	GACAGGGCCC	TCTTTTATA	31920
AACTCAGCCC	ACAACCTGGA	TATTAAC	AAACAAAGGCC	TTTACTTGTT	TACAGCTTCA	31980

AACAAATTCCA	AAAAGCTTGA	GGTTAACCTA	AGCACTGCCA	AGGGGTTGAT	GTTTGACGCT	32040
ACAGCCATAG	CCATTAATGC	AGGAGATGGG	CTTGAATTG	GTCACCTAA	TGCACCAAAC	32100
ACAAATCCCC	TCAAAACAAA	AATTGGCCAT	GGCCTAGAAT	TTGATTCAA	CAAGGCTATG	32160
GTTCTAAAC	TAGGAACTGG	CCTTAGTTT	GACAGCACAG	GTGCCATTAC	AGTAGGAAAC	32220
AAAAATAATG	ATAAGCTAAC	TTTGTGGACC	ACACCAAGCTC	CATCTCCTAA	CTGTAGACTA	32280
AATGCAGAGA	AAGATGCTAA	ACTCACTTG	GTCTTAACAA	AATGTGGCAG	TCAAATACTT	32340
GCTACAGTTT	CAGTTTGGC	TGTTAAAGGC	AGTTGGCTC	CAATATCTGG	AACAGTTCAA	32400
AGTGCTCATC	TTATTATAAG	ATTTGACGAA	AATGGAGTGC	TACTAAACAA	TTCCCTCCTG	32460
GACCCAGAAT	ATTGGAACCT	TAGAAATGGA	GATCTTACTG	AAGGCACAGC	CTATACAAAC	32520
GCTGTTGGAT	TTATGCCTAA	CCTATCAGCT	TATCCAAAAT	CTCACGGTAA	AACTGCAA	32580
AGTAACATTG	TCAGTCAAGT	TTACTTAAAC	GGAGACAAAA	CTAAACCTGT	AACACTAAC	32640
ATTACACTAA	ACGGTACACA	GGAAACAGGA	GACACAAC	CAAGTGCATA	CTCTATGTCA	32700
TTTTCATGGG	ACTGGTCTGG	CCACAACTAC	ATTAATGAA	TATTGCCCAC	ATCCTCTTAC	32760
ACTTTTCTAT	ACATTGCCCA	AGAATAAAGA	ATCGTTGTG	TTATGTTCA	ACGTGTTTAT	32820
TTTTCAATTG	CAGAAAATT	CAAGTCATT	TTCATTCA	AGTATAGCCC	CACCACCAC	32880
TAGCTTATAC	AGATCACCGT	ACCTTAATCA	AACTCACAGA	ACCCCTAGTAT	TCAACCTGCC	32940
ACCTCCCTCC	CAACACACAG	AGTACACAGT	CCTTCTCCC	CGGCTGGCCT	TAAGAACAT	33000
CATATCATGG	GTAACAGACA	TATTCTTAGG	TGTTATATTC	CACACGGTTT	CCTGTCGAGC	33060
CAAACGCTCA	TCAGTGATAT	TAATAAACTC	CCCGGGCAGC	TCACCTAAGT	TCATGTCGCT	33120
GTCCAGCTGC	TGAGCCACAG	GCTGCTGTCC	AACTTGCAGT	TGCTTAACGG	GCGGCGAAGG	33180
AGAAGTCCAC	GCCTACATGG	GGGTAGAGTC	ATAATCGTGC	ATCAGGATAG	GGCGGTGGTG	33240
CTGCAGCAGC	GCGCGAATAA	ACTGCTGCCG	CCGCCGCTCC	GTCCTGCAGG	AATACAACAT	33300
GGCAGTGGTC	TCCTCAGCGA	TGATTGCGAC	CGCCCGCAGC	ATAAGGCGCC	TTGTCCTCCG	33360
GGCACAGCAG	CGCACCCCTGA	TCTCACTTAA	ATCAGCACAG	TAACTGCAGC	ACAGCACCC	33420
AATATTGTT	AAAATCCCAC	AGTGAAGGC	GCTGTATCCA	AAGCTCATGG	CGGGGACCC	33480
AGAACCCACG	TGGCCATCAT	ACCACAAGCG	CAGGTAGATT	AAGTGGCGAC	CCCTCATAAA	33540
CACGCTGGAC	ATAAACATTA	CCTCTTTGG	CATGTTGTAA	TTCACCCACCT	CCCGGTACCA	33600
TATAAACCTC	TGATTAACAC	TGGGCCATC	CACCACCATC	CTAAACCAGC	TGGCCAAAC	33660
CTGCCCCCG	GCTATACACT	GCAGGGAAC	GGGACTGGAA	CAATGACAGT	GGAGAGCCCA	33720
GGACTCGTAA	CCATGGATCA	TCATGCTCGT	CATGATATCA	ATGTTGGCAC	AAACACAGGA	33780
CACGTGCATA	CACTGCCTCA	GGATTACAAG	CTCCCTCCGC	GTTAGAACCA	TATCCCAGGG	33840
AACAACCCAT	TCCTGAATCA	GCGTAAATCC	CACACTGCAG	GGAAGACCTC	GCACGTA	33900
CACGTTGTGC	ATTGTCAAAG	TGTTACATTC	GGGCAGCAGC	GGATGATCCT	CCAGTATGGT	33960
AGCCGGGTT	TCTGTCTCAA	AAGGAGGTAG	ACGATCCCTA	CTGTACGGAG	TGCGCCGAGA	34020
CAACCGAGAT	CGTGTGGTC	GTAGTGTCA	GCCAAATGGA	ACGCCGGACG	TAGTCATATT	34080

TCCTGAAGCA AAACCAGGTG CGGGCGTGAC AAACAGATCT GCGTCTCCGG TCTCGCCGCT	34140
TAGATCGCTC TGTGTAGTAG TTGTAGTATA TCCACTCTCT CAAAGCATCC AGGCGCCCCC	34200
TGGCTTCGGG TTCTATGTAA ACTCCTTCAT GCGCCGCTGC CCTGATAACA TCCACCACCG	34260
CAGAATAAGC CACACCCAGC CAACCTACAC ATTCTGTTCTG CGAGTCACAC ACGGGAGGAG	34320
CGGGAAGAGC TGGAAGAACC ATGTTTTTTT TTTTATTCCA AAAGATTATC CAAAACCTCA	34380
AAATGAAGAT CTATTAAGTG AACCGCGCTCC CCTCCGGTGG CGTGGTCAAA CTCTACAGCC	34440
AAAGAACAGA TAATGGCATT TGTAAGATGT TGCACAATGG CTTCCAAAAG GCAAACGGCC	34500
CTCACGTCCA AGTGGACGTA AAGGCTAAC CCTTCAGGGT GAATCTCCTC TATAAACATT	34560
CCAGCACCTT CAACCAGGCC CAAATAATT TCATCTGCC ACCTTCTCAA TATATCTCTA	34620
AGCAAATCCC GAATATTAAG TCCGGCCATT GTAAAAATCT GCTCCAGAGC GCCCTCCACC	34680
TTCAGCCTCA AGCAGCGAAT CATGATTGCA AAAATTCAAG TTCCTCACAG ACCTGTATAA	34740
GATTCAAAAG CGGAACATTA ACAAAAATAC CGCGATCCCG TAGGTCCCTT CGCAGGGCCA	34800
GCTGAACATA ATCGTGCAGG TCTGCACGGA CCAGCGCGC CACTTCCCCG CCAGGAACCT	34860
TGACAAAAGA ACCCACACTG ATTATGACAC GCATACTCGG AGCTATGCTA ACCAGCGTAG	34920
CCCCGATGTA AGCTTTGTTG CATGGCGGC GATATAAAAT GCAAGGTGCT GCTAAAAAAA	34980
TCAGGCAAAG CCTCGCGCAA AAAAGAAAGC ACATCGTAGT CATGCTCATG CAGATAAAGG	35040
CAGGTAAGCT CCGGAACCAC CACAGAAAAA GACACCATT TTCTCTCAA CATGCTGCG	35100
GGTTTCTGCA TAAACACAAA ATAAAAATAAC AAAAAAACAT TTAACACATTA GAAGCCTGTC	35160
TTACAACAGG AAAAACAAACC CTTATAAGCA TAAGACGGAC TACGGCCATG CCGCGTGAC	35220
CGTAAAAAAA CTGGTCACCG TGATTAAAAA GCACCACCGA CAGCTCCTCG GTCATGTCCG	35280
GAGTCATAAT GTAAGACTCG GTAAACACAT CAGGTTGATT CATCGGTCA TGCTAAAAG	35340
CGACCGAAAT AGCCGGGGG AATACATACC CGCAGCGTA GAGACAACAT TACAGCCCC	35400
ATAGGAGGTA TAACAAAATT ATAGGAGAG AAAAACACAT AAACACCTGA AAAACCTCC	35460
TGCCTAGGCA AAATAGCACC CTCCCGCTCC AGAACACAT ACAGCGCTTC ACAGGGCAG	35520
CCTAACAGTC AGCCTTACCA GTAAAAAGA AAACCTATTA AAAAACACCC ACTCGACACG	35580
GCACCGAGCTC AATCAGTCAC AGTGTAAAAA AGGGCCAAGT GCAGAGCGAG TATATATAGG	35640
ACTAAAAAAAT GACGTAAACGG TTAAAGTCCA CAAAAAACAC CCAGAAAACC GCACGCGAAC	35700
CTACGCCAG AAACGAAAGC CAAAAAACCC ACAACTTCCT CAAATCGTCA CTTCCGTTT	35760
CCCACGTTAC GTAACTTCCC ATTTTAAGAA AACTACAATT CCCAACACAT ACAAGTTACT	35820
CCGCCCTAAA ACCTACGTCA CCCGCCCCGT TCCCACGCC CGGCCACGT CACAAACTCC	35880
ACCCCCCTCAT TATCATATTG GCTTCAATCC AAAATAAGGT ATATTATTGA TGATG	35935

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTCATTTAT GTTCAGGTT CAGGG

25

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTACCGCCAC ACTCGCAGGG

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34303 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTATTTTGA	TTGAAGCAA	TATGATAATG	AGGGGGTGA	GTTTGTGACG	TGGCGCCGGG	60
CGTGGGAACG	GGGCGGGTGA	CGTAGTAGTG	TGGCGGAAGT	GTGATGTTGC	AAGTGTGGCG	120
GAACACATGT	AAGCGACGGA	TGTGGCAAAA	GTGACGTTTT	TGGTGTGCC	CGGATCCACA	180
GGACGGGTGT	GGTCGCCATG	ATCGCGTAGT	CGATAGTGGC	TCCAAGTAGC	GAAGCGAGCA	240
GGACTGGGCG	GCGGCCAAAG	CGGTCGGACA	GTGCTCCGAG	AACGGGTGCG	CATAGAAATT	300
GCATCAACGC	ATATAGCGCT	AGCAGCACGC	CATAGTGA	GGCGATGCTG	TCGGAATGGA	360
CGATATCCCG	CAAGAGGCC	GGCAGTACCG	GCATAACCAA	GCCTATGCCT	ACAGCATCCA	420
GGGTGACGGT	GCCGAGGATG	ACGATGAGCG	CATTGTTAGA	TTTCATACAC	GGTGCCTGAC	480
TGCGTTAGCA	ATTTAACTGT	GATAAACTAC	CGCATTAAAG	CTTATCGATG	ATAAGCTGTC	540
AAACATGAGA	ATTCTTGAAG	ACGAAAGGGC	CTCGTGATAC	GCCTATTTT	ATAGGTTAAT	600
GTCATGATAA	TAATGGTTTC	TTAGACGTCA	GGTGGCACTT	TTGGGGAAA	TGTGCGCGGA	660
ACCCCTATTT	GT	TTTATTTT	CTAAATACAT	TCAAATATGT	ATCCGCTCAT	660
CCCTGATAAA	TT	CCCTTTTT	TGCTTCAATA	ATATTGAAAA	AGGAAGAGTA	720
TGCTTCAATA	TT	CCCTTTTT	ATATTGAAAA	AGGAAGAGTA	TGAGTATTCA	780
GTGCGCCCTTA	TT	CCCTTTTT	TGCGGCATTT	TGCTTCC	ACATTTCCGT	840
CTGGTGAAAG	TT	CCCTTTTT	TGCGGCATTT	TTTTGCTCA	CCCAGAAACG	900
TAAAAGATGC	TT	CCCTTTTT	TGCGGCATTT	TTGGGTGCAC	GAGTGGGTTA	960
TGAAGATCAG	TT	CCCTTTTT	TGCGGCATTT	AAGAACGTTT	CATCGAAGTG	1020
TTGGGTGCAC	TT	CCCTTTTT	TGCGGCATTT	TCCAATGATG	AGCACTTTA	1080
GAGTGGGTTA	TT	CCCTTTTT	TGCGGCATTT	AAGAACGTTT	AAGTTCTGCT	
CATCGAAGTG	TT	CCCTTTTT	TGCGGCATTT	TCCAATGATG	ATGTGGCGCG	
AGCACTTTA	TT	CCCTTTTT	TGCGGCATTT	AAGAACGTTT	GTGTTGACGC	
AAGTTCTGCT	TT	CCCTTTTT	TGCGGCATTT	TGAGTACTC	CGGGCAAGAG	
ATGTGGCGCG	TT	CCCTTTTT	TGCGGCATTT	ACCAAGTCACA	CAACTCGGTC	
GTGTTGACGC	TT	CCCTTTTT	TGCGGCATTT	TGAGTACTC	GCCGCATACA	
CGGGCAAGAG	TT	CCCTTTTT	TGCGGCATTT	ACCAAGTCACA	CTATTCTCAG	
CAACTCGGTC	TT	CCCTTTTT	TGCGGCATTT	TGAGTACTC	AATGACTTGG	
GCCGCATACA	TT	CCCTTTTT	TGCGGCATTT	TTGAGTACTC	TTGAGTACTC	
CTATTCTCAG	TT	CCCTTTTT	TGCGGCATTT	ACCAAGTCACA	ACCAGTCACA	

GAAAAGCCTC TTACGGATGG CATGACAGTA AGAGAATTAT GCAGTGCTGC CATAACCATG	1140
AGTGATAACA CTGCGCCAA CTTACTTCTG ACAACGATCG GAGGACCGAA GGAGCTAAC	1200
GCTTTTTGC ACAACATGGG GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG	1260
AATGAAGCCA TACCAAACGA CGAGCGTGAC ACCACGATGC CTGAGCAAT GGCAACAAAC	1320
TTGCCGAAAC TATTAACTGG CGAACTACTT ACTCTAGCTT CCCGGCAACA ATTAATAGAC	1380
TGGATGGAGG CGGATAAAAGT TGCAGGACCA CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG	1440
TTTATTGCTG ATAAATCTGG AGCCGGTGAG CGTGGGTCTC GCGGTATCAT TGCAAGCACTG	1500
GGGCCAGATG GTAAGCCCTC CCGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT	1560
ATGGATGAAAC GAAATAGACA GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA	1620
CTGTCAGACC AAGTTTACTC ATATATACTT TAGATTGATT TAAAACTTCA TTTTTAATT	1680
AAAAGGATCT AGGTGAAGAT CCTTTTGAT AATCTCATGA CCAAAATCCC TTAACGTGAG	1740
TTTCGTTCC ACTGAGCGTC AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT	1800
TTTTCTGC GCGTAATCTG CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT	1860
TGTTTGCCTT ATCAAGAGCT ACCAACTCTT TTTCCGAAGG TAACTGGCTT CAGCAGAGCG	1920
CAGATACCAA ATACTGTCCT TCTAGTGTAG CCGTAGTTAG GCCACCACCT CAAGAACTCT	1980
GTAGCACCGC CTACATACCT CGCTCTGCTA ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC	2040
GATAAGTCGT GTCTTACCGG GTTGGACTCA AGACGATAGT TACCGGATAA GGCGCAGCGG	2100
TCGGGCTGAA CGGGGGGTTTC GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA	2160
CTGAGATACC TACAGCGTGA GCATTGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGGCG	2220
GACAGGTATC CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC GCACGAGGG GCTTCCAGGG	2280
GGAAACGCTT GGTATTTTA TAGTCCTGTC GGGTTCGCC ACCTCTGACT TGAGCGTCGA	2340
TTTTTGTGAT GCTCGTCAGG GGGCGGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT	2400
TTACGGTTCC TGGCCTTTG CTGGCCTTT GCTCACATGT TCTTCCTGC GTTATCCCCT	2460
GATTCTGTGG ATAACCGTAT TACCGCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA	2520
ACGACCGAGC GCAGCGAGTC AGTGAGCGAG GAAGCGGAAG AGCGCCTGAT GCGGTATTTT	2580
CTCCTTACGC ATCTGTGCGG TATTTCACAC CGCATATGGT GCACTCTCAG TACAATCTGC	2640
TCTGATGCCG CATACTTAAG CCAGTATACA CTCCGCTATC GCTACGTGAC TGGGTATGG	2700
CTGCGCCCCG ACACCCGCCA ACACCCGCTG ACGCGCCCTG ACGGGCTTGT CTGCTCCGG	2760
CATCCGCTTA CAGACAAGCT GTGACCGTCT CCGGGAGCTG CATGTGTAG AGGTTTCAC	2820
CGTCATCACC GAAACCGCG AGGCAGTCTA GACAATAGTA GTACGGATAG CTGTGACTCC	2880
GGTCCTCTTA ACACACCTCC TGAGATACAC CCGGTGGTCC CGCTGTGCC CATTAAACCA	2940
GTTGCCGTGA GAGTTGGTGG GCGTCGCCAG GCTGTGGAAT GTATCGAGGA CTTGCTTAAC	3000
GAGCCTGGC AACCTTGGA CTTGAGCTGT AAACGCCCA GGCCATAAGG TGTAACCTG	3060
TGATTGCCTG TGTGGTTAAC GCCTTTGTT GCTGAATGAG TTGATGTAAG TTTAATAAAG	3120
GGTGAGATAA TGTTAACCTT GCATGGCGTG TTAAATGGGG CGGGGCTTAA AGGGTATATA	3180

ATGCGCCGTG GGCTAATCTT GGTTACATCT GACCTCATGG AGGCTTGGGA GTGTTGGAA	3240
GATTTTCCTG CTGTGCGTAA CTTGCTGGAA CAGAGCTCTA ACAGTACCTC TTGGTTTGG	3300
AGGTTCTGT GGGGCTCATC CCAGGCAAAG TTAGTCTGCA GAATTAAGGA GGATTACAAG	3360
TGGGAATTG AAGAGCTTT GAAATCCTGT GGTGAGCTGT TTGATTCTT GAATCTGGT	3420
CACCAGGGCGC TTTTCCAAGA GAAGGTCTAC AAGACTTGG ATTTTCCAC ACCGGGGCGC	3480
GCTGCGCTG CTGTTGCTT TTTGAGTTT ATAAAGGATA AATGGAGCGA AGAAACCCAT	3540
CTGAGCGGGG GGTACCTGCT GGATTTCTG GCCATGCATC TGTGGAGAGC GGTTGTGAGA	3600
CACAAGAACAT GCCTGCTACT GTTGTCTTC GTCCGCCCG CGATAATACC GACGGAGGAG	3660
CAGCAGCAGC ACCAGGAGGA AGCCAGGCGG CGGCAGCAGG AGCAGAGCCC ATGGAACCCG	3720
AGAGCCGGCC TGGACCTCG GGAATGAATG TTGTACAGGT GGCTGAAC TGATCCAGAAC	3780
TGAGACGCAT TTTGACAATT ACAGAGGATG GGCAGGGCT AAAGGGGTA AAGAGGGAGC	3840
GGGGGGCTTG TGAGGCTACA GAGGAGGCTA GGAATCTAGC TTTTAGCTT ATGACCAGAC	3900
ACCGTCTGA GTGTATTACT TTCACACAGA TCAAGGATAA TTGCGCTAAT GAGCTTGATC	3960
TGCTGGCGCA GAAGTATTCC ATAGAGCAGC TGACCACTTA CTGGCTGCAG CCAGGGGATG	4020
ATTTTGAGGA GGCTATTAGG GTATATGCAA AGGTGGCACT TAGGCCAGAT TGCAAGTACA	4080
AGATCAGCAA ACTTGTAAAT ATCAGGAATT GTTGCTACAT TTCTGGAAC GGGGCCAGG	4140
TGGAGATAGA TACGGAGGAT AGGGTGGCCT TTAGATGTAG CATGATAAT ATGTGGCCGG	4200
GGGTGCTTGG CATGGACGGG GTGGTTATTA TGAATGTAAG GTTTACTGGC CCCAATTAA	4260
GCGGTACCGT TTTCTGGCC AATACCAACC TTATCCTACA CGGTGTAAGC TTCTATGGGT	4320
TTAACAAATAC CTGTGTGGAA GCCTGGACCG ATGTAAGGGT TCGGGCTGT GCCTTTACT	4380
GCTGCTGGAA GGGGGTGGTG TGTCGCCCCA AAAGCAGGGC TTCAATTAAG AAATGCCTCT	4440
TTGAAAGGTG TACCTGGGT ATCCTGTCTG AGGGTAACTC CAGGGTGCAG CACAATGTGG	4500
CCTCCGACTG TGGTTGCTTC ATGCTAGTGA AAAGCGTGGC TGTGATTAAG CATAACATGG	4560
TATGTGGCAA CTGCGAGGAC AGGGCCTCTC AGATGCTGAC CTGCTCGGAC GGCAACTGTC	4620
ACCTGCTGAA GACCATTACAC GTAGCCAGCC ACTCTCGCAA GGCCTGGCCA GTGTTGAGC	4680
ATAACATACT GACCCGCTGT TCCTTGCATT TGGGTAACAG GAGGGGGGTG TTCTTACCTT	4740
ACCAATGCAA TTTGAGTCAC ACTAAGATAT TGCTTGAGCC CGAGAGCATG TCCAAGGTGA	4800
ACCTGAACGG GGTGTTGAC ATGACCATGA AGATCTGGAA GGTGCTGAGG TACGATGAGA	4860
CCCGCACCAAG GTGCAGACCC TGCGAGTGTG GCGGTAAACA TATTAGGAAC CAGCCTGTGA	4920
TGCTGGATGT GACCGAGGAG CTGAGGCCCG ATCACTGGT GCTGGCTGC ACCCGCGCTG	4980
AGTTTGGCTC TAGCGATGAA GATACAGATT GAGGTACTGA AATGTGTGGG CGTGGCTTAA	5040
GGGTGGAAA GAATATATAA GGTGGGGTC TTATGTAGTT TTGTATCTGT TTTGCAGCAG	5100
CCGCCGCCGC CATGAGCACC AACTCGTTG ATGGAAGCAT TGTGAGCTCA TATTGACAA	5160
CGCGCATGCC CCCATGGGCC GGGGTGCAGC AGAATGTGAT GGGCTCCAGC ATTGATGGTC	5220
GCCCCGTCTT GCCCGCAAAC TCTACTACCT TGACCTACGA GACCGTGTCT GGAACGCCGT	5280

TGGAGACTGC AGCCTCCGCC	GGCGCTTCAG CCGCTGCAGC	CACCGCCCGC GGGATTGTGA	5340
CTGACTTTGC TTTCTGAGC	CCGCTTGCAA GCAGTGCAGC	TTCCCGTTCA TCCGCCCGCG	5400
ATGACAAGTT GACGGCTCTT	TTGGCACAAT TGGATTCTTT	GACCCGGGAA CTTAATGTCG	5460
TTTCTCAGCA GCTGTTGGAT	CTGCGCCAGC AGGTTCTGC	CCTGAAGGCT TCCTCCCCCTC	5520
CCAATGCGGT TTAAAACATA	AATAAAAAAC CAGACTCTGT	TTGGATTGAG ATCAAGCAAG	5580
TGTCTTGCTG TCTTATTTA	GGGGTTTGC GCGCGCGTA	GGCCCGGGAC CAGCGGTCTC	5640
GGTCGTTGAG GGTCTGTGT	ATTTTTCCA GGACGTGGTA	AAGGTGACTC TGGATGTTCA	5700
GATACATGGG CATAAGCCCG	TCTCTGGGT GGAGGTAGCA	CCACTGCAGA GCTTCATGCT	5760
GCAGGGGTGGT GTTGTAGATG	ATCCAGTCGT AGCAGGAGCG	CTGGCGTGG TGCCCTAAAAA	5820
TGTCTTCAG TAGCAAGCTG	ATTGCCAGGG GCAGGCCCTT	GGTGTAAAGTG TTTACAAAGC	5880
GGTTAACGCTG GGATGGGTGC	ATACGTGGGG ATATGAGATG	CATCTGGAC TGTATTTTA	5940
GGTTGGCTAT GTTCCCAGCC	ATATCCCTCC GGGGATTCA	GTTGTGCAGA ACCACCAGCA	6000
CAGTGTATCC GGTGCACTTG	GGAAATTGT CATGTAGCTT	AGAAGGAAAT GCGTGGAAAGA	6060
ACTTGGAGAC GCCCTGTGA	CCTCCAAGAT TTTCCATGCA	TTCGTCCATA ATGATGGCAA	6120
TGGGCCACG GGCGCGGCC	TGGCGAAGA TATTTCTGGG	ATCACTAACG TCATAGTTGT	6180
GTTCCAGGAT GAGATCGTCA	TAGGCCATT TTACAAAGCG	CGGGCGGAGG GTGCCAGACT	6240
GCGGTATAAT GGTTCCATCC	GGCCCAGGG CGTAGTTACC	CTCACAGATT TGCATTTCCC	6300
ACGCTTGAG TTCAGATGGG	GGGATCATGT CTACCTGCGG	GGCGATGAAG AAAACGGTTT	6360
CCGGGGTAGG GGAGATCAGC	TGGGAAGAAA GCAGGTTCC	GAGCAGCTGC GACTTACCGC	6420
AGCCGGTGGG CCCGTAAATC	ACACCTATTAA CGGGTGCAA	CTGGTAGTTA AGAGAGCTGC	6480
AGCTGCCGTC ATCCCTGAGC	AGGGGGGCCA CTTCGTTAAG	CATGTCCCTG ACTCGCATGT	6540
TTTCCCTGAC CAAATCCGCC	AGAAGGCCT CGCCGCCAG	CGATAGCAGT TCTTGCAAGG	6600
AAGCAAAGTT TTTCAACGGT	TTGAGACCGT CCGCCGTAGG	CATGCTTTTG AGCGTTTGAC	6660
CAAGCAGTTC CAGGCGGTCC	CACAGCTCGG TCACCTGCTC	TACGGCATCT CGATCCAGCA	6720
TATCTCCTCG TTTCGGGGT	TGGGGCGGCT TTGCTGTAC	GGCAGTAGTC GGTGCTCGTC	6780
CAGACGGGCC AGGGTCATGT	CTTTCCACGG GCGCAGGGTC	CTCGTCAGCG TAGTCTGGGT	6840
CACGGTGAAG GGGTGCCTC	CGGGCTGCGC GCTGGCCAGG	GTGCGCTTGA GGCTGGCCT	6900
GCTGGTGCTG AAGCGCTGCC	GGTCTCGCC CTGCGCGTC	GCCAGGTAGC ATTTGACCCT	6960
GGTGTCTAG TCCAGCCCC	CCGCGCGGTG GCCCTTGGCG	CGCAGCTTGC CCTTGGAGGA	7020
GGCGCCGCAC GAGGGCAGT	GCAGACTTTT GAGGGCGTAG	AGCTTGGCG CGAGAAATAC	7080
CGATTCCGGG GAGTAGGCAT	CCGCGCCGCA GGCCCCGCAG	ACGGTCTCGC ATTCCACGAG	7140
CCAGGTGAGC TCTGGCCGTT	CGGGGTCAAA AACCAGGTTT	CCCCATGCT TTTTGATGCG	7200
TTTCTTACCT CTGGTTCCA	TGAGCCGGTG TCCACGCTCG	GTGACGAAAA GGCTGTCCGT	7260
GTCCCCGTAT ACAGACTTGA	GAGGCCTGTC CTCGAGCGGT	GTTCCCGGGT CCTCCTCGTA	7320
TAGAAACTCG GACCACTCTG	AGACAAAGGC TCGCGTCCAG	GCCAGCACGA AGGAGGCTAA	7380

GTGGGAGGGG TAGCGGTCGT TGTCCACTAG GGGTCCACT CGCTCCAGGG TGTGAAGACA	7440
CATGTCCCC TCTTCGGCAT CAAGGAAGGT GATTGGTTG TAGGTGTAAG CCACGTGACC	7500
GGGTGTTCT GAAGGGGGGC TATAAAAGGG GGTGGGGCG CGTTCGTCCT CACTCTCTC	7560
CGCATCGCTG TCTGCGAGGG CCAGCTGTTG GGGTGAGTAC TCCCTCTGAA AAGCGGGCAT	7620
GACTTCTGCG CTAAGATTGT CAGTTCCAA AAACGAGGAG GATTGATAT TCACCTGGCC	7680
CGCGGTGATG CCTTGAGGG TGGCCGCATC CATCTGGTCA GAAAAGACAA TCTTTTGTT	7740
GTCAAGCTTG GTGGCAAACG ACCCGTAGAG GGC GTTGGAC AGCAACTTGG CGATGGAGCG	7800
CAGGGTTGG TTTTGTCGC GATCGGCGCG CTCCGGCC GCGATGTTA GCTGCACGTA	7860
TTCGCGCGCA ACGCACCGCC ATT CGGGAAA GACGGTGGTG CGCTCGTCGG GCACCAGGTG	7920
CACCGGCCAA CCGCGGTTGT GCAGGGTGAC AAGGTCAACG CTGGTGGCTA CCTCTCCGCG	7980
TAGGCGCTCG TTGGTCCAGC AGAGGCGGCC GCCCTGGCC GAGCAGAATG GCGGTAGGGG	8040
GTCTAGCTGC GTCTCGTCCG GGGGGTCTGC GTCCACGGTA AAGACCCCG GCAGCAGGCG	8100
CGCGTCGAAG TAGTCTATCT TGCATCCTTG CAAGTCTAGC GCCTGCTGCC ATGCGCGGGC	8160
GGCAAGCGCG CGCTCGTATG GTTGAGTGG GGGACCCAT GGCATGGGT GGGTGAGCGC	8220
GGAGGCGTAC ATGCCGAAA TGCGTAAAC GTAGAGGGC TCTCTGAGTA TTCCAAGATA	8280
TGTAGGGTAG CATCTTCCAC CGCGGATGCT GGCGCGCACG TAATCGTATA GTTGTGCGA	8340
GGGAGCGAGG AGGTGGGAC CGAGGTTGCT ACGGGGGGC TGCTCTGCTC GGAAGACTAT	8400
CTGCCTGAAG ATGGCATGTG AGTTGGATGA TATGGTTGGA CGCTGGAAGA CGTTGAAGCT	8460
GGCGTCTGTG AGACCTACCG CGTCACGCAC GAAGGAGGCG TAGGAGTCGC GCAGCTTGT	8520
GACCAGCTCG GCGGTGACCT GCACGTCTAG GGCGCAGTAG TCCAGGGTTT CCTTGATGAT	8580
GTCATACTTA TCCTGTCCT TTTTTTCCA CAGCTCGCG TTGAGGACAA ACTCTCGCG	8640
GTCTTCCAG TACTCTTGGG TCGGAAACCC GTCGGCCTCC GAACGGTAAG AGCCTAGCAT	8700
GTAGAACTGG TTGACGGCCT GGTAGGCGA GCATCCCTT TCTACGGGTA GCGCGTATGC	8760
CTGCGCGGCC TTCCGGAGCG AGGTGTGGGT GAGCGCAAAG GTGTCCCTGA CCATGACTTT	8820
GAGGTACTGG TATTTGAAGT CAGTGTGTC GCATCCGCCC TGCTCCCAGA GCAAAAGTC	8880
CGTGCCTTT TTGGAACGCG GATTGGCAG GGCGAAGGTG ACATCGTTGA AGAGTATCTT	8940
TCCCGCGCGA GGCATAAAAGT TGC GTGTGAT GCGGAAGGGT CCCGGCACCT CGGAACGGTT	9000
GTAAATTACC TGGGCGCGA GCACGATCTC GTCAAAGCCG TTGATGTTGT GGCCCACAAT	9060
GTAAAGTTCC AAGAACGCG GGATGCCCTT GATGGAAGGC AATTTTTAA GTTCTCGTA	9120
GGTGAGCTCT TCAGGGGAGC TGAGCCCCTG CTCTGAAAGG GCCCAGTCTG CAAGATGAGG	9180
GTTGGAAGCG ACGAATGAGC TCCACAGGTC ACGGGCCATT AGCATTGCA GGTGGTCGCG	9240
AAAGGTCTTA AACTGGCGAC CTATGCCAT TTTTTCTGGG GTGATGCAGT AGAAGGTAAG	9300
CGGGTCTTGT TCCCAGCGGT CCCATCCAAG GTTCGCGGCT AGGTCTCGCG CGGCAGTCAC	9360
TAGAGGCTCA TCTCCGCCGA ACTTCATGAC CAGCATGAAG GGCACGAGCT GCTTCCAAA	9420
GGCCCCCATC CAAGTATAGG TCTCTACATC GTAGGTGACA AAGAGACGCT CGGTGCGAGG	9480

ATCGCAGCCG ATCGGGAAAGA ACTGGATCTC CCGCCACCAA TTGGAGGAGT GGCTATTGAT	9540
GTGGTGAAAG TAGAAGTCCC TGCGACGGGC CGAACACTCG TGCTGGCTTT TGTAAAAACG	9600
TGCGCAGTAC TGGCAGCGGT GCACGGGCTG TACATCCTGC ACGAGGTTGA CCTGACGACC	9660
GCCCACACAAGG AAGCAGAGTG GGAATTGAG CCCCTCGCCT GGCGGGTTG GCTGGTGGTC	9720
TTCTACTTCG GCTGCTTGTc CTTGACCGTC TGGCTGCTCG AGGGGAGTTA CGGTGGATCG	9780
GACCACCACG CCGCGCGAGC CCAAAGTCCA GATGTCCGCG CGCGCGGTC GGAGCTTGAT	9840
GACAACATCG CGCAGATGGG AGCTGTCCAT GGTCTGGAGC TCCCGCGGCG TCAGGTCAGG	9900
CGGGAGCTCC TGCAGGTTA CCTCGCATAG ACGGGTCAAGG GCGCGGGCTA GATCCAGGTG	9960
ATACCTAATT TCCAGGGGCT GGTTGGTGGC GGCCTCGATG GCTTGCAAGA GGCGCATTCC	10020
CCCGCGCGCG ACTACGGTAC CGCGCGGCGG GCGGTGGGCC GCGGGGGTGT CCTTGGATGA	10080
TGCATCTAAA AGCGGTGACG CGGGCGAGCC CCCGGAGGTA GGGGGGGCTC CGGACCCGCC	10140
GGGAGAGGGG GCAGGGCAC GTCGGCGCC CGCGCGGGCA GGAGCTGGTG CTGCGCGGT	10200
AGGTTGCTGG CGAACCGCAG GACCGGGCGG TTGATCTCCT GAATCTGGCG CCTCTGCGTG	10260
AAGACGACGG GCCCGGTGAG CTTGAGCCTG AAAGAGAGTT CGACAGAACAT AATTCGGTG	10320
TCGTTGACGG CGGCCTGGCG CAAAATCTCC TGCACGTCTC CTGAGTTGTC TTGATAGGCG	10380
ATCTCGGCCA TGAACTGCTC GATCTCTTCC TCCTGGAGAT CTCCCGTCTC GGCTCGCTCC	10440
ACGGTGGCGG CGAGGTCGTT GGAAATGCGG GCCATGAGCT GCGAGAAGGC GTTGAGGCCT	10500
CCCTCGTTCC AGACCGGGCT GTAGACCACG CCCCCCTCGG CATCGCGGCG GCGCATGACC	10560
ACCTGCGCGA GATTGAGCTC CACGTGCCGG GCGAAGACGG CGTAGTTTCG CAGGCGCTGA	10620
AAGAGGTAGT TGAGGGTGGT GGCGGTGTGT TCTGCCACGA AGAAGTACAT AACCCAGCGT	10680
CGCAACGTGG ATTGTTGAT ATCCCCAAG GCCTCAAGGC GCTCCATGGC CTCGTAGAAG	10740
TCCACGGCGA AGTTGAAAAA CTGGGAGTTG CGCGCCGACA CGGTTAACTC CTCCTCCAGA	10800
AGACGGATGA GCTCGCGAC AGTGTGCGC ACCTCGCGCT CAAAGGCTAC AGGGGCCTCT	10860
TCTTCTTCTT CAATCTCCTC TTCCATAAGG GCCTCCCCCTT CTTCTTCTTC TGGCGCGGT	10920
GGGGGAGGGG GGACACGGCG GCGACGACGG CGCACCGGGA GGCGGTGAC AAAGCGCTCG	10980
ATCATCTCCC CGCGCGGACG GCGCATGGTC TCGGTGACGG CGCGGCCGTT CTCGCGGGGG	11040
CGCAGTTGGA AGACGCCGCC CGTCATGTCC CGGTTATGGG TTGGGGGGGG GCTGCCATGC	11100
GGCAGGGATA CGGCGCTAAC GATGCATCTC AACATTGTT GTGTAGGTAC TCCGCCGCCG	11160
AGGGACCTGA GCGAGTCCGC ATCGACCGGA TCGGAAAACC TCTCGAGAAA GGCGTCTAAC	11220
CAGTCACAGT CGCAAGGTAG GCTGAGCACC GTGGCGGGCG GCAGCGGGCG GCGGTGGGG	11280
TTGTTTCTGG CGGAGGTGCT GCTGATGATG TAATTAAAGT AGGCGGTCTT GAGACGGCGG	11340
ATGGTCGACA GAAGCACCAC GTCCTGGGT CCGGCCTGCT GAATGCGCAG GCGGTGGCC	11400
ATGCCCCAGG CTTCGTTTG ACATCGCGC AGGTCTTGT AGTAGTCTTG CATGAGCCTT	11460
TCTACCGGCA CTTCTTCTTC TCCTTCCCTC TGTCCTGCAT CTCTTGCATC TATCGCTGCG	11520
GGGGCGGGCGG AGTTGGCCG TAGGTGGCGC CCTCTTCCCTC CCATGCGTGT GACCCGAAG	11580

CCCCTCATCG GCTGAAGCAG GGCTAGGTCG GCGACAACGC GCTCGGCTAA TATGGCCTGC 11640
 TGCACCTGCG TGAGGGTAGA CTGGAAGTCA TCCATGTCCA CAAAGCGGTG GTATGCGCCC 11700
 GTGTTGATGG TGTAAGTGCA GTTGGCCATA ACGGACCAGT TAACGGCTG GTGACCCGGC 11760
 TGCAGAGCT CGGTGTACCT GAGACGCGAG TAAGCCCTCG AGTCAAATAC GTAGTCGTTG 11820
 CAAGTCCGCA CCAGGTACTG GTATCCCACC AAAAAGTGC GCGGCGGCTG GCGGTAGAGG 11880
 GCCCAGCGTA GGGTGGCCGG GGCTCCGGGG GCGAGATCTT CCAACATAAG GCGATGATAT 11940
 CCGTAGATGT ACCTGGACAT CCAGGTGATG CCGGCGGCGG TGGTGGAGGC GCGCGGAAAG 12000
 TCGCGGACGC GGTTCCAGAT GTTGGCGAGC GGCAAAAAGT GCTCCATGGT CGGGACGCTC 12060
 TGGCCGGTCA GGCGCGCGCA ATCGTTGACG CTCTACCGTG CAAAAGGAGA GCCTGTAAGC 12120
 GGGCACTCTT CCGTGGTCTG GTGGATAAAAT TCGCAAGGGT ATCATGGCGG ACGACCGGGG 12180
 TTCGAGCCCC GTATCCGGCC GTCCGCCGTG ATCCATGCGG TTACCGCCCG CGTGTGAAAC 12240
 CCAGGTGTGC GACGTCAGAC AACGGGGAG TGCTCCTTT GGCTTCCTTC CAGGCGCGC 12300
 GGCTGCTGCG CTAGCTTTT TGGCCACTGG CCGCGCGCAG CGTAAGCGGT TAGGCTGGAA 12360
 AGCGAAAGCA TTAAGTGGCT CGCTCCCTGT AGCCGGAGGG TTATTTCCA AGGGTTGAGT 12420
 CGCGGGACCC CCGGTTCGAG TCTCGGACCG GCCGGACTGC GGCGAACGGG GGTTGCCTC 12480
 CCCGTATGC AAGACCCCGC TTGCAAATTG CTCCGGAAAC AGGGACGAGC CCCTTTTTG 12540
 CTTTCCCAAG ATGCATCCGG TGCTGCGCA GATGCGCCCC CCTCCTCAGC AGCGGCAAGA 12600
 GCAAGAGCAG CGGCAGACAT GCAGGGCACC CTCCCTCCT CCTACCGCGT CAGGAGGGC 12660
 GACATCCGCG GTTGACGCGG CAGCAGATGG TGATTACGAA CCCCCCGCGC GCCGGGCCCG 12720
 GCACTACCTG GACTTGGAGG AGGGCGAGGG CCTGGCGCGG CTAGGAGCGC CCTCTCCTGA 12780
 GCGGTACCCA AGGGTGCAGC TGAAGCGTGA TACCGGTGAG GCGTACGTGC CGCGGCAGAA 12840
 CCTGTTTGC GACCGCGAGG GAGAGGAGCC CGAGGAGATG CGGGATCGAA AGTTCCACGC 12900
 AGGGCGCGAG CTGCGGCATG GCCTGAATCG CGAGCGGTTG CTGGCGAGG AGGACTTTGA 12960
 GCCCGACGCG CGAACCGGGA TTAGTCCCGC GCGCGCACAC GTGGCGGCCG CCGACCTGGT 13020
 AACCGCATAAC GAGCAGACGG TGAACCAGGA GATTAACCTT CAAAAAAAGCT TTAACAACCA 13080
 CGTCCGTACG CTTGTGGCGC GCGAGGAGGT GGCTATAGGA CTGATGCATC TGTGGGACTT 13140
 TGTAAGCGCG CTGGAGCAAA ACCCAAATAG CAAGCCGCTC ATGGCGCAGC TGTTCCCTAT 13200
 AGTGCAGCAC AGCAGGGACA ACGAGGCATT CAGGGATGCG CTGCTAAACA TAGTAGAGCC 13260
 CGAGGGCCGC TGGCTGCTCG ATTTGATAAA CATCCTGCAG AGCATAGTGG TGCAGGAGCG 13320
 CAGCTTGAGC CTGGCTGACA AGGTGGCCGC CATCAACTAT TCCATGCTTA GCCTGGGCAA 13380
 GTTTTACGCC CGCAAGATAT ACCATAACCC TTACGTTCCC ATAGACAAGG AGGTAAAGAT 13440
 CGAGGGGTTC TACATGCGCA TGGCGCTGAA GGTGCTTACC TTGAGCGACG ACCTGGGCGT 13500
 TTATCGCAAC GAGCGCATCC ACAAGGCCGT GAGCGTGAGC CGGCGGCGCG AGCTCAGCGA 13560
 CCGCGAGCTG ATGCACAGCC TGCAAAGGGC CCTGGCTGGC ACGGGCAGCG GCGATAGAGA 13620
 GGCGAGTCC TACTTGACG CGGGCGCTGA CCTGCGCTGG GCCCAAGCC GACGCGCCCT 13680

GGAGGCAGCT GGGGCCGGAC CTGGGCTGGC GGTGGCACCC GCGCGCGCTG GCAACGTCGG 13740
 CGCGTGGAG GAATATGACG AGGACGATGA GTACGAGCCA GAGGACGGCG AGTACTAAGC 13800
 GGTGATGTTT CTGATCAGAT GATGCAAGAC GCAACGGACC CGCGCGTGGC GGCGCGCTG 13860
 CAGAGCCAGC CGTCCGGCCT TAACTCCACG GACGACTGGC GCCAGGTCAT GGACCGCATC 13920
 ATGTCCGCTGA CTGCCGGCAA TCCTGACGGG TTCCGGCAGC AGCCGCAGGC CAACCGGCTC 13980
 TCCGCAATTG TGGAAGCGGT GGTCCCAGCG CGCGCAAACC CCACGCACGA GAAGGTGCTG 14040
 GCGATCGTAA ACGCGCTGGC CGAAAACAGG GCCATCCGGC CCCACGAGGC CGGCCTGGTC 14100
 TAGGACCGCGC TGCTTCAGCG CGTGGCTCGT TACAACAGCG GCAACGTGCA GACCAACCTG 14160
 GACCGGCTGG TGGGGGATGT GCGCGAGGCC GTGGCGCAGC GTGAGCGCAGC GCAGCAGCAG 14220
 GGCAACCTGG GCTCCATGGT TGCACAAAC GCCTTCTGA GTACACAGCC CGCCAACGTG 14280
 CCGCGGGGAC AGGAGGACTA CACCAACTTT GTGAGCGCAC TGCGGCTAAT GGTGACTGAG 14340
 ACACCGCAAA GTGAGGTGTA CCAGTCTGGG CCAGACTATT TTTTCCAGAC CAGTAGACAA 14400
 GGCCTGCAGA CCGTAAACCT GAGCCAGGCT TTCAAAAACT TGCAGGGGCT GTGGGGGTG 14460
 CGGGCTCCCA CAGGCCGACCG CGCGACCGTG TCTAGCTTG TGACGCCAA CTCGCGCTG 14520
 TTGCTGCTGC TAATAGCGCC CTTCACGGAC AGTGGCAGCG TGTCCCAGGA CACATACCTA 14580
 GGTCACTTGC TGACACTGTA CCGCGAGGCC ATAGGTCAAG CGCATGTGGA CGAGCATACT 14640
 TTCCAGGAGA TTACAAGTGT CAGCCGCGCG CTGGGGCAGG AGGACACGGG CAGCCTGGAG 14700
 GCAACCTAA ACTACCTGCT GACCAACCGG CGGCAGAAGA TCCCCTCGTT GCACAGTTA 14760
 AACAGCGAGG AGGAGCGCAT TTTGCGCTAC GTGCAGCAGA GCGTGAGCCT TAACCTGATG 14820
 CGCGACGGGG TAACGCCAG CGTGGCGCTG GACATGACCG CGCGCAACAT GGAACCGGGC 14880
 ATGTATGCCT CAAACCGGCC GTTTATCAAC CGCCTAATGG ACTACTTGCA TCGCGGGCC 14940
 GCCGTGAACC CCGAGTATTT CACCAATGCC ATCTTGAACC CGCACTGGCT ACCGCCCCCT 15000
 GTTTCTACA CGGGGGATT CGAGGTGCC GAGGGTAACG ATGGATTCCCT CTGGGACGAC 15060
 ATAGACGACA GCGTGTTC CCGCAACCG CAGACCTGC TAGAGTTGCA ACAGCGCAG 15120
 CAGGCAGAGG CGCGCTGCG AAAGGAAAGC TTCCGAGGC CAAGCAGCTT GTCCGATCTA 15180
 GGCGCTGCGG CCCCAGGGTC AGATGCTAGT AGCCCATTT CAAGCTTGAT AGGGTCTCTT 15240
 ACCAGCACTC GCACCAACCG CCCGCGCTG CTGGGGAGG AGGAGTACCT AAACAACCTG 15300
 CTGCTGCAGC CGCAGCGCGA AAAAAACCTG CCTCCGGCAT TTCCCAACAA CGGGATAGAG 15360
 AGCCTAGTGG ACAAGATGAG TAGATGGAAG ACGTACGCGC AGGAGCACAG GGACGTGCCA 15420
 GGCGCGGCC CGCCCACCCG TCGTCAAAGG CACGACCGTC AGCGGGGTCT GGTGTGGAG 15480
 GACGATGACT CGGCAGACGA CAGCAGCGTC CTGGATTGG GAGGGAGTGG CAACCCGTTT 15540
 GCGCACCTTC GCCCCAGGCT GGGGAGAATG TTTTAAAAAA AAAAAAGCAT GATGCAAAAT 15600
 AAAAAACTCA CCAAGGCCAT GGCACCGAGC GTTGGTTTC TTGTATTCCC CTTAGTATGC 15660
 GGCGCGCGGC GATGTATGAG GAAGGTCCCTC CTCCCTCCTA CGAGAGTGTG GTGAGCGCG 15720
 CGCCAGTGGC GGCAGCGCTG GGTTCTCCCT TCGATGCTCC CCTGGACCCG CCGTTGTGC 15780

CTCCCGGGTA CCTGCGGCCT ACCGGGGGGA GAAACAGCAT CCGTTACTCT GAGTTGGCAC	15840
CCCTATTGCA CACCACCGT GTGTACCTGG TGGACAACAA GTCAACGGAT GTGGCATCCC	15900
TGAACTACCA GAACGACCAC AGCAACTTC TGACCACGGT CATTCAAAC AATGACTACA	15960
GCCCCGGGGA GGCAAGCACA CAGACCATCA ATCTTGACGA CCGGTGCGAC TGGGGCGCG	16020
ACCTGAAAAC CATCCTGCAT ACCAACATGC CAAATGTGAA CGAGTTCATG TTTACCAATA	16080
AGTTTAAGGC GCGGGTGTG GTGTCGCGCT TGCCTACTAA GGACAATCAG GTGGAGCTGA	16140
AATACGAGTG GGTGGAGTTC ACGCTGCCG AGGGCAACTA CTCCGAGACC ATGACCATAG	16200
ACCTTATGAA CAACCGGATC GTGGAGCACT ACTTGAAAGT GGGCAGACAG AACGGGGTTC	16260
TGGAAAGCGA CATCGGGTA AAGTTGACA CCCGCAACTT CAGACTGGGG TTTGACCCCG	16320
TCACTGGTCT TGTATGCCT GGGGTATATA CAAACGAAGC CTTCCATCCA GACATCATT	16380
TGCTGCCAGG ATGCGGGGTG GACTTCACCC ACAGCCGCCT GAGCAACTT GAGGGCATCC	16440
GCAAGCGGCA ACCCTTCCAG GAGGGCTTA GGATCACCTA CGATGATCTG GAGGGTGGTA	16500
ACATTCCCGC ACTGTTGGAT GTGGACGCCT ACCAGGGCAG CTTGAAAGAT GACACCGAAC	16560
AGGGCGGGGG TGGCGCAGGC GGCAGCAACA GCAGTGGCAG CGGCGCGGAA GAGAACTCCA	16620
ACGCGGCAGC CGCGGCAATG CAGCCGGTGG AGGACATGAA CGATCATGCC ATTGCGGCG	16680
ACACCTTTGC CACACGGCT GAGGAGAAC GCGCTGAGGC CGAAGCAGCG GCCGAAGCTG	16740
CCGCCCCCGC TGCGCAACCC GAGGTCGAGA AGCCTCAGAA GAAACCGGTG ATCAAACCCC	16800
TGACAGAGGA CAGCAAGAAA CGCAGTTACA ACCTAATAAG CAATGACAGC ACCTTCACCC	16860
AGTACCGCAG CTGGTACCTT GCATACAAC TCGCGACCC TCAGACCGGA ATCCGCTCAT	16920
GGACCCCTGCT TTGCACTCCT GACGTAACCT GCGGCTCGGA GCAGGTCTAC TGGTCGTTGC	16980
CAGACATGAT GCAAGACCCC GTGACCTTCC GCTCCACCGC CCAGATCAGC AACTTTCCGG	17040
TGGTGGCGC CGAGCTGTTG CCCGTGCACT CCAAGAGCTT CTACAACGAC CAGGCCGTCT	17100
ACTCCCAACT CATCCGCCAG TTTACCTCTC TGACCCACGT GTTCAATCGC TTTCCCGAGA	17160
ACCAGATTTT GGCGCGCCCG CCAGCCCCA CCATCACAC CGTCAGTGAA AACGTTCCCTG	17220
CTCTCACAGA TCACGGGACG CTACCGCTGC GCAACAGCAT CGGAGGAGTC CAGCGAGTGA	17280
CCATTACTGA CGCCAGACGC CGCACCTGCC CCTACGTTA CAAGGCCCTG GGCATAGTCT	17340
CGCCGCGCGT CCTATCGAGC CGCACTTTT GAGCAAGCAT GTCCATCCTT ATATGCCCA	17400
GCAATAACAC AGGCTGGGC CTGCGCTTCC CAAGCAAGAT GTTTGGCGGG GCCAAGAAC	17460
GCTCCGACCA ACACCCAGTG CGCGTGCAGC GGCACCTACCG CGCAGCCCTGG GGCGCGCACA	17520
AACGGCGCCG CACTGGCGC ACCACCGTCA ATGACGCCAT CGACCGGGTG GTGGAGGAGG	17580
CGCGCAACTA CACGCCACG CCGCCACCAAG TGTCCACAGT GGACCGGGCC ATTCAAGACCG	17640
TGGTGCAGCG AGCCCGGCGC TATGCTAAAA TGAAGAGACG GCGGAGGCGC GTAGCACGTC	17700
GCCACCGCCG CCGACCCGGC ACTGCCGCC AACGCGCGC GGCAGCCCTG CTTAACCGCG	17760
CACGTGCGAC CGGCGACGG GCGGCCATGC GGGCCGCTCG AAGGCTGGCC GCGGGTATTG	17820
TCACTGTGCC CCCCAGGTCC AGGGGACGAG CGGCCGCCGC AGCAGCCGCG GCCATTAGTG	17880

CTATGACTCA	GGGTGCGCAGG	GGCAACGTGT	ATTGGGTGCG	CGACTCGGTT	AGCGGCCTGC	17940
GCGTGCCCGT	GCGCACCCGC	CCCCCGCGCA	ACTAGATTGC	AAGAAAAAAC	TACTTAGACT	18000
CGTACTGTTG	TATGTATCCA	GCGGCGGCGG	CGCGCAACGA	AGCTATGTCC	AAGCGAAAA	18060
TCAAAGAAGA	GATGCTCCAG	GTCATCGCGC	CGGAGATCTA	TGGCCCCCG	AAGAAGGAAG	18120
AGCAGGATTA	CAAGCCCCGA	AAGCTAAAGC	GGGTCAAAAA	GAAAAGAAA	GATGATGATG	18180
ATGAACTTGA	CGACCGAGGTG	GAACTGCTGC	ACGCTACCGC	GCCCAGGCCA	CGGGTACAGT	18240
GGAAAGGTG	ACGCGTAAAA	CGTGTGTTGC	GACCCGGCAC	CACCGTAGTC	TTTACGCCG	18300
GTGAGCGCTC	CACCCGCACC	TACAAGCGCG	TGTATGATGA	GGTGTACGGC	GACGAGGACC	18360
TGCTTGAGCA	GGCCAACGAG	CGCCTCGGGG	AGTTTGCTA	CGGAAAGCGG	CATAAGGACA	18420
TGCTGGCGTT	GCCGCTGGAC	GAGGGCAACC	CAACACCTAG	CCTAAAGCCC	GTAACACTGC	18480
AGCAGGTGCT	GCCCCGCGTT	GCACCGTCCG	AAGAAAAGCG	CGGCCTAAAG	CGCGAGTCTG	18540
GTGACTTGGC	ACCCACCGTG	CAGCTGATGG	TACCCAAGCG	CCAGCGACTG	GAAGATGTCT	18600
TGGAAAAAAT	GACCGTGGAA	CCTGGGCTGG	AGCCCCAGGT	CCGCGTGC GG	CCAATCAAGC	18660
AGGTGGCGCC	GGGACTGGGC	GTGCAGACCG	TGGACGTTCA	GATACCCAC	ACCAGTAGCA	18720
CCAGTATTGC	CACCGCCACA	GAGGGCATGG	AGACACAAAC	GTCCCCGGTT	GCCTCAGCGG	18780
TGGCGGATGC	CGCGGTGCAG	CGGGTCGCTG	CGGCCGCGTC	CAAGACCTCT	ACGGAGGTGC	18840
AAACGGACCC	GTGGATGTTT	CGCGTTTCAG	CCCCCCGGCG	CCCGCGCGGT	TCGAGGAAGT	18900
ACGGCGCCGC	CAGCCGCTA	CTGCCCCAAT	ATGCCCTACA	TCCCTTCCATT	GCGCCTACCC	18960
CCGGCTATCG	TGGCTACACC	TACCGCCCCA	GAAGACGAGC	AACTACCCGA	CGCCGAACCA	19020
CCACTGGAAC	CCGCCGCCGC	CGTCGCCGTC	GCCAGCCCGT	GCTGGCCCCG	ATTTCCGTGC	19080
GCAGGGTGGC	TCGCGAAGGA	GGCAGGACCC	TGGTGCTGCC	AACAGCGCGC	TACCACCCCA	19140
GCATCGTTA	AAAGCCGGTC	TTTGTGGTTC	TTGCAGATAT	GGCCCTCACC	TGCCGCCTCC	19200
GTTCCTCGGT	GCCGGGATTC	CGAGGAAGAA	TGCACCGTAG	GAGGGGCATG	GCCGGCCACG	19260
GCCTGACGGG	CGGCATGCGT	CGTGCACACC	ACCGGGCGCG	GCGCGCGTCG	CACCGTCGCA	19320
TGCGCGGCCG	TATCCTGCC	CTCCTTATTG	CACTGATCGC	CGCGCGATT	GGCGCCGTGC	19380
CCGGAATTGC	ATCCGTGGCC	TTGCAGGCGC	AGAGACACTG	ATTAAAAACA	AGTTGCATGT	19440
GGAAAAAATCA	AAATAAAAAG	TCTGGACTCT	CACGCTCGCT	TGGTCTGTG	ACTATTTGT	19500
AGAATGGAAG	ACATCAACTT	TGCGTCTCTG	GCCCCGCGAC	ACGGCTCGCG	CCCCTTCATG	19560
GGAAACTGGC	AAGATATCGG	CACCAAGCAAT	ATGAGCGGTG	GCGCCTTCAG	CTGGGGCTCG	19620
CTGTGGAGCG	GCATTAAGAA	TTTCGGTTCC	ACCGTTAAGA	ACTATGGCAG	CAAGGCCTGG	19680
AACAGCAGCA	CAGGCCAGAT	GCTGAGGGAT	AAGTTGAAAG	AGCAAAATT	CCAACAAAAG	19740
GTGGTAGATG	GCCTGGCCTC	TGGCATTAGC	GGGGTGGTGG	ACCTGGCCAA	CCAGGCAGTG	19800
CAAAATAAGA	TTAACAGTAA	GCTTGATCCC	CGCCCTCCCG	TAGAGGAGCC	TCCACCGGCC	19860
GTGGAGACAG	TGTCTCCAGA	GGGGCGTGGC	GAAAGCGTC	CGCGCCCCGA	CAGGGAAGAA	19920
ACTCTGGTGA	CGCAAATAGA	CGAGCCTCCC	TGTCAGGAGG	AGGCACTAAA	GCAAGGCCTG	19980

CCCACCAACC	GTCCCCATCGC	GCCCATGGCT	ACCGGAGTGC	TGGGCCAGCA	CACACCCGTA	20040
ACGCTGGACC	TGCCTCCCCC	CGCCGACACC	CAGCAGAAAC	CTGTGCTGCC	AGGCCCGACC	20100
GCCGTTGTTG	TAACCCGTCC	TAGCCGCGG	TCCCTGCGCC	GCGCCGCCAG	CGGTCCGCGA	20160
TCGTTGCCGC	CCGTAGCCAG	TGGCAACTGG	CAAAGCACAC	TGAACAGCAT	CGTGGGTCTG	20220
GGGGTGCAAT	CCCTGAAGCG	CCGACGATGC	TTCTGAATAG	CTAACGTGTC	GTATGTGTGT	20280
CATGTATGCG	TCCATGTCGC	CGCCAGAGGA	GCTGCTGAGC	CGCCGCCGCG	CCGCTTCCA	20340
AGATGGCTAC	CCCTTCGATG	ATGCCGCAGT	GGTCTTACAT	GCACATCTCG	GGCCAGGACG	20400
CCTCGGAGTA	CCTGAGCCCC	GGGCTGGTGC	AGTTTGCCCG	CGCCACCGAG	ACGTACTTCA	20460
GCCTGAATAA	CAAGTTAGA	AACCCCACGG	TGGCGCCTAC	GCACGACGTG	ACCACAGACC	20520
GGTCCCAGCG	TTTGACGCTG	CGGTTCATCC	CTGTGGACCG	TGAGGATACT	GCGTACTCGT	20580
ACAAGGCGCG	GTTCACCCCTA	GCTGTGGGTG	ATAACCGTGT	GCTGGACATG	GCTTCCACGT	20640
ACTTTGACAT	CCGGGGCGTG	CTGGACAGGG	GCCCTACTTT	TAAGCCCTAC	TCTGGCACTG	20700
CCTACAAACGC	CCTGGCTCCC	AAGGGTGCC	CAAATCCTTG	CGAATGGGAT	GAAGCTGCTA	20760
CTGCTCTTGA	AATAAACCTA	GAAGAAGAGG	ACGATGACAA	CGAAGACGAA	GTAGACGAGC	20820
AAGCTGAGCA	GCAAAAAACT	CACGTATTTG	GGCAGGGGCC	TTATTCTGGT	ATAAAATATTA	20880
CAAAGGAGGG	TATTCAAATA	GGTGTGAG	GTCAAACACC	TAATATGCC	GATAAAACAT	20940
TTCAACCTGA	ACCTCAAATA	GGAGAATCTC	AGTGGTACGA	AACTGAAATT	AATCATGCAG	21000
CTGGGAGAGT	CCTTAAAAAG	ACTACCCCAA	TGAAACCATG	TTACGGTTCA	TATGCAAAAC	21060
CCACAAATGA	AAATGGAGGG	CAAGGCATTC	TTGTAAAGCA	ACAAAATGGA	AAGCTAGAAA	21120
GTCAAGTGGA	AATGCAATT	TTCTCAACTA	CTGAGGGCAC	CGCAGGCAAT	GGTGATAACT	21180
TGACTCCTAA	AGTGGTATTG	TACAGTGAAG	ATGTAGATAT	AGAAAACCCA	GACACTCATA	21240
TTTCTTACAT	GCCCACATT	AAGGAAGGTA	ACTCACGAGA	ACTAATGGGC	CAACAATCTA	21300
TGCCCAACAG	GCCTAATTAC	ATTGCTTTA	GGGACAATT	TATTGGTCTA	ATGTATTACA	21360
ACAGCACGGG	TAATATGGGT	GTTCTGGCGG	GCCAAGCATC	GCAGTTGAAT	GCTGTTGTAG	21420
ATTTGCAAGA	CAGAAACACA	GAGCTTTCAT	ACCACTTTT	GCTTGATTCC	ATTGGTGATA	21480
GAACCAGGTA	CTTTCTATG	TGGAATCAGG	CTGTTGACAG	CTATGATCCA	GATGTTAGAA	21540
TTATTGAAAA	TCATGGAAC	GAAGATGAAC	TTCCAAATT	CTGCTTCCA	CTGGGAGGTG	21600
TGATTAATAC	AGAGACTCTT	ACCAAGGTAA	AACCTAAAAC	AGTCAGGAA	AATGGATGGG	21660
AAAAAGATGC	TACAGAAATT	TCAGATAAAA	ATGAAATAAG	AGTTGGAAAT	AATTTGCCA	21720
TGAAATCAA	TCTAAATGCC	AACCTGTGGA	GAAATTCCCT	GTACTCCAAC	ATAGCGCTGT	21780
ATTTGCCCGA	CAAGCTAAAG	TACAGTCCTT	CCAACGTAAA	AATTCTGAT	AACCCAAACA	21840
CCTACGACTA	CATGAACAAG	CGAGTGGTGG	CTCCGGGTT	AGTGGACTGC	TACATTAACC	21900
TTGGAGCACG	CTGGTCCCTT	GACTATATGG	ACAACGTCAA	CCCATTAAAC	CACCACCGCA	21960
ATGCTGGCCT	GCGCTACCGC	TCAATGTTGC	TGGGCAATGG	TCGCTATGTG	CCCTTCCACA	22020
TCCAGGTGCC	TCAGAAGTTC	TTGCCATT	AAAACCTCCT	TCTCCTGCCG	GGCTCATACA	22080

CCTACGAGTG	GAACTTCAAGG	AAGGATGTTA	ACATGGTCT	GCAGAGCTCC	CTAGGAAATG	22140
ACCTAAGGGT	TGACGGAGCC	AGCATTAAGT	TTGATAGCAT	TTGCCCTTAC	GCCACCTTCT	22200
TCCCCATGGC	CCACAACACC	GCCTCCACGC	TTGAGGCCAT	GCTTAGAAC	GACACCAACG	22260
ACCAAGTCCTT	TAACGACTAT	CTCTCCGCCG	CCAACATGCT	CTACCCCTATA	CCCGCCAACG	22320
CTACCAACGT	GCCCATATCC	ATCCCCCTCCC	GCAACTGGGC	GGCTTTCCGC	GGCTGGGCCT	22380
TCACGCGCCT	TAAGACTAAG	GAAACCCCAT	CACTGGGCTC	GGGCTACGAC	CCTTATTACA	22440
CCTACTCTGG	CTCTATACCC	TACCTAGATG	GAACCTTTA	CCTCAACCAC	ACCTTTAAGA	22500
AGGTGGCCAT	TACCTTGAC	TCTTCTGTCA	GCTGGCCTGG	CAATGACCGC	CTGCTTACCC	22560
CCAACGAGTT	TGAAATTAAG	CGCTCAGTTG	ACGGGGAGGG	TTACAACGTT	GCCCAGTGTA	22620
ACATGACCAA	AGACTGGTTC	CTGGTACAAA	TGCTAGCTAA	CTACAACATT	GGCTACCAGG	22680
GCTTCTATAT	CCCAGAGAGC	TACAAGGACC	GCATGTACTC	CTTCTTTAGA	AACTTCCAGC	22740
CCATGAGCCG	TCAGGTGGTG	GATGATACTA	AATAACAAGGA	CTACCAACAG	GTGGGCATCC	22800
TACACCAACA	CAACAACACT	GGATTTGTTG	GCTACCTTGC	CCCCACCATG	CGCGAAGGAC	22860
AGGCCTACCC	TGCTAACCTTC	CCCTATCCGC	TTATAGGCAA	GACCGCAGTT	GACAGCATT	22920
CCCAGAAAAA	GTTTCTTGC	GATGCACCC	TTTGGCGCAT	CCCATTCTCC	AGTAACTTA	22980
TGTCCATGGG	CGCACTCACA	GACCTGGGCC	AAAACCTTCT	CTACGCCAAC	TCCGCCACG	23040
CGCTAGACAT	GACTTTGAG	GTGGATCCCA	TGGACGAGCC	CACCCCTCTT	TATGTTTGT	23100
TTGAAGTCTT	TGACGTGGTC	CGTGTGCACC	GGCCGCACCG	CGCGTCATC	GAAACCGTGT	23160
ACCTGCGCAC	GCCCTTCTCG	GCCGGCAACG	CCACAACATA	AAGAAGCAAG	CAACATCAAC	23220
AACAGCTGCC	GCCATGGGCT	CCAGTGAGCA	GGAACTGAAA	GCCATTGTCA	AAGATCTTGG	23280
TTGTGGGCCA	TATTTTTGG	GCACCTATGA	CAAGCGCTT	CCAGGCTTTG	TTTCTCCACA	23340
CAAGCTGCC	TGCGCCATAG	TCAATACGGC	CGGTGCGAG	ACTGGGGCG	TACACTGGAT	23400
GGCCTTGCC	TGGAACCCGC	ACTCAAAAAC	ATGCTACCTC	TTTGAGCCCT	TTGGCTTTTC	23460
TGACCAGCGA	CTCAAGCAGG	TTTACCAAGTT	TGAGTACGAG	TCACTCCTGC	GCCGTAGCGC	23520
CATTGCTTCT	TCCCCGACC	GCTGTATAAC	GCTGGAAAAG	TCCACCCAAA	GCGTACAGGG	23580
GCCCAACTCG	GCCGCCTGTG	GACTATTCTG	CTGCATGTT	CTCCACGCCT	TTGCCAACTG	23640
GCCCCAAACT	CCCATGGATC	ACAACCCCAC	CATGAACCTT	ATTACCGGGG	TACCCAACTC	23700
CATGCTAAC	AGTCCCAGG	TACAGCCCAC	CCTGCGTCGC	AACCAGGAAC	AGCTCTACAG	23760
CTTCCTGGAG	CGCCACTCGC	CCTACTTCCG	CAGCCACAGT	GCGCAAGATTA	GGAGGCCAC	23820
TTCTTTTGT	CACTGAAAA	ACATGTAAA	ATAATGTACT	AGAGACACTT	TCAATAAAGG	23880
CAAATGCTTT	TATTTGTACA	CTCTCGGGTG	ATTATTACG	CCCACCCCTG	CCGTCTGCGC	23940
CGTTTAAAAA	TCAAAGGGT	TCTGCCGCGC	ATCGCTATGC	GCCACTGGCA	GGGACACGTT	24000
GCGATACTGG	TGTTTAGTGC	TCCACTTAAA	CTCAGGCACA	ACCATCCGCG	GCAGCTCGGT	24060
GAAGTTTCA	CTCCACAGGC	TGCGCACCAC	CACCAACGCG	TTTAGCAGGT	CGGGGCCGA	24120
TATCTTGAAG	TCGCAGTTGG	GGCCTCCGCC	CTGCGCGCG	GAGTTGCGAT	ACACAGGGTT	24180

GCAGCACTGG AACACTATCA GCGCCGGGTG GTGCACGCTG GCCAGCACGC TCTTGTGGA	.24240
GATCAGATCC GCGTCCAGGT CCTCCGCGTT GCTCAGGGCG AACGGAGTC AACTTGTTAG	24300
CTGCCTTCCC AAAAAGGGCG CGTGCCCAGG CTTTGAGTTG CACTCGCACC GTAGTGGCAT	24360
CAAAAAGGTGA CCGTCCCCGG TCTGGCGTT AGGATACAGC GCCTGCATAA AAGCCTTGAT	24420
CTGCTTAAAAA GCCACCTGAG CCTTGCGCC TTCAGAGAAG AACATGCCGC AAGACTTGCC	24480
GGAAAACGTGA TTGCCGGAC AGGCCGCGTC GTGCACGCAG CACCTTGCGT CGGTGTTGGA	24540
GATCTGCACC ACATTCGGC CCCACCGGTT CTTCACGATC TTGGCCTTGC TAGACTGCTC	24600
CTTCAGCGCG CGCTGCCCGT TTTCGCTCGT CACATCCATT TCAATCAGT GCTCCTTATT	24660
TATCATAATG CTTCCGTGTA GACACTTAAG CTCGCCTTCG ATCTCAGGCC AGCGGTGCAG	24720
CCACAACCGC CAGCCCGTGG GCTCGTGTG CTTGTAGGTC ACCTCTGCAA ACGACTGCAG	24780
GTACGCCCTGC AGGAATCGCC CCATCATCGT CACAAAGGTC TTGTTGCTGG TGAAGGTCAG	24840
CTGCAACCCG CGGTGCTCCT CGTTCAGCCA GGTCTGCA ACGGCCGCCA GAGCTTCCAC	24900
TTGGTCAGGC AGTAGTTGA AGTTCGCCTT TAGATCGTTA TCCACGTGGT ACTTGTCCAT	24960
CAGCGCGCGC GCAGCCTCCA TGCCCTTCTC CCACGCAGAC ACGATCGGC CACTCAGCGG	25020
GTTCATCACC GTAATTTCAC TTTCCGCTTC GCTGGGCTCT TCCTCTTCCCT CTTGCGTCCG	25080
CATACCACGC GCCACTGGGT CGTCTTCATT CAGCCGCCGC ACTGTGCGCT TACCTCCTT	25140
GCCATGCTTG ATTAGCACCG GTGGGTTGCT GAAACCCACC ATTTGTAGCG CCACATCTTC	25200
TCTTTCTTCC TCGCTGTCCA CGATTACCTC TGGTGATGGC GGCGCGCTCGG GCTTGGGAGA	25260
AGGGCGCTTC TTTTCTTCT TGGCGCAAT GGCCAAATCC GCCGCCGAGG TCGATGGCCG	25320
CGGGCTGGGT GTGCGCGGC CAAGCGCGTC TTGTGATGAG TCTTCCTCGT CCTCGGACTC	25380
GATACGCCGC CTCATCCGCT TTTTGGGGG CGCCCGGGGA GGCGCGGGCG ACGGGGACGG	25440
GGACGACACG TCCTCCATGG TTGGGGGACG TCGCGCCGCA CGCGTCCGC GCTCGGGGGT	25500
GGTTTCGCGC TGCTCCTCTT CCCGACTGGC CATTTCCTTC TCCTATAGGC AGAAAAAGAT	25560
CATGGAGTCA GTCGAGAAGA AGGACAGCCT AACCGCCCCC TCTGAGTTCG CCACCACCGC	25620
CTCCACCGAT GCCGCCAACG CGCCTACAC CTTCCCCGTC GAGGCACCCCC CGTTGAGGA	25680
GGAGGAAGTG ATTATCGAGC AGGACCCAGG TTTTGTAAGC GAAGACGACG AGGACCGCTC	25740
AGTACCAACA GAGGATAAAA AGCAAGACCA GGACAACGCCA GAGGCAAACG AGGAACAAGT	25800
CGGGCGGGGG GACGAAAGGC ATGGCGACTA CCTAGATGTG GGAGACGACG TGCTGTTGAA	25860
GCATCTGCAG CGCCAGTGC CGATTATCTG CGACGCGTTG CAAGAGCGCA GCGATGTGCC	25920
CCTCGCCATA GCGGATGTCA GCCTGCCTA CGAACGCCAC CTATTCTCAC CGCGCGTACC	25980
CCCCAAACGC CAAGAAAACG GCACATGCGA GCCCAACCCG CGCCTCAACT TCTACCCCGT	26040
ATTTGCCGTG CCAGAGGTGC TTGCCACCTA TCACATCTT TTCCAAAAGT GCAAGATACC	26100
CCTATCCTGC CGTGCCAACC GCAGCCGAGC GGACAAGCAG CTGGCCTTGC GGCAGGGCGC	26160
TGTCATACCT GATATCGCCT CGCTCAACGA AGTGCCAAAATCTTGAGG GTCTTGGACG	26220
CGACGAGAAG CGCGCGGCCA ACGCTCTGCA ACAGGAAAAC AGCGAAAATG AAAGTCACTC	26280

TGGAGTGTG	GTGGAACTCG	AGGGTGACAA	CGCGCGCTA	GCCGTACTAA	AACGCAGCAT	26340
CGAGGTCA	CACTTGCCT	ACCCGGCACT	TAACCTACCC	CCCAAGGTCA	TGAGCACAGT	26400
CATGAGTGAG	CTGATCGTGC	GCCGTGCGCA	GCCCCTGGAG	AGGGATGCAA	ATTTGCAAGA	26460
ACAAACAGAG	GAGGGCCTAC	CCGCAGTTGG	CGACGAGCAG	CTAGCGCGCT	GGCTTCAAAC	26520
GCGCGAGCCT	GCCGACTTGG	AGGAGCCACG	CAAACTAATG	ATGGCCGCAG	TGCTCGTTAC	26580
CGTGGAGCTT	GAGTGCATGC	AGCGGTTCTT	TGCTGACCCG	GAGATGCAGC	GCAAGCTAGA	26640
GGAAACATTG	CACTACACCT	TTCGACAGGG	CTACGTACGC	CAGGCCTGCA	AGATCTCCAA	26700
CGTGGAGCTC	TGCAACCTGG	TCTCCTACCT	TGGAATTTG	CACGAAAACC	GCCTTGGGCA	26760
AAACGTGCTT	CATTCCACGC	TCAAGGGCGA	GGCGCGCCGC	GAETACGTCC	GCGACTGCGT	26820
TTACTTATT	CTATGCTACA	CCTGGCAGAC	GGCCATGGGC	GTTTGGCAGC	AGTGCTTGGA	26880
GGAGTGCAAC	CTCAAGGAGC	TGCAGAAACT	GCTAAAGCAA	AACTTGAAGG	ACCTATGGAC	26940
GGCCTTCAAC	GAGCGCTCCG	TGGCCGCGCA	CCTGGCGGAC	ATCATTTC	CCGAACGCC	27000
GCTTAAAACC	CTGCAACAGG	GTCTGCCAGA	CTTCACCAGT	CAAAGCATGT	TGCAAGACTT	27060
TAGGAAC	TTTATCCTAGAGC	GCTCAGGAAT	CTTGCCGCC	ACCTGCTGTG	CACTTCCTAG	27120
CGACTTTGTG	CCCATTAAAGT	ACCGCGAATG	CCCTCCGCCG	CTTTGGGGCC	ACTGCTACCT	27180
TCTCCAGCTA	GCCAAC	TTGCCTACCA	CTCTGACATA	ATGGAAGACG	TGAGCGGTGA	27240
CGGTCTACTG	GAGTGTCACT	GTCGCTGCAA	CCTATGCACC	CCGCACCGCT	CCCTGGTTG	27300
CAATTGCGAG	CTGCTTAACG	AAAGTCAAAT	TATCGGTACC	TTTGAGCTGC	AGGGTCCCTC	27360
GCCTGACGAA	AAGTCCGCGG	CTCCGGGTT	GAAACTCACT	CCGGGGCTGT	GGACGTCGGC	27420
TTACCTTCGC	AAATTGTAC	CTGAGGACTA	CCACGCCAC	GAGATTAGGT	TCTACGAAGA	27480
CCAATCCGC	CCGCCAAATG	CGGAGCTTAC	CGCCTGCGTC	ATTACCCAGG	GCCACATTCT	27540
TGGCCAATTG	CAAGCCATCA	ACAAAGCCCG	CCAAGAGTTT	CTGCTACGAA	AGGGACGGGG	27600
GGTTTACTTG	GACCCCCAGT	CCGGCGAGGA	GCTCAACCCA	ATCCCCCGC	CGCCGCAGCC	27660
CTATCAGCAG	CAGCCGCGGG	CCCTTGCTTC	CCAGGATGGC	ACCCAAAAAG	AAGCTGCAGC	27720
TGCCGCCGCC	ACCCACGGAC	GAGGAGGAAT	ACTGGACAG	TCAGGCAGAG	GAGGTTTGG	27780
ACGAGGAGGA	GGAGGACATG	ATGGAAGACT	GGGAGAGCCT	AGACGAGGAA	GCTTCCGAGG	27840
TCGAAGAGGT	GTCAGACGAA	ACACCGTCAC	CCTCGGTCCG	ATTCCCCCTCG	CCGGCGCCCC	27900
AGAAATCGGC	AACCGGTTCC	AGCATGGCTA	CAACCTCCGC	TCCTCAGGCG	CCGCCGGCAC	27960
TGCCC GTT C	CCGACCCAAAC	CGTAGATGGG	ACACCACTGG	AACCAGGGCC	GGTAAGTCCA	28020
AGCAGCCGCC	GCCGTTAGCC	CAAGAGCAAC	AACAGCGCA	AGGCTACCGC	TCATGGCGCG	28080
GGCACAAGAA	CGCCATAGTT	GCTTGCTTGC	AAGACTGTGG	GGGCAACATC	TCCTTGC	28140
GGCGCTTCT	TCTCTACCAT	CACGGCGTGG	CCTTCCCCCG	TAACATCCTG	CATTACTACC	28200
GTCATCTCTA	CAGCCCATAC	TGCACCGCG	GCAGCGGCAG	CGGCAGCAAC	AGCAGCGGCC	28260
ACACAGAACG	AAAGGCAGCC	GGATAGCAAG	ACTCTGACAA	AGCCCAAGAA	ATCCACAGCG	28320
GCGGCAGCAG	CAGGAGGAGG	AGCGCTGCGT	CTGGCGCCCA	ACGAACCGT	ATCGACCCGC	28380

GAGCTTAGAA ACAGGATTT TCCCACCTGT TATGCTATAT TTCAACAGAG CAGGGCCAA	28440
GAACAAGAGC TGAAAATAAA AAACAGGTCT CTGCATCCC TCACCCGCAG CTGCCGTAT	28500
CACAAAAGCG AAGATCAGCT TCGGCGCACG CTGGAAGACG CGGAGGCTCT CTTCACTAAA	28560
TACTGCCGC TGACTCTTAA GGACTAGTTT CGCGCCCTT CTCAAATTAA AGCGCGAAAA	28620
CTACGTCACTC TCCAGCGGCC ACACCCGGCG CCAGCACCTG TCGTCAGCGC CATTATGAGC	28680
AAGGAAATTTC CCACGCCCTA CATGTGGAGT TACCAGCCAC AAATGGGACT TCGGGCTGGA	28740
GCTGCCAAG ACTACTAAC CCGAATAAAC TACATGAGCG CGGGACCCCCA CATGATATCC	28800
CGGGTCAACG GAATCCGCGC CCACCGAAAC CGAATTCTCT TGGAACAGGC GGCTATTACC	28860
ACCACACCTC GTAATAACCT TAATCCCCGT AGTTGGCCCG CTGCCCTGGT GTACCAGGAA	28920
AGTCCCGCTC CCACCACTGT GGTACTTCCC AGAGACGCC AGGCCGAAGT TCAGATGACT	28980
AACTCAGGGG CGCAGCTTGC GGGCGGCTT CGTCACAGGG TGCGGTGCC CGGGCAGGGT	29040
ATAACTCACC TGACAATCAG AGGGCGAGGT ATTCAGCTCA ACCACGAGTC GGTGAGCTCC	29100
TCGCTTGTC TCCGTCCGGA CGGGACATT CAGATCGCG GCGCCGGCCG TCCTTCATTC	29160
ACGCCTCGTC AGGCAATCCT AACTCTGCAG ACCTCGTCCCT CTGAGCCGCG CTCTGGAGGC	29220
ATTGGAACTC TGCAATTAT TGAGGAGTTT GTGCCATCGG TCTACTTTAA CCCCTTCTCG	29280
GGACCTCCCG GCCACTATCC GGATCAATT ATTCTAACT TTGACGCGGT AAAGGACTCG	29340
GCGGACGGCT ACGACTGAAT GTTAATTAAG TTCTGTCCA TCCGCACCCA CTATCTTCAT	29400
GTTGTTGCAG ATGAAGCGCG CAAGACCGTC TGAAGATACC TTCAACCCCG TGTATCCATA	29460
TGACACGGAA ACCGGTCCTC CAACTGTGCC TTTTCTTA CTCCTCTTG TATCCCCCAA	29520
TGGGTTCAA GAGAGTCCCC CTGGGGTACT CTCTTGCGC CTATCGAAC CTCTAGTTAC	29580
CTCCAATGGC ATGCTGCGC TCAAAATGGG CAACGGCTC TCTCTGGACG AGGCCGGCAA	29640
CCTTACCTCC CAAAATGTAA CCACTGTGAG CCCACCTCTC AAAAAAACCA AGTCAAACAT	29700
AAACCTGGAA ATATCTGCAC CCCTCACAGT TACCTCAGAA GCCCTAACTG TGGCTGCCGC	29760
CGCACCTCTA ATGGTCGCGG GCAACACACT CACCATGCAA TCACAGGCC CGCTAACCGT	29820
GCACGACTCC AAACTTAGCA TTGCCACCCA AGGACCCCTC ACAGTGTAGC AGTACCTTA CTATCACTGC	29880
AGCCCTGCAA ACATCAGGCC CCCTCACCAC CACCGATAGC AGTACCTTA CTATCACTGC	29940
CTCACCCCCCT CTAACACTTG CCACTGGTAG CTTGGCATT GACTTGAAAG AGCCCATTAA	30000
TACACAAAAT GGAAAATAG GACTAAAGTA CGGGGCTCCT TTGCATGTAA CAGACGACCT	30060
AAACACTTTG ACCGTAGCAA CTGGTCCAGG TGTGACTATT AATAATACTT CCTTGCAAAC	30120
TAAAGTTACT GGAGCCTTGG GTTTGATTC ACAAGGCAAT ATGCAACTTA ATGTAGCAGG	30180
AGGACTAAGG ATTGATTCTC AAAACAGACG CCTTATACTT GATGTTAGTT ATCCGTTGA	30240
TGCTCAAAAC CAACTAAATC TAAGACTAGG ACAGGGCCCT CTTTTATAA ACTCAGCCCA	30300
CAACTTGGAT ATTAACTACA ACAAAAGGCCT TTACTTGTAA ACAGCTCAA ACAATTCCAA	30360
AAAGCTTGAG GTTAACCTAA GCACTGCCAA GGGGTTGATG TTTGACGCTA CAGCCATAGC	30420
CATTAATGCA GGAGATGGGC TTGAATTGG TTCACCTAAT GCACCAAACA CAAATCCCCCT	30480

CAAAACAAAA ATTGGCCATG GCCTAGAATT TGATTCAAAC AAGGCTATGG TTCCCTAACT	30540
AGGAACTGGC CTTAGTTTG ACAGCACAGG TGCCATTACA GTAGGAAACA AAAATAATGA	30600
TAAGCTAACT TTGTGGACCA CACCAGCTCC ATCTCCTAAC TGTAGACTAA ATGCAGAGAA	30660
AGATGCTAAA CTCACCTTGG TCTTAACAAA ATGTGGCAGT CAAATACTTG CTACAGTTTC	30720
AGTTTGGCT GTTAAAGGCA GTTGGCTCC AATATCTGGA ACAGTTCAA GTGCTCATCT	30780
TATTATAAGA TTTGACGAAA ATGGAGTGCT ACTAAACAAT TCCTTCCTGG ACCCAGAATA	30840
TTGGAACTTT AGAAATGGAG ATCTTACTGA AGGCACAGCC TATACAAACG CTGTTGGATT	30900
TATGCCTAAC CTATCAGCTT ATCCAAAATC TCACGGTAAA ACTGCCAAAA GTAACATTGT	30960
CAGTCAGTT TACTTAAACG GAGACAAAAC TAAACCTGTA ACACTAACCA TTACACTAAA	31020
CGGTACACAG GAAACAGGAG ACACAACCTCC AAGTGCATAC TCTATGTCAT TTTCATGGGA	31080
CTGGTCTGGC CACAAC TACA TTAATGAAAT ATTTGCCACA TCCTCTTACA CTTTTTCATA	31140
CATTGCCAA GAATAAAGAA TCGTTGTGT TATGTTCAA CGTGTATT TTTCAATTGC	31200
AGAAAATTC AAGTCATTT TCATTCACTA GTATAGCCCC ACCACCACAT AGCTTATACA	31260
GATCACCGTA CCTTAATCAA ACTCACAGAA CCCTAGTATT CAACCTGCCA CCTCCCTCCC	31320
AACACACAGA GTACACAGTC CTTTCTCCCC GGCTGGCCTT AAAAAGCATC ATATCATGGG	31380
TAACAGACAT ATTCTTAGGT GTTATATTCC ACACGGTTTC CTGTCGAGCC AAACGCTCAT	31440
CAGTGATATT AATAAACTCC CCGGGCAGCT CACTTAAGTT CATGTCGCTG TCCAGCTGCT	31500
GAGCCACAGG CTGCTGTCCA ACTTGCAGTT GCTTAACGGG CGGCGAAGGA GAAGTCCACG	31560
CCTACATGGG GGTAGAGTCA TAATCGTGCA TCAGGATAGG GCGGTGGTGC TGCAGCAGCG	31620
CGCGAATAAA CTGCTGCCGC CGCCGCTCCG TCCTGCAGGA ATACAACATG GCAGTGGTCT	31680
CCTCAGCGAT GATTGCCACC GCCCGCAGCA TAAGGCGCCT TGTCCTCCGG GCACAGCAGC	31740
GCACCCCTGAT CTCACTTAAA TCAGCACAGT AACTGCAGCA CAGCACCACA ATATTGTTCA	31800
AAATCCCACA GTGCAAGGCG CTGTATCCAA AGCTCATGGC GGGGACCACA GAACCCACGT	31860
GGCCATCATA CCACAAGCGC AGGTAGATTA AGTGGCGACC CCTCATAAAC ACGCTGGACA	31920
TAAACATTAC CTCTTTGGC ATGTTGTAAT TCACCACCTC CCGGTACCAT ATAAACCTCT	31980
GATTAAACAT GGCGCCATCC ACCACCATCC TAAACCAGCT GGCCAAAACC TGCCCGCCGG	32040
CTATACACTG CAGGGAACCG GGACTGGAAC AATGACAGTG GAGAGCCCAG GACTCGTAAC	32100
CATGGATCAT CATGCTCGTC ATGATATCAA TGTTGGCACA ACACAGGCAC ACGTGCATAC	32160
ACTTCCTCAG GATTACAAGC TCCTCCCGCG TTAGAACCAT ATCCCAGGGA ACAACCCATT	32220
CCTGAATCAG CGTAAATCCC ACACTGCAGG GAAGACCTCG CACGTAACTC ACGTTGTGCA	32280
TTGTCAAAGT GTTACATTG GGCAGCAGCG GATGATCCTC CAGTATGGTA GCGCGGGTTT	32340
CTGTCTCAA AGGAGGTAGA CGATCCCTAC TGTACGGAGT GCGCCGAGAC AACCGAGATC	32400
GTGTTGGTCG TAGTGTCTG CCAAATGGAA CGCCGGACGT AGTCATATTT CCTGAAGCAA	32460
AACCAGGTGC GGGCGTGACA AACAGATCTG CGTCTCCGGT CTCGCCGCTT AGATCGCTCT	32520
GTGTAGTAGT TGTAGTATAT CCACTCTCTC AAAGCATCCA GGCGCCCCCT GGCTTCGGGT	32580

TCTATGTA~~AA~~ CTCCTTCATG CGCCGCTGCC CTGATAACAT CCACCACCGC AGAATAAGCC 32640
 ACACCCAGCC AACCTACACA TTCGTTCTGC GAGTCACACA CGGGAGGAGC GGGAAAGAGCT 32700
 GGAAGAACCA TGTTTTTTT TTTATTCCAA AAGATTATCC AAAACCTCAA AATGAAGATC 32760
 TATTAAGTGA ACGCGCTCCC CTCCGGTGGC GTGGTCAAAC TCTACAGCCA AAGAACAGAT 32820
 AATGGCATT T GTAAGATGTT GCACAATGGC TTCCAAAAGG CAAACGGCCC TCACGTCCAA 32880
 GTGGACGTAA AGGCTAAACC CTTCAGGGTG AATCTCCTCT ATAAACATT CAGCACCTTC 32940
 AACCATGCCA AAATAATTCT CATCTCGCCA CCTTCTCAAT ATATCTCTAA GCAAATCCCG 33000
 AATATTAAGT CCGGCCATTG TAAAAATCTG CTCCAGAGCG CCCTCCACCT TCAGCCTCAA 33060
 GCAGCGAACATC ATGATTGCAA AAATTCAGGT TCCTCACAGA CCTGTATAAG ATTCAAAAGC 33120
 GGAACATTAAC CAAAAATACC GCGATCCCGT AGGTCCCTTC GCAGGGCCAG CTGAACATAA 33180
 TCGTGCAGGT CTGCACGGAC CAGCGCGGCC ACTTCCCCGC CAGGAACCTT GACAAAAGAA 33240
 CCCACACTGA TTATGACACG CATACTCGGA GCTATGCTAA CCAGCGTAGC CCCGATGTAA 33300
 GCTTTGTTGC ATGGCGGGCG ATATAAAATG CAAGGTGCTG CTCAAAAAAAT CAGGCAAAGC 33360
 CTCGCGAAA AAAGAAAGCA CATCGTAGTC ATGCTCATGC AGATAAAAGGC AGGTAAGCTC 33420
 CGGAACCACC ACAGAAAAAG ACACCATT TCTCTCAAAC ATGTCTGCAG GTTTCTGCAT 33480
 AAACACAAAA TAAAATAACA AAAAAACATT TAAACATTAG AAGCCTGTCT TACAACAGGA 33540
 AAAACAACCC TTATAAGCAT AAGACGGACT ACGGCCATGC CGCGGTGACC GTAAAAAAAC 33600
 TGGTCACCGT GATTAAAAAG CACCACCGAC AGCTCCTCGG TCATGTCCGG AGTCATAATG 33660
 TAAGACTCGG TAAACACATC AGGTTGATTG ATCGGTCACT GCTAAAAAGC GACCGAAATA 33720
 GCCCGGGGGA ATACATACCC GCAGGGCGTAG AGACAAACATT ACAGCCCCA TAGGAGGTAT 33780
 AACAAAATTA ATAGGAGAGA AAAACACATA AACACCTGAA AAACCCCTCCT GCCTAGGCAA 33840
 AATAGCACCC TCCCGCTCCA GAACAAACATA CAGCGCTTCA CAGCGGCAGC CTAACAGTC 33900
 GCCTTACCAAG TAAAAAAGAA AACCTATTAA AAAAAACACCA CTCGACACGG CACCAAGCTCA 33960
 ATCAGTCACA GTGTAAAAAA GGGCCAAGTG CAGAGCGAGT ATATATAGGA CTAAAAAAATG 34020
 ACGTAACGGT TAAAGTCCAC AAAAAACACC CAGAAAACCG CACGCGAACCC TACGCCAGA 34080
 AACGAAAGCC AAAAAACCCA CAACTTCCTC AAATCGTCAC TTCCGTTTTC CCACGTTACG 34140
 TAACTTCCCA TTTTAAGAAA ACTACAATT CCAACACATA CAAGTTACTC CGCCCTAAAA 34200
 CCTACGTAC CCGCCCCGTT CCCACGCCCG GCGCCACGTC ACAAAACTCCA CCCCTCATT 34260
 ATCATATTGG CTTCAATCCA AAATAAGGTA TATTATTGAT GAT 34303

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 380 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCAGGGTTTA CACTTATGC TTCCGGCTCG TATGTTGTGT GGAATTGTGA GCGGATAACA	60
ATTCACACA GGAAACAGCT ATGACCATGA TTACGCCAAG CGCGCAATTAA ACCCTCACTA	120
AAGGGAACAA AAGCTGGTA CCGGGCCCCC CCTCGAGGTC GACGGTATCG ATAAGCTTAC	180
GCGTGGCCTA GGCGGCCGAA TTCTGCAGC CCGGGGGATC CACTAGTTCT AGAGCGGCCG	240
CCACCGCGGC GCCTTAATTAA ATACGTAAGC TCCAATTGCG CCTATAGTGA GTCTATTAC	300
GCGCGCTCAC TGGCCGTCGT TTTACAACGT CGTGACTGGG AAAACCCTGG CGTTACCAA	360
CTTAATCGCC TTGCAGCACA	380

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGCCGCAGCA CCGGATGCAT C

21

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCGTCCGGAG GCTGCCATGC GGCAGGG

27

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1481 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGCTGCCATG CGGCAGGGAT ACGGCGCTAA CGATGCATCT CAACAATTGT TGTGTAGGTA	60
CTCCGCCGCC GAGGGACCTG AGCGAGTCCG CATCGACCGG ATCGGAAAAC CTCTCGAGAA	120
AGGCGTCTAA CCAGTCACAG TCGCAAGGTA GGCTGAGCAC CGTGGCGGGC GGCAGCGGGC	180
GGCGGTGGG GTTGTTCCTG GCGGAGGTGC TGCTGATGAT GTAATTAAAG TAGGCGGTCT	240
TGAGACGGCG GATGGTCGAC AGAACGACCA TGTCCCTGGG TCCGGCCTGC TGAATGCGCA	300
GGCGGTGGC CATGCCAG GCTTCGTTT GACATCGCG CAGGTCTTG TAGTAGTCTT	360
GCATGAGCCT TTCTACCGGC ACTTCTTCTT CTCCTCCTC TTGTCTGCA TCTCTTGAT	420

CTATCGCTGC	GGCGGGGGCG	GAGTTGGCC	GTAGGTGGCG	CCCTCTTCT	CCCATGCGTG	480
TGACCCCGAA	GCCCCTCATC	GGCTGAAGCA	GGGCTAGGTC	GGCGACAACG	CGCTCGGCTA	540
ATATGGCCTG	CTGCACCTGC	GTGAGGGTAG	ACTGGAAGTC	ATCCATGTCC	ACAAAGCGGT	600
GGTATGCGCC	CGTGGTGTAG	GTGTAAGTGC	AGTTGCCAT	AACGGACCAG	TTAACGGTCT	660
GGTGACCCGG	CTGCGAGAGC	TCGGTGTACC	TGAGACCGA	GTAAGCCCTC	GAGTCAAATA	720
CGTAGTCGTT	GCAAGTCCGC	ACCAGGTACT	GGTATCCAC	AAAAAAGTGC	GGCGGGCGCT	780
GGCGGTAGAG	GGGCCAGCGT	AGGGTGGCCG	GGGCTCCGGG	GGCGAGATCT	TCCAACATAA	840
GGCGATGATA	TCCGTAGATG	TACCTGGACA	TCCAGGTGAT	GCCGGCGGC	GTGGTGGAGG	900
CGCGCGGAAA	GTCGCGGACG	CGGTTCCAGA	TGTTGCGCAG	CGGCAGAAAG	TGCTCCATGG	960
TCGGGACGCT	CTGGCCGGTC	AGGCGCGCGC	AATCGTTGAC	GCTCTACCGT	GCAGAAAGGAG	1020
AGCCTGTAAG	CGGGCACTCT	TCCGTGGTCT	GGTGGATAAA	TTCGCAAGGG	TATCATGGCG	1080
GACGACCGGG	GTTCGAGCCC	CGTATCCGGC	CGTCCGCCGT	GATCCATGCG	GTTACCGCCC	1140
GCGTGTGAA	CCCAGGTGTG	CGACGTCAGA	CAACGGGGGA	GTGCTCCCTT	TGGCTTCCTT	1200
CCAGGCGCGG	CGGCTGCTGC	GCTAGCTTTT	TTGGCCACTG	GCCGCGCGCA	GCGTAAGCGG	1260
TTAGGCTGGA	AAGCGAAAGC	ATTAAGTGGC	TCGCTCCCTG	TAGCCGGAGG	GTTATTTCC	1320
AAGGGTTGAG	TCGCGGGACC	CCCAGTTCGA	GTCTCGGACC	GGCCGGACTG	CGGCGAACGG	1380
GGGTTTGCCT	CCCCGTATG	CAAGACCCCG	CTTGCAAATT	CCTCCGGAAA	CAGGGACGAG	1440
CCCCTTTTTT	GCTTTCCCA	GATGCATCCG	GTGCTGCGGC	A		1481

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3364 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAATTCCCCA	TCCTGGTCTA	TAGAGAGAGT	TCCAGAACAG	CCAGGGCTAC	AGATAAACCC	60
ATCTGGAAAA	ACAAAGTTGA	ATGACCCAAG	AGGGGTTCTC	AGAGGGTGGC	GTGTGCTCCC	120
TGGCAAGCCT	ATGACATGGC	CGGGGCCTGC	CTCTCTCTGC	CTCTGACCCCT	CAGTGGCTCC	180
CATGAACCTCC	TTGCCAATG	GCATTTTTT	CCTGCGCTCC	TTGGGTTATT	CCAGTCTCCC	240
CTCAGCATTG	CTTCCTCAGG	GCCTCGCTCT	TCTCTCTGCT	CCCTCCTTGC	ACAGCTGGCT	300
CTGTCCACCT	CAGATGTCAC	AGTGTCTCT	CAGAGGAGGA	AGGCACCATG	TACCCCTCTGT	360
TTCCCAGGTA	AGGGTTCAAT	TTTTAAAAT	GGTTTTTGT	TTGTTTGT	TTTGTGTTGT	420
TTGTTTGT	TTCAAGACAG	GGCTCCTCTG	TGTAGTCCTA	ACTGTCTTGA	AACTCCCTCT	480
GTAGACCAGG	TCGACCTCGA	ACTCTTGAAA	CCTGCCACGG	ACCACCCAGT	CAGGTATGGA	540
GGTCCCTGGA	ATGAGCGTCC	TGAAAGCTAG	GTGGGTAAGG	GTTCGGCGGT	GACAAACAGA	600
AACAAACACA	GAGGCAGTTT	GAATCTGAGT	GTATTTGCA	GCTCTCAAGC	AGGGGATTTT	660

ATACATAAAAA	AAAAAAAAAA	AAAAAAAACC	AAACATTACA	TCTCTTAGAA	ACTATATCCA	720
ATGAAACAAT	CACAGATACC	AACCAAAACC	ATTGGGCAGA	GTAAGCACA	AAAATCATCC	780
AAGCATTACA	ACTCTGAAAC	CATGTATTCA	GTGAATCACA	AACAGAACAG	GTAACATCAT	840
TATTAAATATA	AATCACCAAA	ATATAACAAT	TCTAAAAGGA	TGTATCCAGT	GGGGGCTGTC	900
GTCCAAGGCT	AGTGGCAGAT	TTCCAGGAGC	AGGTTAGTAA	ATCTTAACCA	CTGAACTAAC	960
TCTCCAGCCC	CATGGTCAAT	TATTATTTAG	CATCTAGTGC	CTAATTTTT	TTTATAAATC	1020
TTCACTATGT	AATTTAAAAC	TATTTTAATT	CTTCCTAATT	AAGGCTTCT	TTACCATATA	1080
CCAAAATTCA	CCTCCAATGA	CACACGCGTA	GCCATATGAA	ATTTTATTGT	TGGAAAATT	1140
TGTACCTATC	ATAATAGTTT	TGTAAATGAT	TTAAAAAGCA	AAGTGTAGC	CGGGCGTGGT	1200
GGCACACGCC	TTTAATCCCT	GCACTCGGGA	GGCAGGGGCA	GGAGGATTTC	TGAGTTGAG	1260
GCCAGCCTGG	TCTACAGAGT	GAGTTCCAGG	ACAGCCAGGG	CTACACAGAG	AAACCTGTC	1320
TCGAACCCCC	CACCCCCAA	AAAAAGCAA	GTGTTGGTTT	CCTTGGGAT	AAAGTCATGT	1380
TAGTGGCCCA	TCTCTAGGCC	CATCTCACCC	ATTATTCTCG	CTTAAGATCT	TGGCCTAGGC	1440
TACCAGGAAC	ATGTAAATAA	GAAAAGGAAT	AAGAGAAAAC	AAAACAGAGA	GATTGCCATG	1500
AGAACTACGG	CTCAATATTT	TTTCTCTCCG	GCGAAGAGTT	CCACAACCAT	CTCCAGGAGG	1560
CCTCCACGTT	TTGAGGTCAA	TGGCCTCAGT	CTGTGGAAC	TGTACACAG	ATCTTACTGG	1620
AGGTGGTGTG	GCAGAAACCC	ATTCTTTTA	GTGTCTGGG	CTAAAAGTAA	AAGGCCAGA	1680
GGAGGCCTTT	GCTCATCTGA	CCATGCTGAC	AAGGAACACG	GGTGCCAGGA	CAGAGGCTGG	1740
ACCCCAGGAA	CACCTTAAAC	ACTTCTCCC	TTCTCCGCC	CCTAGAGCAG	GCTCCCTCA	1800
CCAGCCTGGG	CAGAAATGGG	GGAAGATGGA	GTGAAGCCAT	ACTGGCTACT	CCAGAATCAA	1860
CAGAGGGAGC	CGGGGGCAAT	ACTGGAGAAG	CTGGTCTCCC	CCCAGGGGCA	ATCCTGGCAC	1920
CTCCCAGGCA	GAAGAGGAA	CTTCCACAGT	GCATCTCACT	TCCATGAATC	CCCTCCTCGG	1980
ACTCTGAGGT	CCTGGTCAC	AGCTGAGGTG	CAAAGGCTC	CTGTCATATT	GTGTCCTGCT	2040
CTGGTCTGCC	TTCCACAGCT	TGGGGGCCAC	CTAGCCCACC	TCTCCCTAGG	GATGAGAGCA	2100
GCCACTACGG	GTCTAGGCTG	CCCATGTAAAG	GAGGCAAGGC	CTGGGGACAC	CCGAGATGCC	2160
TGGTTATAAT	TAACCCAGAC	ATGTGGCTGC	CCCCCCCCCC	CCAACACCTG	CTGCCTGAGC	2220
CTCACCCCCA	CCCCGGTGCC	TGGGTCTTAG	GCTCTGTACA	CCATGGAGGA	GAAGCTCGCT	2280
CTAAAAATAA	CCCTGTCCCT	GGTGGATCCA	GGGTGAGGGG	CAGGCTGAGG	GCGGCCACTT	2340
CCCTCAGCCG	CAGGTTGTT	TTCCCAAGAA	TGGTTTTCT	GCTTCTGTAG	CTTTCTCGT	2400
CAATTCTGCC	ATGGTGGAGC	AGCCTGCACT	GGGCTCTGG	GAGAAACCAA	ACCGGGTTCT	2460
AACCTTCAG	CTACAGTTAT	TGCCTTCCT	GTAGATGGGC	GACTACAGCC	CCACCCCCAC	2520
CCCCGTCTCC	TGTATCCTTC	CTGGGCCTGG	GGATCCTAGG	CTTCACTGG	AAATTTCCCC	2580
CCAGGTGCTG	TAGGCTAGAG	TCACGGCTCC	CAAGAACAGT	GCTTGCCTGG	CATGCATGGT	2640
TCTGAACCTC	CAACTGCAA	AAATGACACA	TACCTTGACC	CTTGGAAGGC	TGAGGCAGGG	2700
GGATTGCCAT	GAGTGCAGAG	CCAGACTGGG	TGGCATAGTT	AGACCCCTGTC	TCAAAAAACC	2760

AAAAACAATT AAATAACTAA AGTCAGGCAA GTAATCCTAC TCGGGAGACT GAGGCAGAGG	2820
GATTGTTACA TGTCTGAGGC CAGCCTGGAC TACATAGGGT TTCAGGCTAG CCCTGTCTAC	2880
AGAGTAAGGC CCTATTCAA AAACACAAAC AAAATGGTC TCCCAGCTGC TAATGCTCAC	2940
CAGGCAATGA AGCCTGGTGA GCATTAGCAA TGAAGGCAAT GAAGGAGGGT GCTGGCTACA	3000
ATCAAGGCTG TGGGGGACTG AGGGCAGGCT GTAACAGGCT TGGGGGCCAG GGCTTATACG	3060
TGCCTGGGAC TCCCAGAGTA TTACTGTTCC ATGTTCCCGG CGAAGGGCCA GCTGTCCCC	3120
GCCAGCTAGA CTCAGCACTT AGTTTAGGAA CCAGTGAGCA AGTCAGCCCT TGGGGCAGCC	3180
CATACAAGGC CATGGGGCTG GGCAAGCTGC ACGCCTGGGT CCGGGGTGGG CACGGTGCCC	3240
GGGCAACGAG CTGAAAGCTC ATCTGCTCTC AGGGGCCCT CCCTGGGAC AGCCCCTCCT	3300
GGCTAGTCAC ACCCTGTAGG CTCCCTCTATA TAACCCAGGG GCACAGGGGC TGCCCCCGGG	3360
TCAC	3364

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGTACCACTA CGGGTCTAGG CTGCCATGT AAGGAGGCAA GGCTGGGA CACCCGAGAT	60
GCCTGGTTAT AATTAACCCC AACACCTGCT GCCCCCC CCCAACACCC TGCTGCCTGA	120
GCCTGAGCGG TTACCCACC CCGGTGCCTG GGTCTTAGGC TCTGTACACC ATGG	174

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 699 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGATCTTCCT AGAAATTTCGC TGTCTGCGAG GGCGGCTGT TGGGGTGAGT ACTCCCTCTC	60
AAAAGCGGGC ATGACTTCTG CGCTAAGATT GTCAGTTCC AAAAACGAGG AGGATTTGAT	120
ATTCACCTGG CCCGCGGTGA TGCCTTGAG GGTGGCCGCG TCCATCTGGT CAGAAAAGAC	180
AATCTTTTG TTGTCAAGCT TGAGGTGTGG CAGGCTTGAG ATCGATCTGG CCATACACTT	240
GAGTGACAAT GACATCCACT TTGCCTTCT CTCCACAGGT GTCCACTCCC AGGTCCAACC	300
GCGGATCTCC CGGGACCATG CCCAAGAAGA AGAGGAAGGT GTCCAATTAA CTGACCGTAC	360
ACCAAAATTT GCCTGCATTA CCGGTGATG CAACGAGTGA TGAGGTTCGC AAGAACCTGA	420
TGGACATGTT CAGGGATCGC CAGGCCTTT CTGAGCATACT CGGAAAATG CTTCTGTCCG	480

TTTGCCTGTC GTGGCGGCA TGGTGCAAGT TGAATAACCG GAAATGGTTT CCCGCAGAAC	540
CTGAAGATGT TCGCGATTAT CTTCTATATC TTCAGGCGCG CGGTCTGGCA GTAAAAACTA	600
TCCAGCAACA TTTGGGCCAG CTAACATGC TTCATCGTCG GTCCGGGCTG CCACGACCAA	660
GTGACAGCAA TGCTGTTCA CTGGTTATGC GGCGGATCC	699

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 68 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAAGATCTAT AACTTCGTAT AATGTATGCT ATACGAAGTT ATTACCGAAG AAATGGCTCG	60
AGATCTTC	68

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 68 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAAGATCTCG AGCCATTCTC TCGGTAATAA CTTCGTATAG CATACTATTAC ACGAAGTTAT	60
AGATCTTC	68

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCACATGTAT AACTTCGTAT AGCATACATT ATACGAAGTT ATACATGTGG	50
--	----

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCACATGTAT AACTTCGTAT AATGTATGCT ATACGAAGTT ATACATGTGG	50
--	----

CLAIMS

1. A recombinant plasmid, comprising in operable combination:
 - a) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element;
 - b) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone;
 - c) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs; and
 - d) a first gene of interest operably linked to said promoter element.

5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95

2. The recombinant plasmid of Claim 1 wherein the total size of said plasmid is between 27 and 40 kilobase pairs.

3. The recombinant plasmid of Claim 1, wherein said 5' end of said packaging sequence is linked to said 3' end of said left ITR.

4. The recombinant plasmid of Claim 3, wherein said first gene of interest is linked to said 3' end of said packaging sequence.

5. The recombinant plasmid of Claim 4, wherein said first gene of interest is the dystrophin cDNA gene.

6. The recombinant plasmid of Claim 4, further comprising a second gene of interest.

7. The recombinant plasmid of Claim 6, wherein said second gene of interest is linked to said 3' end of said right ITR.

8. The recombinant plasmid of Claim 7, wherein said second gene of interest is a reporter gene.

9. The recombinant plasmid of Claim 8, wherein said reporter gene is selected from the group consisting of the *E. coli* β -galactosidase gene, the human placental alkaline phosphatase gene, the green fluorescent protein gene and the choramphenicol acetyltransferase gene.

5 10. A mammalian cell line containing the recombinant plasmid of
Claim 1.

11. The cell line of Claim 10, wherein said cell line is a 293-derived cell line.

10 12. A helper adenovirus comprising i) first and a second *loxP* sequences,
and ii) the adenovirus packaging sequence, said packaging sequence having a 5'
and a 3' end.

13. The helper adenovirus of Claim 12, wherein said first *loxP* sequence
is linked to the 5' end of said packaging sequence and said second *loxP* sequence is
linked to said 3' end of said packaging sequence.

15 14. The helper adenovirus of Claim 12, further comprising at least one
adenovirus gene coding region.

15. A mammalian cell line, comprising:
a) a recombinant plasmid, comprising, in operable combination:
20 i) a plasmid backbone, comprising an origin of
replication, an antibiotic resistance gene and a eukaryotic promoter
element,
ii) the left and right inverted terminal repeats (ITRs) of
adenovirus, said ITRs each having a 5' and a 3' end and arranged in
a tail to tail orientation on said plasmid backbone,
25 iii) the adenovirus packaging sequence, said packaging
sequence having a 5' and a 3' end and linked to one of said ITRs,
and

iv) a first gene of interest operably linked to said promoter element: and

5 b) a helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end.

16. The cell line of Claim 15, wherein said helper adenovirus further comprises at least one adenovirus gene coding region.

17. The cell line of Claim 15, wherein said first gene of interest is the dystrophin cDNA gene

10 18. A method of producing an adenovirus minichromosome, comprising:

A) providing a mammalian cell line containing:

15 a) a recombinant plasmid, comprising, in operable combination, i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukarotic promoter element, ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone, iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs, and iv) a first gene of interest operably linked to said promoter element: and

20 b) a helper adenovirus comprising i) first and a second *loxP* sequences, ii) at least one adenovirus gene coding region, and iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end; and

25 B) growing said cell line under conditions such that said adenovirus gene coding region is expressed and said recombinant plasmid directs the production of at least one adenoviral minichromosome.

19. The method of Claim 18, wherein said adenovirus minichromosome is encapsitated.

20. The method of Claim 18, further comprising 3) recovering said encapsidated adenovirus minichromosome.
21. The method of Claim 20, further comprising 4) purifying said recovered encapsidated adenovirus minichromosome.
- 5 22. The method of Claim 21, further comprising 5) administering said purified encapsidated adenovirus minichromosome to a host.
23. The method of Claim 22, wherein said host is a mammal.
24. The method of Claim 23, wherein said mammal is a human.
- 10 25. A recombinant adenovirus comprising the adenovirus E2b region having a deletion, said adenovirus capable of self-propagation in a packaging cell line and said E2b region comprising the DNA polymerase gene and the adenovirus preterminal protein gene.
26. The recombinant adenovirus of Claim 25, wherein said deletion is within the adenovirus DNA polymerase gene.
- 15 27. The recombinant adenovirus of Claim 25, wherein said deletion is within the adenovirus preterminal protein gene.
28. The recombinant adenovirus of Claim 25, wherein said deletion is within the adenovirus DNA polymerase and preterminal protein genes.
- 20 29. A mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase.
30. The cell line of Claim 29, wherein said cell line comprises a recombinant adenovirus comprising a deletion within the E2b region, said recombinant adenovirus being capable of self-propagation in said cell line.

31. The cell line of Claim 30, wherein said deletion within said E2b region comprises a deletion within the adenoviral DNA polymerase gene.

32. The cell of Claim 29, wherein the genome of said cell line contains a nucleotide sequence encoding adenovirus DNA polymerase operably linked to a heterologous promoter.
5

33. The cell line of Claim 32, wherein said cell line is selected from the group consisting of the B-6, B-9, C-1, C-4, C-7, C-13, and C-14 cell lines.

34. The cell line of Claim 29 further constitutively expressing the adenovirus preterminal protein gene product.

10 35. The cell line of Claim 34, wherein said cell line comprises a recombinant adenovirus comprising a deletion within the E2b region, said recombinant adenovirus being capable of self-propagation in said cell line.

36. The cell line of Claim 35, wherein said deletion within said E2b region comprises a deletion within the adenoviral preterminal protein gene.

15 37. The cell line of Claim 36, wherein said deletion within said E2b region comprises a deletion within the adenoviral DNA polymerase and preterminal protein genes.

20 38. The cell line of Claim 34, wherein the genome of said cell line contains a nucleotide sequence encoding adenovirus preterminal protein operably linked to a heterologous promoter.

39. The cell line of Claim 38, wherein said cell line is selected from the group consisting of the C-1, C-4, C-7, C-13, and C-14 cell lines.

40. A method of producing infectious recombinant adenovirus particles containing an adenoviral genome containing a deletion within the E2b region. comprising

a) providing:

5 i) a mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase;

10 ii) a recombinant adenovirus comprising a deletion within the E2b region, said recombinant adenovirus being capable of self-propagation in said cell line;

b) introducing said recombinant adenovirus into said cell line under conditions such that said recombinant adenovirus is propagated to form infectious recombinant adenovirus particles; and

c) recovering said infectious recombinant adenovirus particles.

15 41. The method of Claim 40, further comprising d) purifying said recovered infectious recombinant adenovirus particles.

42. The method of Claim 41, further comprising e) administering said purified recombinant adenovirus particles to a host.

20 43. The method of Claim 40, wherein said mammalian cell line further constitutively expresses the adenovirus preterminal protein.

44. A recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, said E2b sequences containing a deletion within the polymerase gene, said deletion resulting in reduced polymerase activity.

25 45. The recombinant plasmid of Claim 44, wherein said deletion comprises a deletion of nucleotides 8772 to 9385 in SEQ ID NO:4.

46. The recombinant plasmid of Claim 45, wherein said plasmid has the designation pΔpol.

47. The recombinant plasmid of Claim 45, wherein said plasmid has the designation pBHG11Δpol.

48. A recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, said E2b sequences containing a deletion 5 within the preterminal protein gene, said deletion resulting in the inability to express functional preterminal protein without disruption of the VA RNA genes.

49. The recombinant plasmid of Claim 48, wherein said deletion within said preterminal protein gene comprises a deletion of nucleotides 10,705 to 11,134 in SEQ ID NO:4.

10 50. The recombinant plasmid of Claim 49, wherein said plasmid has the designation pΔpTP.

51. The recombinant plasmid of Claim 49, wherein said plasmid has the designation pBHG11ΔpTP.

15 52. The recombinant plasmid of Claim 48 further comprising a deletion within the polymerase gene, said deletion resulting in reduced polymerase activity.


53. The recombinant plasmid of Claim 52, wherein said deletion within said polymerase and said preterminal protein genes comprises a deletion of nucleotides 8,773 to 9586 and 11,067 to 12,513 in SEQ ID NO:4.

20 54. The recombinant plasmid of Claim 53, wherein said plasmid has the designation pAXBΔpolΔpTPVARNA+t13.

55. The recombinant plasmid of Claim 53, wherein said plasmid has the designation pBHG11ΔpolΔpTPVARNA+t13.

FIGURE 1

A



B




FIGURE 2




FIGURE 3





FIGURE 4

FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18





FIGURE 19



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/19541

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 5/06, 5/10, 7/01, 7/02, 15/86

US CL :435/235.1, 320.1, 369

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/235.1, 320.1, 369

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	KUMAR-SINGH et al. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. July 1996, Vol.5, No.7, pages 913-921, see entire document.	1-11 --- 15-24
X,P --- Y,P	PARKS et al. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA. November 1996, Vol.93, pages 13565-13570, see entire document.	12-14 --- 15-24

 Further documents are listed in the continuation of Box C.

See patent family annex.


* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"a"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document not published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 JANUARY 1998

Date of mailing of the international search report

10 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized by
ROBERT SCHWARTZMAN


INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/19541

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MITANI et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci USA. April 1995, Vol.92, pages 3854-3858, especially pages 3855-3856.	25, 27
X	AMALFITANO et al. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA. April 1996, Vol.93, pages 3352-3356, see entire document.	29, 32, 33
X	CHAMBERLAIN et al. Packaging cells expressing the adenovirus (Ad) E1, polymerase, and preterminal proteins to allow the growth of a new class of replication defective Ad-vector for use in Duchenne muscular dystrophy (DMD). Am. J. Hum. Genet. 24 SEP 1996, Vol.59, No.4 Suppl., page A377, see entire document.	25-32, 34-38, 40-44, 48, 52
X	AMALFITANO et al. Modification of adenoviral vectors for use in gene therapy of Duchenne muscular dystrophy. Am. J. Hum. Genet. October 1995, Vol.57, No. 4 Suppl., page A234, see entire document.	25, 26, 29-33, 40, 41

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19541

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN: Medline, Biosis, Embase, CAPlus, WPIDS, JAPIO, PATOSEP, PATOSWO
APS

Search Terms: adenovirus, vector, LTR, inverted, E2B, DNA polymerase, preterminal protein, Cre, loxP